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Abstract 
Hospital acquired pneumonia (HAP) occurs in 1% of all hospital in-patients, 
and in around 10% of patients with lower limb fracture, with a mortality of 18-
43%.  HAP arises from interactions between three main risk factor groups: 
resident oral microbiota, aspiration potential (dysphagia, reduced conscious 
level) and host factors (age, frailty, comorbidity).  In this work novel multiplex 
real time PCR assays were used to study prospectively the oral colonisation 
dynamics of seven major commensal pathogens over the first fortnight after 
hospital admission in relation to oral health variables, medical variables and 
subsequent development of HAP.  Of the 93 patients recruited, 10% developed 
HAP and 60% of in-hospital deaths after lower limb fracture were due to HAP.    
Persistent oral colonisation with E. coli or S. aureus was significantly associated 
with HAP or HAP/lower respiratory tract infection in older patients with lower 
limb fracture.  In turn, S. aureus was associated with increased dental plaque at 
admission and with increased xerostomia indices at 14 days.  Other factors such 
as witnessed aspiration and post-operative cough were also strongly associated 
with subsequent development of HAP.  HAP was associated with increased risk 
of death and increased length of hospital admission.  These findings suggest 
several potentially modifiable clinical risk factors, and a high risk population 
for HAP, to whom interventions could be targeted.  Given the rise in the older 
population and the increased costs associated with HAP, early detection and 
prevention will become increasingly important.  Further work is needed to 
understand the relationships between dental plaque, S. aureus and xerostomia, 
and also to identify microbial biomarkers which could be used at the start of 
hospital admission to stratify patients’ risk of HAP.     
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Chapter 1 Introduction 
1.1 Pneumonia 
Over 100 years ago, Sir William Osler described pneumonia as “the most 
widespread and fatal of all acute diseases… now Captain of the men of death” 
[1].  Since then the mortality from pneumonia has decreased considerably over 
the 20th century [2, 3], mainly due to antibiotics and vaccination.  However 
pneumonia remains the leading causing of death globally in children under five 
years [4], and influenza and pneumonia remain the fifth commonest cause of 
death in England and Wales in 2010 [5].  In 2011, 87% of the 25,696 deaths in 
England and Wales from pneumonia were in persons over age 75 [6].  In 
England, the number of people over age 75 is projected to increase from 4.9 
million in 2010 to 6.1 million in 2020, and to 8.1 million by 2030 [7].  The 
proportions of persons with pneumonia would be expected to rise accordingly, 
but the incidence in older people may also be rising independently of 
demographic trends [8]. 
Pneumonia is characterised by the accumulation of bacteria and inflammatory 
exudate in the alveolar spaces of the lung, which can be visualised on chest 
radiography as consolidation (or a non-lucent “white” area) when sufficiently 
widespread.  Pneumonia is caused by bacteria [9-12], and viruses [13-15] which 
are either inhaled or aspirated (or more rarely spread by the blood from a 
distant site) and which provoke an inflammatory immune response by the lung.  
Bacteria and viruses adhere to and replicate in the oro- and nasopharynx first 
before moving to the lung. 
The commonest bacterial causes of pneumonia are Streptococcus pneumoniae, 
Haemophilus influenzae and Morhaxella cattarhalis, while the commonest viral 
pathogens are influenza and respiratory syncytial virus [9].  In older adults S. 
pneumoniae accounts for 20-60% of cases of community acquired pneumonia 
[14-16], however, other bacteria such as Staphylococcus aureus, and gram 
negative aerobic bacilli are also identified from pulmonary secretions [17, 18], 
the latter probably coinciding with the onset of routine use of antibiotics [12] .  
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Pneumonia may also occur in hospital, after admission with a separate 
problem, and this is known as hospital acquired pneumonia (HAP). HAP refers 
to a respiratory infection associated with new infiltrates on chest radiography 
which develops after 48 hours or more in a hospital environment [10, 19].    
Respiratory infections are now the commonest healthcare acquired infection in 
England [20], and the mortality associated with HAP is high, and ranges from 
18-43% depending on the group studied [21-26].  National Health Service 
(NHS) patients on general wards are not currently screened or stratified for risk 
of nosocomial respiratory infections, and no preventative measure are 
undertaken, in contrast with other healthcare associated infections.  By 
screening and treating MRSA carriers, improving awareness about hand-
washing and reducing unnecessary intravenous devices, government strategies 
have reduced the rates of MRSA bacteraemias according to Health Protection 
agency figures (http://www.hpa.org.uk/hpr/infections/hcai.htm).  However 
these strategies have not affected rates of HAP, and respiratory infections have 
become proportionally more common since the 2006 hospital infection 
prevalence survey was undertaken [27].   
Commonly identified risk factors for HAP include difficulty with feeding or 
oral secretions [21, 28-31], episodes of disorientation [21, 28] or decreased 
conscious level [24], aspiration [24, 28, 32] and oral colonisation with respiratory 
commensal pathogens [21, 29, 33].  The term “commensal pathogen” will be 
used in this work, and refers to organisms which may either be carried 
asymptomatically or act as pathogens (see 1.5.1), described in relation to S. 
pneumoniae by Henriques-Normark et al.[34] .  Oral colonisation with 
respiratory commensal pathogens may represent a potential target for 
interventions to prevent HAP.  Respiratory commensal pathogens have also 
been identified from the oral cavity in community dwelling persons without 
respiratory infection [35-37], but appear to increase during illness, proportional 
to illness severity [36, 38].  There remains confusion about the significance of 
potential pathogens being identified from the oropharynx in both community 
dwelling persons and those in hospitals or institutions.  Several reports have 
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suggested that the organism causing pneumonia was isolated first from the 
oropharynx [39-42].   However relatively few studies have analysed 
prospectively the association between prior oral colonisation with respiratory 
commensal pathogens and HAP in non-ventilated patients [21, 33, 43].  
Increased dental plaque has also been linked with respiratory tract infection [44, 
45], and it has been proposed that dental plaque might modulate the risk of 
HAP either by inflammatory means, or by acting as a possible stable reservoir 
for opportunistic HAP pathogens [46, 47].  Further investigation is warranted as 
the oropharynx could be a target for preventative therapy.   
1.1.1 Hospital acquired pneumonia in older people with lower limb fracture 
Surgical patients are prone to developing HAP, and surgical wards are the 
second commonest location for HAP to be diagnosed, after intensive care units 
[20, 27, 48].  Patients with lower limb fracture (which requires urgent surgery) 
appear to be at particular risk of HAP, with an incidence of 8.6-10% [23, 49, 50].  
Preventing HAP in older patients with hip fracture or other fractures of the 
lower limb is important because approximately a third of these patients will die 
within a year of hip fracture [51].   Pneumonia is one of the commonest 
postoperative complications, and the second commonest cause of death in these 
patients after cardiac disease and 43% of patients with HAP after hip fracture 
die [23].   Preventing HAP in a proportion of patients with lower limb fracture 
could potentially have a large impact on overall mortality and quality of life. 
1.1.2 Epidemiology 
Respiratory infections are now the commonest healthcare associated infection 
in England, with a prevalence of 1.5% (95% confidence intervals 1.4-1.6) across 
all hospital in-patients [20].  The prevalence of HAP has been estimated at 1.1-
1.8% [52-54] in general ward patients, 1-31% in surgical patients [33, 48, 55-65], 
18-22% in stroke patients [66, 67], 3-44% in long term care facilities [29, 30, 68, 
69], and 4-5% in geriatric hospitals [53, 70].  Respiratory tract infections are the 
second commonest healthcare acquired infection in a variety of countries [71-
73].  Assuming a rate of 1% of hospital patients developing HAP, of the 
12,976273 admissions to hospital in 2005-2006 [74], nearly 130,000 patients will 
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have developed HAP.  Infections due to Streptococcus pneumoniae and several 
respiratory viruses are more common in winter months [75, 76], and 
pneumonia is therefore more common overall in winter months.   
1.1.3 Cost 
A recent study of culture–positive pneumonia conducted in the United States 
(US) between 2002-2003 calculated the median cost of HAP as $31,220, 
compared with community acquired pneumonia (CAP) which had a median 
cost of $13,358 and ventilator asscociated pneumonia (VAP) which cost $ 98,192 
[11].  Length of stay was greater in HAP (median 11 days versus 5 days in CAP) 
which may account for some of the increased costs.  A 1993 study estimated the 
cost of one person developing HAP in the US to be $14,000 [77], which was 
extrapolated to suggest that overall cost for the 1.5 million US nursing home 
residents developing HAP was approximately 8 billion dollars.  Thompson et 
al. studied a database of 618,495 patients undergoing intra-abdominal surgery 
of whom 13,292 developed HAP (2.2%) and found a greater length of stay (17 
days versus 6 days) in those with HAP, a four-fold increase in the likelihood of 
transfer to an institution and a 75% increase in mean healthcare cost [78].    
Other studies showed that HAP lengthened hospital stay by up to 12 days [22, 
48, 79-81].  Antibiotics, bed days and increased need for rehabilitation are the 
most likely explanatory factors for increased cost associated with HAP. 
1.2 Diagnosis of HAP  
1.2.1 Clinical diagnosis 
Pneumonia is diagnosed by a combination of clinical symptoms (cough, green 
or yellow sputum, fevers and chills, chest pain, malaise), new radiographic 
infiltrates on chest X-ray (CXR) and signs of inflammation (fever, raised white 
cell count).  Despite the well recognised clinical syndrome, there is currently no 
gold standard diagnostic test to diagnose pneumonia, because new radiological 
infiltrates on chest radiograph alone could represent a number of pathologies, 
most notably pulmonary oedema.  Indeed pneumonia and cardiac compromise 
resulting in pulmonary oedema can coexist.  The best diagnostic criteria are a 
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combination of clinical signs in conjunction with new infiltrates on chest 
radiograph.   Definitions used in research studies, and those from national 
guidelines are described in Table 1, and there is considerable variation both in 
criteria employed and the cut-offs for diagnostic values such as white cell 
count.  The American Thoracic Society (ATS) and British Society for 
Antimicrobial Chemotherapy (BSAC) have both formulated guidelines for 
diagnosis [10, 19], the former semi-evidence based (no formalised quality 
assessment made of studies used) and the latter evidence-based (using Scottish 
Intercollegiate Guideline Network (SIGN) methodology).  However both 
criteria involve the inflammatory response.  There is conflicting evidence as to 
whether the inflammatory response may be absent or reduced in older people 
with HAP, with studies showing both a reduction [14, 82] and no reduction [83] 
in inflammatory response during episodes of CAP or blood stream infection 
with P. aeruginosa or Enterococcus sp. [84].  In addition, older people may 
present with delirium or decreased mobility [14, 28] or other non-respiratory 
symptoms such as falls, incontinence or diarrhoea.   
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Table 1. Definitions of HAP in national guidelines and selected journal articles relevant to HAP in older people 
Type Major criterion Minor criteria 
Semi-evidence based 
guidelines (US)[19] 
New infiltrates on 
CXR 
Plus two of Fever: over 38°C, Secretions: purulent, Leukocytosis/leukopenia 
Evidence based 
guidelines (UK)[10] 
New infiltrates on 
CXR or Secretions: 
purulent 
Fever: over 38.3°C , White cells: > 10 or < 4, Increased oxygen requirement 
Journal article[11] ICD-9 code  
Journal article[70] New infiltrates on 
CXR 
Plus 2 of: Fever: over 38°C. Secretions: purulent, Chest pain, Auscultatory findings, 
Respiratory rate >20 breaths per min , Purulent sputum 
Journal article[29] Opinion of 
pulmonary 
physician 
In conjunction with new infiltrates on CXR, Fever: over 99.5ºF, Secretions: purulent, White 
cells: rise of 5 or more, Attending physician opinion, Observed aspiration, Cough with 
fever, Dyspnoea, Pleuritic chest pain, Positive respiratory culture 
 
Journal article[22] 
 
New infiltrates on 
CXR 
 
Fever: over 38 ºC, Secretions: purulent, White cells: >12 or <3, Matching blood/respiratory 
cultures or gram stain of sputum 
Journal article [18] New infiltrates on 
CXR 
Plus two of, Fever: over 38 ºC, Secretions: purulent or change in character and increasing 
arterial-alveolar gradient, White cells: >11 or neutrophils <3.5 
Journal article[54] New infiltrates on 
CXR or bronchial 
breathing on  
Plus all of, Fever: over 38 ºC, Positive sputum/tracheal culture, Secretions: purulent , White 
cells: >12 or neutrophils <3 
 
Journal article[85] New infiltrates on 
CXR 
Fever: over 38.5 ºC, White cells: >15 48 hours before death, Positive sputum culture, 
Worsening gas exchange 
Journal article[86] New infiltrates on 
CXR 
Plus one of, Fever: over 37.8 ºC, Cough, Dyspnoea 
 
Note: White cell count is measured in cells/metre3
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1.2.2 Histological diagnosis 
Ideally, pulmonary histology would be used as a gold standard to further refine 
clinical and microbiological criteria.  However studies have demonstrated poor 
inter-rater agreement [87], poor correlation with clinical diagnosis [85, 88], and 
a recent UK systematic review did not recommend that histology was used as a 
gold standard [10].  It seems highly probable that histological diagnosis will 
become the most accurate diagnostic method in the future, and thus allow 
correlation with clinical diagnosis.  Other diagnostic approaches might include 
the use of metabolomics [89] or assaying immunological responses (such as 
tumour necrosis factor or immunoglobulins) along with microbiological 
analysis of invasive respiratory samples [90, 91]. However research is needed 
into both of these approaches before their adoption into clinical practice could 
be considered. 
1.2.3 Aetiology  
Differing rates of bacterial species have been identified from microbiological 
samples according to where the patient acquired the infection, hence the 
terminology community acquired pneumonia (CAP), hospital acquired 
pneumonia (HAP), ventilator associated pneumonia (VAP), post-operative 
pneumonia or nursing home acquired pneumonia (NHAP).  In this work, HAP 
will be used to refer to those who are not or have not been mechanically 
ventilated and VAP for those who have been ventilated (excluding intra-
operative ventilation).  Community acquired pneumonia is caused most 
commonly by S. pneumoniae, Morhaxhella cattarhalis and Haemophilus influenzae 
[11, 14, 92, 93], whereas HAP, VAP and NHAP are also commonly caused by S. 
aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and other gram-negative 
organisms such as Klebsiella pneumoniae [11, 17, 18, 26] (see Table 2).  HAP which 
occurs within four days of hospital admission is said to more often resemble 
CAP in terms of bacterial aetiology [19].  However, a large French study of 
postoperative HAP found the bacterial aetiology more similar to that of 
ventilated patients [26] (see Table 2).   Studies from the UK and Germany have 
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reported lower rates (1-1.3%) of gram negative bacilli as causative organisms of 
CAP than those found in the US (Table 2) [14, 94, 95], however there are no 
more recent UK studies with which to compare.  The 2011 English National 
Point Prevalence Survey of Healthcare Associated Infections captured culture 
results from patients with HAP and VAP [20], but detailed results from this 
survey are yet to be published. 
The concept of infections being of polymicrobial aetiology is now accepted [55, 
96-99], a departure from the traditional view that monomicrobial cultures 
signify infection and polymicrobial cultures represent contamination [14].  
Polymicrobial cultures were reported in 29% of patients with HAP in one study 
[26], with the commonest combinations of two organisms including either S. 
aureus and Enterobactericeae (24%) or Enterobactericeae and Streptococci (17%).  
In other studies of HAP, polymicrobial infections were identified in 13.3-28% of 
patients [17, 55, 99].   
Recently it has been noted that persons who frequent healthcare environments 
as day patients (e.g. for renal dialysis) develop pneumonias from bacteria which 
are more like the hospital group than the community group, and pneumonia in 
this group is now known as healthcare associated pneumonia [11, 100] (HCAP).   
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Table 2. Bacterial aetiology of pneumonia in UK community setting versus hospital settings in the UK, US and France expressed in mean % 
 Hospital acquired  
pneumonia, non-
ventilated[11] 
Ventilator  associated  
pneumonia[11] 
Hospital acquired 
pneumonia (ventilated 
and non-ventilated)[26] 
Community acquired 
pneumonia, UK[9] 
 
Community acquired  
pneumonia, US[11] 
S. pneumoniae 3.1 5.8 10 39 16.6 
H. influenzae 5.6 * 12.2* 19 5.2 16.6* 
S. aureus 47.1 42.5 27 1.9 25.5 
Gram negative 
enteric bacilli 
21.8 29.6 33 1 22.9 
Pseudomonas 18.4 21.2 17 n/a 17.1 
1US 2002-2003, respiratory culture positive from Atlas database             2 France 1997-1998  
*Haemophilus species recorded only 
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1.2.4 Aspiration pneumonia 
Aspiration pneumonia (AP) is used to describe persons who develop 
pneumonia following witnessed or suspected episodes of aspiration of food, 
drink, saliva or any combination of these.    Many studies do not distinguish 
between aspiration pneumonia and HAP [86, 101], and it is difficult to know 
whether to consider aspiration pneumonia as a distinct entity.  The main 
differences between micro- and macro-aspiration are summarised in Table 3.  It 
may be better to consider a spectrum between no aspiration, microaspiration 
and macroaspiration.  HAP, NHAP, VAP and even sometimes CAP [102, 103] 
may be associated with aspiration (albeit micro-aspiration) as will be discussed 
below.  In addition, those who are diagnosed with HAP may have experienced 
an episode of unwitnessed moderate-large volume aspiration.  The bacterial 
aetiology of AP is broadly the same as HAP and anaerobes appear to be less 
common than previously thought [18, 104, 105]. 
Table 3. Comparing micro- and macro-aspiration  
Parameter Microaspiration Macroaspiration 
Cause of aspiration Decreased conscious 
level 
Neurological disease or 
decreased conscious level 
Visibility of aspiration Silent May or may not be 
witnessed 
Contents of aspirated 
fluid 
Saliva Food, drink, saliva 
Volume of aspirated 
material 
Small Large 
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1.3 Antibiotic therapy 
The main modality of treatment of HAP is antibiotic therapy; inadequate 
antibiotic therapy is associated with higher mortality (OR 2.6 95% CI 1.4-23.9) 
[17, 24, 106].  However no causative organism was identified in 14-60% of 
patients in studies specifically considering aetiology of pneumonia [17, 26, 92, 
107], despite invasive respiratory sampling.  Age over 70 was found to be 
associated with unknown aetiology of CAP despite adequate respiratory 
sampling, along with cardiac and renal comorbidity and non-alveloar infiltrates 
on chest radiography in one study [92].  In clinical practice in the UK, sputum 
samples are more routinely sent for analysis, and invasive respiratory sampling 
is rare unless patients are undergoing mechanical ventilation.  However in a 
study of 73 patients over age 65 with CAP, 37% could not spontaneously 
produce sputum [14].  The sputum sample may contain a mix of material from 
upper and lower respiratory tracts as well as the mouth, and may not reflect the 
infecting organism from the lung [108].   
Both diagnosis and treatment of HAP are more difficult without a positive 
microbiological culture, particularly in patients who do not get better after 
initial therapy.  In the Eole study, 62% of patients needed a change in antibiotic 
therapy, and of these, 33%were because of persistent infection not responding 
to treatment, and 34% due to the organism being resistant to antibiotic therapy 
[26].   Inadequate treatment of HAP in non-ventilated patients may account in 
part for its high mortality.   
1.4 Risk factors for HAP  
Otherwise “healthy” hospital patients do not generally develop HAP; it is a 
disease of the compromised patient.  Pneumonia overall affects those at the 
extremes of ages, pointing to a common immunological explanation for 
infection.  Few studies investigating the occurrence of HAP in patients with 
lower limb fracture have been undertaken. Therefore observational studies 
from both older patients and patients exposed to surgery were considered in 
order to extrapolate risk factors which might be pertinent to older patients with 
lower limb fracture.  Observational studies of HAP in older persons are 
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summarised in Table 4, and these and other potential risk factors are discussed 
below, and risk factors in surgical patients are summarised in Table 5 and 
discussed in 1.4.10. 
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Table 4. Observational studies of HAP in older patients 
Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Terpenning 
et al. 2001 
[101] 
 
358 Veterans 
from inpatient, 
outpatient and 
day centre 
attendees 
 
 
14% (AP) 
 
S. aureus in saliva                                 (OR=8.3) 
Needing help with feeding                (OR=4.7) 
COPD                                                    (OR= 2.5) 
Retrospective diagnosis of AP by expert 
panel opinion (pulmonary physician) after 
ten years. 
 
 
Michel et al. 
1991 [53]  
1919 French 
and Swiss 
geriatric 
hospital in-
patients 
 
 
5% (HAP) Swallowing disorders                        (OR= 5.74) 
Chronic bronchitis                              (OR 5.00) 
Intravenous catheter                           (OR=5.49)  
Urethral catheter                                 (OR=3.33)  
Nutrition abnormalities                      (OR=3.18) 
One day prevalence study 
Rothan-
Tondeur et 
al. 2003 [70] 
2142 French 
geriatric 
hospital in-
patients 
4% (HAP) HAP in previous 6 months                (OR=4.5) 
Oxygen therapy                                (OR=16.15) 
Low albumin level                            (OR=4.81) 
Recent antibiotic therapy                  (OR=3.20) 
 
Case control study 
Mortality 12.2% at 30 days 
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Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Merchant et 
al. 1998 [54] 
 
1886 patients 
Bombay 
hospital, India 
 
1% (HAP) Age over 50                                         (OR=4.49) 
GCS < 8                                                (OR=10.5) 
Tracheostomy                                     (OR=30.28) 
Nasogastric tube feeding               (OR=75.5) 
Histamine 2 receptor antagonists (OR=19.1) 
 
88% mortality 
Includes medical ICU patients and general 
ward patients 
Harkness et 
al. 1990 [28] 
740 bed acute-
care hospital 
and 640-bed 
chronic disease 
hospital in 
New York 
State. 
 
1.7 per 
1000 days    
(acute care, 
HAP) 
 
 
 
 
 
0.74 per 
1000 days 
(long-term 
care, HAP) 
Neurologic disease                             (OR 4.4) 
Renal disease                                       (OR 10.0) 
Deteriorating health (acute)              (OR 2.7)                           
Decreased consciousness                   (OR 2.6) 
Disorientation                                      (OR 3.0) 
Aspiration                                            (OR 17.0) 
Difficulty with oral secretions           (OR 5.8) 
  
Deteriorating health (acute)              (OR 24) 
Malnourished appearance                 (OR 15) 
Recent weight change                         (OR 5.7) 
Decreased consciousness                    (OR 20) 
Disorientation                                      (OR 10.5) 
Agitation                                               (OR 120) 
Aspiration                                             (OR 130)  
Nasogastric tube                                  (OR 120) 
 
Case-control study, patients >age 65 
 
Using logistic regression, best predictors 
in acute care setting was difficulty with 
oropharyngeal secretions and nasogastric 
tube. 
 
 
In long term care setting was difficulty 
with oropharyngeal secretions, 
deteriorating health and occurrence of 
unusual event. 
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Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Quagirello 
et al.  
2005 [69] 
613 residents 
of nursing 
homes in 
Connecticut, 
US 
18% 
(NHAP) 
Inadequate oral care                           (HR=1.55) 
Swallowing difficulty                         (HR=1.61)  
Prospective study, radiographic 
pneumonia.  Inadequate oral care was 
defined as absence of dental examination. 
Swallowing difficulty was defined as 
cough during swallow. 
 
Hanson et 
al. 1992 [21]   
600-bed 
university 
hospital, North 
Carolina, US. 
 
N/A Albumin <3.0 g/dl                     (OR 14.7) 
Neuromuscular disease             (OR 24.8) 
Endotracheal intubation             (OR 5.2) 
Oropharyngeal colonisation present in 29% 
cases versus 3% controls (p<0.001) but samples 
taken in <50% cases. 
 
Case-control, prospective case 
acertainment. 
Cases over age 65 compared to cases 
between age 25 and 50. 
Did not distinguish aspiration pneumonia; 
large volume aspiration noted in 24% 
patients who developed HAP. 
     
Alvarez et 
al. 1988 [31] 
Nursing home 
care unit (61 
beds) and 
intermediate 
care unit (60 
and 59 beds) in 
Johnson City, 
Tennessee, US,  
1980 -1983. 
4 per 1000 
days  
(HAP and 
NHAP) 
Needs feeding                               p<0.01 
Urinary incontinence                    p<0.5 
Faecal incontinence                       p<0.5 
Unstable medical condition           p<0.5 
No pneumococcal vaccine             p<0.5 
Nasogastric feeding                       p<0.01 
Prevalence varied depending on unit 
studied 
Ward A 7.5% (unstable, mainly self-
caring) 
Ward B 14.5% (unstable, needing care) 
Ward C 2.4% (stable nursing home 
patients) 
 
Multiple sources for case finding 
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Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Celis et al. 
1988 [24] 
118 patients 
with HAP and 
120 controls in 
Spain 
 
N/A Tracheal intubation 
Depressed level of consciousness 
Thoracic or upper abdominal surgery 
Prior episode large volume aspiration 
Age over 70 
Case-control, mortality 36% 
Controls appear to be paediatric and 
neutropaenic patients with NP. 
Did not distinguish between AP, VAP and 
HAP.  
 
Redelmeier 
et al. [48] 
 
Clinical 
database 
review, 
Canada 
 
1% (HAP) 
 
No association with gastric acid suppression 
 
No microbiological parameters measured. 
Very large study over 16 years. 
Postoperative patients age>65 
Oliveira et 
al. 2011 
[109]  
 
46 cases, 165 
controls 
21.8% 
HAP/VAP 
Hypertension 
Stay greater than 5 days 
Not using dental floss or mouthwash 
Case control 
Mean age 41 
Van der 
Maarel-
Wierink et 
al.  [110] 
Meta-analysis AP Dyspahgia  (OR 9.84) Included 4 cohort studies, 1 case control, 1 
case cohort study. 
 
 
Vergis et al. 
[32] 
104 case 
controls pairs 
in long term 
care facility 
 
HAP Witnessed aspiration  (OR 13.9) 
Sedative medication   (OR 2.6) 
Comorbidity score      (OR 1.2) 
Mortality from HAP 23% after 14 days 
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Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Sellars et al. 
[67] 
412 Stroke 
patients 
18.9% 
HAP 
Age >65 
Dysarthria/aphasia 
Modified Rankin score >=4 
Abbreviated mental test score <8 
Failed swallow test 
 
 
 
Walter et al. 
[66] 
236 acute 
stroke patients 
admitted to 
neurointensive 
care 
 
 
22% 
VAP/HAP 
Dysphagia   (RR 9.92) 
National Institute for Health Stroke Score >=10 
(RR 6.57) 
Non lacunar basal ganglia infarction (RR 3.10) 
Other infection at admission (RR 3.78) 
 
Langmore 
et al. [68] 
102,842 
Nursing home 
patients, US 
3% NHAP Suctioning needed 
COPD, heart failure 
Feeding tube 
Bedfast, delirium 
Weight loss 
Swallowing problems 
Urinary tract infection 
Dependence for eating 
 
Univariate analysis only 
   
 
21 
 
Authors/year 
published 
Participants Incidence/ 
prevalence 
of 
pneumonia 
Significant associations (multivariate analysis 
reported where possible) 
Comments 
Langmore 
et al. [30] 
189 Clinic, 
ward and 
nursing home 
residents 
21.7%AP 
(NH=44%) 
All patients (no dental variables): 
Dependent for feeding or oral care 
Tube feeding 
Dentate patients only (n=101) 
Number of decayed teeth 
More than one medical diagnosis 
Dentate oral feeders only (n=90): 
Dependent for feeding 
Multiple medical diagnoses 
Pneumonia diagnosed by consensus 
panel, most weight given to chest 
radiograph 
AP significantly commoner in NH 
patients with 
radiologically/endoscopically confirmed 
dysphagia, and in ward patients with 
prior tube feeding. 
 
 
ACE- inhibitor= Angiotensin converting enzyme inhibitor, AP=Aspiration pneumonia, HAP=Hospital acquired pneumonia, OR=Odds 
ratio, HR= Hazards ratio, NHAP= Nursing home acquired pneumonia, COPD= Chronic obstructive pulmonary disease, NH= Nursing 
home 
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1.4.1 Age and gender 
Age over 65 or 70 years has been consistently found to be a risk factor for HAP 
[24, 48, 54, 67, 81, 111] and one study found that  people over the age of 65 were 
twice as likely to develop HAP compared to younger people aged 25-50 [28].  
Importantly, older patients are more likely to die [24, 111], and less likely to 
regain pre-morbid functional status at discharge than their younger 
counterparts after HCAI [80], leading to change of residence at discharge, or 
loss of independent living.  Impaired neutrophil chemotaxis, declining IgM 
activity and production of naïve B cells, and impaired memory T cell formation 
may be contributing factors [112-114], however it is not yet well understood 
how immunosenescence contributes to the development HAP.  Interestingly, 
risk factors for HAP in older people appear similar to those in younger persons 
[28].  HAP appears to occur more frequently in males [50, 71, 115] for reasons 
which are unknown.   
1.4.2 Mechanical ventilation 
Mechanical ventilation is one the most important risk factors for developing 
pneumonia [24, 54], and intensive care units are the commonest location for 
pneumonias to occur in England [20], with incidences of VAP quoted at 8-36% 
[40, 116, 117].  Mortality may exceed 50% [116].  During mechanical ventilation, 
the presence of the endotracheal tube means both patients’ mouths and tracheas 
are open, allowing continual access of microorganisms to the lungs.  The tube 
itself also becomes colonised with bacteria which produce and reside within a 
biofilm [118].  While the risk of contracting HAP while undergoing mechanical 
ventilation  is high,  non-ventilated patients who acquire HAP on hospital 
wards represent over 75% of the total group who develop pneumonia in 
hospital [10, 119].   
1.4.3 Chronic obstructive pulmonary disease (COPD) 
Patients with COPD are more likely to develop community acquired 
pneumonia [120] and HAP [30, 53, 61, 102, 121].   The exact pathophysiological 
mechanism is unknown, but is likely to be related to persistent bacterial 
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presence in the lungs and impaired host immune function in patients with 
COPD [122].  Oral colonisation with opportunistic respiratory pathogens 
increases as COPD severity increases [38].  In addition, the TORCH and 
INSPIRE studies, which recruited large cohorts of COPD patients, showed that 
the use of inhaled corticosteroids such as fluticasone was associated with a 
higher risk of pneumonia despite reducing exacerbations [123, 124].   While 
pneumonia was not a predefined endpoint in the larger TORCH study, risk 
factors for pneumonia included increased age, more severe COPD, any 
exacerbation of COPD in the year preceding the study, lower body mass index 
and worse Medical Research Council (MRC) dyspnoea score.  Interestingly 
smoking status (current versus ex) did not influence incidence of pneumonia in 
this group, in contrast with results from other studies of HAP [59, 61-63], which 
may have been because the prevalence of smoking was high overall in the 
cohorts. 
1.4.4 Proton pump inhibitors (PPI) and bacterial overgrowth 
Several studies have suggested that gastric acid suppression may be associated 
with HAP [125, 126] via bacterial overgrowth.  Bacterial overgrowth (measured 
by counting bacteria per ml of gastric fluid) is commoner in those taking PPIs 
[127], and appears to be inversely proportional to gastric pH [127, 128].  The 
bacteria cultured were mainly oral bacteria (Streptococci, Staphylococci, 
Neisseriae) as well as E. coli, Lactobacilli and Aeromonads.   However a large 
Canadian database study refuted the association between HAP and PPI via a 
population-wide case control study using a large healthcare database [48].  
Redelmeier et al. also concluded that bacterial colonisation may be a less 
important risk factor than hypoalbuminaemia, and nasogastric tube placement 
(amongst other factors), because gastric acid suppression was not found to be 
associated with HAP.  However several of the potential risk factors found to be 
associated with pneumonia are also risk factors for bacterial colonisation, and 
no microbiological parameters were examined in this study.   
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1.4.5 Reduced level of consciousness and microaspiration  
Decreased level of consciousness and disorientation have been noted previously 
as risk factors for HAP [24, 28, 54], and use of antipsychotic drugs (which can 
cause both of these signs) has also been found to increase admissions to hospital 
with both pneumonia and hip fracture [129].  A common underlying 
mechanism to these risk factors may be microaspiration.  Microaspiration or 
silent aspiration can occur during sleep in those with certain patterns of stroke 
[130] and occurs in a proportion of older patients with CAP [102].  Nakagawa et 
al. [130] attached a radio-labelled paste to the inner surface of participants’ teeth 
which melted over a night.  The participant’s thorax was scanned the following 
day and the radiolabel was detected lateral to the midline in the thorax 
demonstrating the occurrence of aspiration.  Silent aspiration (as evidenced by 
radiolabelled material) also occurs commonly in healthy people during sleep 
[131, 132] and is therefore likely to occur at other times of reduced 
consciousness such as hypoactive delirium or anaesthetic.   
1.4.6 Dysphagia, nasogastric tubes and dependence on others for feeding and 
oral care 
Dysphagia [53, 66, 69, 110] and aspiration [24, 28, 32] have been found to be 
important risk factors for HAP, the former probably because of the increased 
risk of the latter.  Odds ratios for aspiration and dysphagia are consistently high 
in observational studies (see Table 4).  Other proxies for aspiration and 
dysphagia may include the presence of a nasogastric tube for feeding, and 
dependence on others for oral care and feeding, and HAP has been associated 
with all of these factors  [21, 28, 29].  Nasogastric tubes inserted for feeding put 
patients at greater risk of HAP both because of underlying dysphagia (and 
consequent aspiration risk) [110] and by being a source of respiratory 
commensal pathogens (especially P. aeruginosa, and K. pneumoniae) [133, 134].  
Biofilms form on nasogastric tubes within 24 hours of insertion [135], and the 
colonised tube is situated in close proximity to the entrance to the trachea.  Oral 
flora is also altered by enteral feeding tubes to include organisms such as 
Corynebacteria, Peptostreptococci and Fusobacteria more commonly [136].     
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1.4.7 Gastro-oesophageal reflux 
Gastro-oesophageal reflux has also been associated with histological changes in 
the lungs of rats [137], and could play a role in the development of HAP.  
Indeed, gastro-oesophageal reflux of gastric contents colonised with respiratory 
pathogens is one of the proposed mechanisms for the development of VAP, and 
selective gut decontamination has been found to reduce rates of VAP [138], 
though oropharygeal colonisation may be a more important route of 
transmission [40]. However a study of 189 clinic, ward and nursing home 
patients suggested that nuclear scintigraphy confirmed gastro-oesophageal 
reflux was commoner in patients who did not develop pneumonia [30], and 
further work is needed in this area in non-ventilated patients. 
1.4.8 Colonisation with respiratory commensal pathogens at sites proximal 
to the lungs 
Culture based techniques have been used to link HAP with presence of 
respiratory commensal pathogens in both oro-pharyngeal [21], salivary (S. 
aureus only) [29] and bronchial samples [33] in non-ventilated patients in 
longitudinal studies.  Studies in ventilated patients also found that nosocomial 
infection was commoner in patients with colonised dental plaque [42], or 
oropharyngeal samples [40].  Identical organisms were found in 
bronchoalveolar lavage samples and dental plaque from 8/14 patients with 
VAP [139] using pulsed-field gel electrophoresis.  In a similar study, Heo et al. 
found genetic similarities (>95%) between bacteria found in dental plaque and 
those from bronchoalveolar lavage in 30 ICU patients suspected of having VAP 
[140].  A range of infecting pathogens were identified in the above studies 
including S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa, H. influenzae and 
Morhaxhella cattarhalis.  Studies predominantly classified patients into 
“colonised” or “uncolonised” groups rather than considering the influence of 
acquisition versus colonisation, and this may also be important in determining 
risk of HAP. 
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1.4.9 Dental risk factors 
Number of teeth and number of decayed teeth were identified as risk factors for 
aspiration pneumonia (AP) in dentate patients only in two studies [29, 30].  In 
addition, Terpenning et al. identified that AP was associated with S. aureus in 
saliva and P. gingivalis in dental plaque.  Few of the other studies above 
investigated dental risk factors.  However one study investigating nosocomial 
infection in ventilated patients found associations with caries and colonised 
dental plaque (mainly with aerobic gram negative bacilli) [42].    These findings 
suggest that HAP may be associated with dental factors, but further research is 
needed. 
1.4.10 Risk factors associated with surgery 
Post-surgical patients have additional risk factors for HAP, including pain 
preventing both adequate expansion of the lungs and adequate cough, 
anaesthesia with endotracheal intubation, and potential post-surgical 
complications local to the site of operation.  Observational studies of post-
operative patients are summarised in Table 5.  The commonest risk factors 
identified in surgical patients include blood transfusion [22, 50, 55, 57, 64, 65], 
nasogastric tube insertion [48, 55, 56, 58], duration of anaesthetic or surgery [48, 
56, 58, 59], and hypoalbuminaemia [48, 59, 141].  Other risk factors identified 
were pain or increased dose of opiates [22, 33] and cough or presence of sputum 
pre-operatively [56, 58].  Nasogastric tubes are usually inserted peri-operatively 
to manage ileus, vomiting or bowel obstruction rather than feeding, and this 
suggests that nasogastric tubes are a risk factor for HAP independent of the 
patient’s ability to swallow.  Redelmeier et al. conducted a highly 
comprehensive cohort study from a large Canadian database of post operative 
patients, and found that the risk factor with highest odds ratio was post-
operative hypoalbuminaemia (odds ratio 5.74) [48].   Thoracic surgery and 
nasogastric tube insertion were the next most important risk factors (odds ratio 
2.72 and 1.24 respectively).  Unfortunately, they did not investigate blood 
transfusion as a risk factor, which appears to be one of the more important risk 
factors identified.  It is unclear whether peri-operative blood loss or transfusion 
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itself is important, though renal ischaemia-reperfusion injury in mice has been 
shown to induce lung inflammation, without blood product transfusion [142].
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Table 5. Summary of observational studies investigating post-operative pneumonia 
Authors Type of surgery Study type Sample size Significant risk factors  Notes 
Garcia-Alvarez et 
al. 
2010 [50] 
 Thompson’s 
hemi-
arthoplasty for 
hip fracture 
Prospective 208 Blood transfusion                             
Male sex                                              
Fever during admission                   
Died within 1 year of study  
Time to operation           
9% (HAP) 
Redelmeier et al. 
2010 [48] 
All, >age 65 Retrospective 
cohort 
593,265 Low albumin 
Thoracic surgery 
Nasogastric tube 
HAP 1% incidence 
Lead-Noval et al. 
[55].  
 
Cardiac  Case control Cases n=42, 
controls 
n=90 
Reintubation, nasogastric tube, > 
4units blood transfused, empirical 
broad spectrum antibiotics used 
13.3% HAP 
polymicrobial, 77.3% of 
bacteria isolated were 
gram negative rods. 
El Solh et al. [22] 
 
Cardiac Case control 73 case 
control pairs 
Charlson index >2, reintubation, 
transfusion more than 4 units blood, 
mean daily dose of morphine 
 
Mean time to pneumonia 
7.2 +-4.9 days 
Belda et al. [33] 
 
Lung cancer  Cohort N=78 Higher postoperative pain, 
colonisation with potential respiratory 
microorganisms 
 
31% incidence 
pneumonia 
McAlister et al. 
[56] 
 
Elective non-
thoracic  
Cohort N=1055 Age over 65 
Positive cough test*, perioperative 
nasogastric tube, duration of 
anaesthesia >2.5 hours 
 
2.7% had postoperative 
pulmonary complication 
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Authors Type of surgery Study type Sample size Significant risk factors  Notes 
Mohri et al. [57] 
 
Gastric cancer  Cohort N=529 Male gender, blood transfusion HAP in 3.6% 
Mitchell [58] et al. 
 
Elective non-
thoracic 
Cohort N=148 Nasogastric tube placement, longer 
duration of anaesthetic, preoperative 
sputum production 
 
Postoperative pulmonary 
complication in 11% 
Garibaldi et al.  
1981 [59] 
Elective 
thoracic/ 
abdominal  
Prospective N=520 
 
Low albumin 
High American Society of 
Anaesthetists score 
Smoking history 
Longer preoperative stay 
Longer duration of operation 
Thoracic or upper abdominal surgery 
Incidence 17.5% 
Classified pneumonia 
into 3 classes 1= good 
diagnosis with positive 
microbiology, 2= good 
diagnosis with no 
microbiology or 3= 
features suggestive of 
HAP 
Daily monitoring for 5 
days after operation but 
no mention of further 
follow up 
Dilworth et al. 
[43] 
Upper 
abdominal 
 N=127 Smokers 
H. influenzae on pre-operative 
oropharyngeal sample 
Incidence 4% 
Lee et al. 2011 
[64] 
Lung cancer  N=417 Blood transfusion     (OR 4.67) 
Age >70                      (OR 3.56) 
Other complication  (OR 3.03) 
Obstructive airways  (OR 3.90) 
Incidence 6.2% 
Mortality 27% 
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Authors Type of surgery Study type Sample size Significant risk factors  Notes 
Blank et al. 2011 
[65] 
Pneumonectomy  N=129 Transfusion of blood product (OR 
1.47) 
Incidence 21% 
Riera et al. 2010 
[60] 
Cardiac surgery  N=1600 Left ventricular ejection fraction <30% 
Chronic renal impairment 
Urgent surgery 
Incidence 1.2% 
Mortality 42% in HAP 
patients 
Semi-quantitative 
endotracheal tube 
aspirates used 
Agostini et al. 
2010 [61] 
Thoracic surgery  N=234 Body mass index >30 
Smoking history 
COPD 
Age >75 
ASA score >3 
14.5% incidence 
Tsubosa et al. 
2010 [62] 
Eosophagectomy  N=191 No significant risk factors found Incidence 10%, even after 
oral care, chest 
physiotherapy, 
rehabilitation for 
swallowing disorders 
Huang et al. 2010 
[141] 
Gastroinestinal   N= 215 Albumin                   (OR 0.27) 
Physical disability   (OR 3.8) 
10 year study- few 
patients 
*Cough test is defined as patient taking deep breath and coughing once- any further coughing is deemed a positive test 
COPD= Chronic Obstructive Pulmonary disease, ASA= American College of Anaesthesiologists
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1.4.11 Putative risk factors for HAP in patients with lower limb fracture 
 Based on the findings above, important risk factors for older patients with 
lower limb fracture might include the presence of nasogastric tube, blood 
transfusion, COPD, aspiration, oral colonisation with respiratory pathogens, 
dental factors, duration of anaesthetic, reduced conscious level or disorientation 
and pain or analgesia use.  Of these, colonisation with respiratory pathogens 
and dental factors are potentially the most amenable to modification.  Reducing 
the bioburden in the oral cavity could be a potential method of preventing 
pneumonia in older patients prone to aspiration.  Given that HAP is the second 
commonest complication after hip fracture and nearly half of these patients 
die[23], preventing HAP may have an important impact on survival after hip 
fracture. 
1.5 Literature search strategy 
In order to investigate what was known about the significance of oral 
colonisation with respiratory commensal pathogens and dental factors in the 
development of HAP, a literature search was conducted using Medline 1950-
2010 and EMBASE 1980-2010.  The search strategy “Nosocomial pneumonia” 
OR “Pneumonia AND Cross-infection” OR “nursing home acquired 
pneumonia” or “hospital acquired pneumonia” was used.  Aspiration 
pneumonia was not specifically included in the search strategy, however 
relevant papers retrieved relating to aspiration pneumonia were considered.  
Studies conducted on patients in both hospitals and nursing homes were 
retrieved.  A further search of the same databases was conducted using a 
variety of terms including “potential respiratory pathogens in the mouth” and 
“aerobic gram negative bacteria”, “respiratory commensal pathogens”, 
“oropharyngeal colonisation”, “Oral microbiota”, “Oral microbiome” and the 
MESH terms “gram negative bacteria” and “gram negative bacterial infections”.  
Extensive iterative bibliography searching of retrieved papers was also 
undertaken.  Regular email alerts were established in June 2009 using key 
words “pneumonia” and “nosocomial pneumonia” in Ovid and Scopus 
 32 
 
respectively, and a citation alert for a key paper [86] was set up. The literature 
search was initially carried out in June 2009, updated in October 2011 and 
updated again in October 2012. 
1.5.1 Observational studies investigating oral colonisation with respiratory 
commensal pathogens 
Next generation sequencing techniques have revealed that the core or normal 
oral flora of adults is composed predominantly of 13 phyla including 
Acintobacteria, Bacteroidetes, Firmicutes, Chloroflexi, Tenericutes, 
Fusobacteria, Proteobacteria, Spichochaetes, Synergisteles, and two unnamed 
phyla [143].  While respiratory commensal pathogens (e.g. E. coli, P. aeruginosa) 
are identified in a percentage of “healthy” adults (Table 6), they are not 
commonly identified in studies of the normal oral flora [144].  Persons in whom 
these organisms were detected were not obviously unwell and therefore 
carriage was assumed to be asymptomatic.  However, in certain groups of 
patients (E.g those on intensive care), it has been shown that oral carriage of 
commensal pathogens is related to subsequent nosocomial infection with the 
same organisms [42].  It is hypothesised that the same mechanism also occurs in 
hospital patients not on intensive care and those in nursing homes or even 
community dwelling patients. The term ”commensal pathogen” has previously 
been coined in relation to S. pneumoniae which can cause disease in otherwise 
healthy persons but may also be carried asymptomatically [34].  It should also 
be noted that the terms colonization and carriage are used interchangably in 
this work, and assume that an organism has adhered to and multipled on the 
mucosa.  Given that the mouth is essentially open (via the nasopharynx), 
repeated transient acquisition may occur rather than colonization in senso 
strictu.   
The prevalence of oral aerobic gram negative bacilli (AGNB), including H. 
influenzae, P. aeruginosa, E. coli, and other coliforms, and A. baumannii, has been 
investigated in a variety of observational studies (Table 6).  These organisms 
appear to occur more commonly in those who are more unwell, and those who 
are fed via nasogastric tube.  An important study of healthy volunteers showed 
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that counts of gargled E. coli, K. pneumoniae and Proteus mirabilis reduced 
rapidly within three hours, even when using piliated E. coli [145].  Counts fell 
most rapidly at the buccal surface and least rapidly on the tongue.  These data 
imply that healthy humans are able to clear these bacteria from their mouths.  It 
is difficult to compare results between studies in Table 6 as both sampling sites 
and microbiological techniques vary (e.g. whether enrichment culture was 
used) leading to a wide variation in rates of both acquisition and 
colonisation/carriage.  In addition, some of the variation may be explained 
because investigators were testing for several bacteria rather than a single 
bacterium.  Mobbs et al. summarised results from 45 studies investigating 
AGNB in healthy volunteers dating back to 1921 and found rates of up to 61% 
[35].  Again, different sampling techniques such as swabs, oral rinses and saliva 
samples were used in different studies.  Most of these 45 studies did not 
distinguish between acquisition and carriage which may have led to the high 
incidence of colonisation in some groups.  The effects of diurnal variation, prior 
food or drinks and sleep on colonisation and acquisition of AGNB is unknown, 
and may also explain some of the variation seen.   
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Table 6. Observational studies of oral acquisition or colonisation with Gram negative bacilli 
Population/setting Sample 
size 
Sampling technique; 
frequency 
Prevalence in healthy 
controls  
Prevalence in patients Acquisition (A) or 
colonisation (C) 
Hospital patients, varying types, 
hospital workers, fire fighters[36] 
253 Area sampling 
device; 1 sample 
0-2% Orthopaedic 16%  
Moribund 57% 
A 
Nurses, medical students and 
laboratory staff[35] 
120 Oral rinse (n=2), 
two days apart  
Colonisation 6% 
Acquisition 35.8%  
N/A Both 
COPD patients[38] 40 Oral rinse (n=2), 
two days apart 
N/A Mild 0%  
Moderate  7.7% 
Severe 29.7% 
 
C 
Hospital patients and after 
discharge[146] 
183 ICU  
228  
general 
ward 
Oropharyngeal 
swabs 
N/A Admission 1.1% 
7 days 3.4% 
Discharge 12.4% 
1 month after 
discharge 19.4% 
3 months after 
discharge 20% 
 
A 
Medical admission ward 
patients[41] 
28 Palatal swabs N/A 43% A 
Older chronic care facility patients 
and controls (dental 
outpatient)[147] 
28 (30 
controls) 
Dental plaque 0% (>1% cultivable 
flora) 
14.3% A 
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Population/setting Sample 
size 
Sampling technique; 
frequency 
Prevalence in healthy 
controls  
Prevalence in patients Acquisition (A) or 
colonisation (C) 
Male residents of two long term 
care wards [148]  
68 Pharyngeal swabs 37-43% (three 
samples) 
N/A A 
Nasogastric fed patients, PEG 
patients and orally fed patients 
from nursing and skilled nursing 
facilities [149] 
215 Oropharyngeal 
sample 
N/A NG fed 81%* 
PEG fed 51% 
Orally fed  17% 
A 
Older patients in long term care, 
NG fed or orally fed[134] 
90 Saliva N/A NG 73% 
Orally fed 13% 
A 
Patients waiting in hospital for 
cardiac revascularisation [150] 
30 Saliva and dental 
plaque 
N/A P. aeruginosa in dental 
plaque 12% 
Acinetobacter spp 
63% Saliva 
59% Dental plaque 
A 
Older adults needing nursing care 
Healthy older adults 
Healthy adults <20 [151] 
 
54, 21,22                           Oral rinse S. pneumoniae 76% 
Staphylococcal sp. 
24% 
MRSA 0% 
P. aeruginosa 4.8% 
C. albicans 66% 
S. pneumoniae 63% 
Staphylococcal sp. 
37% 
MRSA 14.8% 
P. aeruginosa 5.6% 
C. albicans  66.7% 
A 
 COPD= Combined obstructive pulmonary disease    PEG= Percutaneous endoscopic gastrostomy NG=Nasogastric 
*Also tested for S. aureus
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1.5.2 Respiratory commensal pathogens and oral or dental factors  
A number of studies have investigated the relationship between respiratory 
tract infection and dental factors such as plaque, caries, and periodontitis.  
Unfortunately, it is difficult to synthesise the results from these studies into a 
coherent picture to explain the relationships between these variables because of 
inconsistent results and varying endpoints.  Dentate persons appear to have 
higher rates of respiratory infection [44, 86], and AP appears to be associated 
with increased tooth number in dentate patients [29].  One study found similar 
rates of pneumonia in dentate versus edentulous (no remaining dentition) 
patients, though rates in the latter were lower [152]. However, other studies 
either found no relationship with tooth number [152], or have not reported the 
relationship between HAP and number of teeth [30, 42], inferring that no 
relationship was found.  Edentulous patients were more likely to be colonised 
with S. pneumoniae, MRSA or C. albicans in one study[152], but samples were 
taken from buccal mucosa in edentulous patients and form dental plaque in 
dentate patients, which may explain this finding.  AP has been associated both 
with number of decayed teeth [29, 30], and salivary S. sobrinus [29] in dentate 
patients.  Nosocomial infections in ICU patients have also been associated with 
caries [42]. In contrast, presence of respiratory pathogens was not associated 
with number of teeth [37, 147] or caries [37] in other studies.   
Respiratory tract infections have been associated with heavier dental plaque 
deposits [44, 45] and with presence of respiratory commensal pathogens in 
dental plaque [147].  However, no relationship was found between presence of 
respiratory commensal pathogens in dental plaque and heavier dental plaque 
[42, 153]. Aspiration pneumonia has also been shown to be associated with P. 
gingivalis in dental plaque, and diabetes mellitus in dentate persons [29], but 
was not associated with increased gingival bleeding index.  Presence of 
respiratory commensal pathogens in community dwelling older Japanese 
persons was associated with positive occult salivary blood [37].  In persons with 
learning difficulties, pneumonia was associated with an increased Oral 
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Assessment Guide (OAG) score, with individual components of “tongue” and 
“swallow” being significantly higher, and “gingiva” trending towards 
significance in those with pneumonia [152].  However, few studies have 
included measures of gingival health, and it is difficult to draw conclusions 
because of this.   
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Table 7. Observational studies linking pneumonia or  presence of respiratory 
pathogens in oral cavity with dental factors 
Setting Sample 
size 
Findings 
Clinic, ward and 
institution, US 
[29] 
357 AP in dentate patients associated with:  
Number of teeth, number of decayed units, S. 
sobrinus in saliva, P. gingivalis in dental plaque, 
diabetes mellitus, periodontal disease. 
 
Clinic, ward and 
nursing home 
patients, US [30] 
189 AP associated with number of decayed teeth and 
multiple medical diagnoses in dentate patients.  
No link with xerostomia. 
Patients with 
learning 
difficulties  
63 Pneumonia associated with microorganisms ( S. 
pneumoniae, MRSA, P. melaninogenica, C. albicans 
by PCR) at baseline, worse OAG score, increased 
age and enteral feeding.  Only OAG score 
associated in multivariate analysis (OR 1.6). No 
patient had caries.  
Nursing home, 
Switzerland [44] 
302 Respiratory tract infection associated with being 
dentate or needing to visit the dentist in 
emergency.   
Dentate patients with RTI had significantly higher 
plaque scores.  
ICU patients, 
France [42] 
57 Dental plaque increased (non-significantly) over 
time in ICU.   
High caries score (but not plaque score) 
associated with nosocomial infection.   
No correlation between plaque score and caries 
score.   
No correlation between plaque colonisation and 
plaque score.   
Dental plaque colonisation with AGNB but not S. 
aureus associated with subsequent infection.  
Plaque colonisation at day 5 associated with 
subsequent nosocomial infection (RR 9.6) 
 
ICU patients, US 
[153] 
34 Colonisation with respiratory pathogens (MRSA, 
P. aeruginosa, AGNB) in 22/34 patients was 
associated with antibiotic therapy but not with 
increased dental plaque score or illness severity. 
Independent 
living patients, 
Japan [37] 
265 Opportunistic respiratory pathogens (P. 
aeruginosa, S. marcescens, K. pneumoniae,C. 
albicans) detected by culture of single tongue 
sample more common if occult blood in saliva 
and increased age. 
No association with salivary flow (stimulated or 
unstimulated), caries, denture wearing or salivary 
pH. 
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Setting Sample 
size 
Findings 
Nursing home, 
US [147]  
28 Colonisation with S. aureus, E. cloacae, P. 
aeruginosa, K. pneumoniae or E. coli in 7/28, >1% of 
aerobic flora in 4/28.   
Cultures of dental and denture plaque, and buccal 
mucosa samples. 
Presence of respiratory organisms commoner if 
high plaque score or COPD, no difference in 
number of teeth or if dentures present. 
 
Institutionalised 
and long term 
hospitalised 
patients, Japan 
[154] 
343 HAP associated with Clusters C and D 
(Prevotella, Treponema, Veillonella) compared 
with cluster A (Streptococcus) detected by 
Terminal Restriction Fragment length 
polymorphism 
Nursing home 
residents, health 
older and 
younger adults, 
Japan [151] 
54,21,22 Higher Staphylococcal species but lower P. 
aeruginosa seen in those with poorer oral hygiene.  
Professional oral hygiene only reduced C. 
albicans significantly. 
Nursing home 
residents, Japan 
[155] 
71 Pneumonia commoner in those with higher 
tongue plaque. 
Higher salivary bacterial counts seen in those 
with higher tongue plaque. 
Hospitalised 
patients awaiting 
cardiac 
revascularisation 
[150] 
30 P. aeruginosa commoner in patients with <14 teeth 
Co-colonisation of P. aeruginosa and Acinetobacter 
spp. observed 
RTI= respiratory tract infection, ICU=Intensive Care Unit, AGNB=Aerobic 
gram negative bacilli, RR=relative risk, COPD= Chronic obstructive pulmonary 
disease, OAG= Oral assessment guide 
Despite the contradictory and incomplete nature of the above findings, it does 
appear that there is a relationship between respiratory tract infection and oral 
health, but the relationship may be indirect and complex.  These findings have 
led some authors to hypothesise that dental plaque may be a stable reservoir of 
respiratory commensal pathogens, and that removal of plaque [47, 156-161] or 
disinfection of the oral surfaces might reduce the risk of respiratory infection.  
A number of oral hygiene intervention studies have been undertaken in 
ventilated and non-ventilated persons, and are described below. 
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1.5.3 Intervention trials to prevent HAP, VAP and AP 
A summary of studies investigating oral hygiene interventions to prevent HAP 
are shown in Table 8.  The majority of trials took place in Japan and contained 
small numbers of patients.  Successful intervention trials in non-ventilated 
persons all included weekly dental hygienist attention, and interestingly there 
appeared to be a cumulative benefit over a number of months of professional 
oral hygiene [162].  Interventions took place over 2 years in successful studies in 
nursing home patients, and it was noted that no benefit was seen at six months 
[162], possibly due to temporal spacing in the occurrence of pneumonias, or 
because of cumulative effects of oral care.  It has been noted that patients being 
uncooperative is one of the major difficulties in undertaking mechanical oral 
hygiene interventions in older people, and use of chlorhexidine may be more 
acceptable to older patients with challenging behaviour [163].  However, 
Bourigault et al. did not find a reduction in NHAP after tooth-brushing three 
times daily and use of chlorhexidine mouthwash (though frequency of use was 
unspecified) [164].  The majority of studies have used 0.12% chlorhexidine 
solution or 0.2% topical chlorhexidine, though some trials in ventilated persons 
have used 2% chlorhexidine solution to good effect, but one noted a 10% 
incidence of oral mucosal irritation [165]. 
Several groups have found strong relationships between VAP and prior 
presence of potentially pathogenic oral bacteria [40, 42].  Intervention studies 
conducted in ventilated patients have had mixed results, with some initial 
successful studies using chlorhexidine [166-169] or decontamination with 
topical antibiotic therapy [170], followed by several studies which did not show 
significantly reduced  rates of VAP.  In two such unsuccessful trials, P. 
aeruginosa, A. baumannii [171, 172] and MRSA [172] were not eradicated by 
chlorhexidine which was the main intervention.  A meta-analysis in 2006 was 
unable to show that use of chlorhexidine reduced VAP [173].  However several 
more recent meta-analyses have revealed reductions in the incidence of VAP 
from using antiseptic decontamination with chlorhexidine [165, 174-177] or 
topical antibiotic therapy [176], though no reduction in mortality was seen [116, 
176].  
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Several systematic reviews investigated interventions other than oral hygiene to 
prevent AP (though definitions are very similar to HAP).  These have included 
studies investigating pharmacological methods [178, 179], and interventions to 
reduce aspiration [178].  However none of the methods (which included use of 
anti-thrombotic agents, amantadine, and feeding programmes) could be 
recommended.  The anti-thrombotic agent, cilastazol, was found to be effective 
in preventing AP but caused bleeding which outweighed the benefits.   The 
authors concluded that the studies retrieved were too few and of too poor 
quality to make robust conclusions. 
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Table 8. Summary of oral hygiene intervention trials to prevent HAP in non-ventilated persons 
Setting Study type N control: N 
intervention                
Intervention Findings Quality issues 
Nursing home, Japan 
[86]  
Randomised 182:184 Brushing teeth, tongue and buccal 
mucosa without dentifrice after each 
meal plus 1% povidone iodine in 
some.  Weekly hygienist 
intervention. 
Significant reduction 
in pneumonia (RR 
1.67) and febrile days 
51 patients 
excluded as died 
from other causes 
Nursing home, Japan 
[180] 
Crossover 21:25 Daily oral care from dentist and 
hygienist, povidone iodine applied to 
mouth after each meal 
No reduction in 
febrile days 
Small sample, 
pneumonia not an 
endpoint 
Nursing home, US 
[181] 
Non- 
randomised 
65:78 Nursing assistant providing oral 
hygiene care- toothbrushing, 
antiseptic mouthwash (unspecified), 
oral and denture cleaning in 
edentulous, dilute hydrogen 
peroxide used in patients with 
decreased conscious level with 30º 
head up. 
Incidence of 
pneumonia same.  
With adjustment for 
comorbidity and 
frailty, death in 
control group higher 
OR 3.57 
Intervention group 
significantly more 
dependent and 
cognitively 
impaired at 
baseline 
Nursing home 
residents, Japan [182] 
[183] 
Randomised 48:40 Professional oral hygiene care by 
dental hygienist including electric 
toothbrushing (with water supply), 
sponge brush and interdental brush 
to clean teeth, buccal mucosa, tongue 
and dentures.  Normal care was 
sponge brushing and denture 
cleaning 
 
Reduction in fever 
and fatal aspiration 
pneumonia. 
No significant 
reduction in 
Staphylococci or 
Pseudomonas sp. in 
oral care group 
No definition 
aspiration 
pneumonia, 
randomisation not 
described 
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Setting Study type N control: N 
intervention                
Intervention Findings Quality issues 
Gastrointestinal 
surgery patients, 
Japan [184]  
Randomised 15:15 Daily nurse led povidone iodine 
gargles (0.02%), toothbrushing, 
denture and tongue cleaning versus 
just iodine gargles in control group. 
No reduction in fever, 
significant reduction 
in number of patients 
with pulmonary rales 
heard.  Reduction in 
number of species of 
bacteria identified 
with oral care 
 
 
Pneumonia not 
measured as an 
endpoint.  Study 
underpowered 
Nursing home 
residents, Japan [162] 
Cluster 
randomised 
A n=62 
B n=59 
C n=41 
A= once weekly hygienist 6/12 
B=nil 2/12, weekly hygienist 3/12 
C= 0.35% povidone iodine gargles 
2/12, weekly hygienist 3/12 
No reduction in 
febrile days or 
aspiration pneumonia 
Significant reductions 
in bacterial species 
after hygienist 
intervention, 
cumulative over 6 
months. 
 
 
Small sample- 
pneumonia 
incidence 
compared to 
preceding 6/12 
during summer 
period 
Nursing home 
residents, Japan [185] 
   Reports findings from 
[151, 183] 
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Setting Study type N control: N 
intervention                
Intervention Findings Quality issues 
Maxillofacial surgery 
patients, Japan [186]  
Randomised 16:16 Electric toothbrush with 0.5% 
povidone iodine supply twice daily 
before and after surgery 
Reduction in 
Methicillin sensitive 
Staphylococcal 
species, H. influenzae 
and S. pneumoniae by 
oral care, but not 
MRSA or P. 
aeruginosa. 
No cases of 
pneumonia found 
Small study, not 
blinded 
Geriatric facility 
patients, France [164] 
Cluster 
randomised 
868:1645 Annual visit to dentist, brushing of 
teeth, mucosa and tongue 3 times 
daily, use of chlorhexidine 
mouthwash (unclear when) 
No significant 
difference between 
rates of first 
pneumonia or 
mortality 
Control group had 
higher mortality 
and higher 
incidence of first 
episode of HAP 
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1.5.4 The case for investigating HAP in relation to oral respiratory 
commensal pathogens and oral hygiene  
Although there is evidence that HAP may be preventable by improving oral 
hygiene, the body of evidence is limited and mainly of suboptimal quality.  The 
majority of oral hygiene intervention trials have not investigated oral bacteria 
or dental factors, which appear to be the most modifiable risk factors, as 
outcome measures.  Accurate data regarding the dynamics of oral colonization 
with opportunistic respiratory pathogens in hospital patients are currently 
lacking, and “dose” of organism may be important and has not been 
investigated [187].  Future intervention studies in older patients at risk of HAP 
are likely to be more robust if more information is known about some of these 
issues.   
However traditional bacterial culture requires a minimum of 48 hours for a 
reliable result, and relies on timely delivery of samples to the laboratory to 
detect viable organisms.  If the presence of certain oral bacteria were a 
biomarker of future risk of HAP, then more rapid testing would facilitate earlier 
intervention and theoretically prevent more disease.  In addition, non-viable 
organisms can be detected by molecular methods thus reducing false-negative 
results.  Many bacteria within the mouth are contained within biofilms and it is 
unclear how this may influence growth in laboratory conditions.   Detection 
rates appear to be higher using molecular methods such as PCR compared with 
culture in clinical studies of CAP [188-190], especially after antibiotic treatment 
has been started [191].  Therefore molecular methods of detecting oral 
organisms may be superior to culture for this purpose. 
1.6 Part 2 Molecular detection of respiratory commensal pathogens in the 
oral environment 
It has been estimated that 1ml of saliva contains 100 million bacterial cells [143], 
and a highly specific molecular assay is therefore required to avoid high levels 
of false positive results.  A variety of molecular assays could be used for the 
purpose of detecting a number of specific organisms from the oral cavity, such 
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as low density arrays [192, 193], PCR-luminex [194], and nested PCR [195]. 
However for logistical reasons, the real-time polymerase chain reaction (PCR) 
was most appropriate for this study, due to its availability in NHS and Health 
Protection Agency laboratories (because it is rapid, reliable, and quantitative, 
theoretically detecting a single copy of target DNA within a sample).   
1.6.1  The polymerase chain reaction 
The discovery of the PCR reaction was attributed to Kary Mullis in 1993 [196], 
and remains, with modifications, one of the most important and commonly 
used techniques in molecular biology [197]. PCR can be used to detect DNA in a 
range of samples, including clinical (e.g. blood or sputum) [198-202] or 
environmental (e.g. water) samples [203-205].  The concept of PCR is well 
established, and a summary of the reaction follows.  If a specific organism is 
sought, the investigator identifies DNA which is well conserved within that 
species, and not seen in other organisms by comparing DNA sequences from 
national databases.  Short single-strands of DNA complimentary to the regions 
flanking the double stranded target DNA are chosen and manufactured, and 
are known as primers.  One primer is designed to flank the target area on the 
sense strand of DNA, and one primer to flank the other side of the target DNA 
on the anti-sense strand.  The target DNA can then be amplified (or copied) 
using a heating block, the primers, and reagents which can synthesise new 
DNA.  Reagents used include Taq polymerase, magnesium sulphate and each 
of the four nucleotide bases (A, G, C, T) of which DNA is made.  Taq 
polymerase is a heat-stable enzyme whose function is to create new DNA 
polymers that are complimentary to a template strand of DNA using 
nucleotides in solution within a reaction.  The nucleotides incorporated into the 
new DNA polymer are complimentary to the nucleotides on the template 
strand.  During the PCR reaction, heat is used to anneal and denature double 
stranded DNA, in order to amplify target DNA sought within a sample.  When 
the temperature is elevated to 95°C, all double stranded DNA denatures.  As 
the temperature is lowered to 55°C, DNA is able to anneal once more, but 
primers may now anneal to any complimentary segments of target DNA.  As 
the temperature rises again to 65°C, the DNA remains annealed, and the Taq 
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polymerase actively extends the primers (and other DNA segments) where 
there is a complimentary strand using the nucleotides included in the reaction.  
This sequence of temperature changes is known as a cycle, and a standard PCR 
reaction comprises 40 cycles.  During each cycle, exponentially increasing 
numbers of copies of any target DNA present within the sample are generated.  
The final sample needs to be stained, and DNA products separated by gel 
electrophoresis and compared to known DNA products of different sizes under 
ultraviolet light.  Products of the anticipated base pair length are considered to 
be the target DNA sought.  Further analysis such as sequencing may be 
undertaken. 
1.6.2  Disadvantages of PCR 
Probably the greatest disadvantage of PCR is that the user chooses the target 
segment of gene to assay, and will be unaware of other organisms present 
within the sample.   Inappropriate choice of gene target could lead to false 
positive and negative results, via detection of other species or the exclusion of 
relevant target species.  Good sequence data is required for a number of strains 
of bacteria in order that primers can be designed confidently.  GenBank and 
EMBL are the US and European banks of DNA sequences respectively, but 
sequence data is not validated so care is needed to align as many different 
sequences as possible to overcome any quality issues.   
In addition, unless sequencing is undertaken, the user cannot be sure that the 
PCR product seen on gel electrophoresis is the target DNA rather than another 
similarly size segment of DNA (e.g. due to mispriming).  Amplification of all 
DNA, not just of target DNA occurs during the PCR reaction, and non-specific 
products may occur [206].  However these issues can be overcome by the use of 
real-time PCR. 
1.6.3  Real-time PCR 
Real-time PCR is so called because data is generated during the PCR reaction 
(around 90 minutes), which obviates the need for further processing.  Real-time 
PCR also allows you to quantify the amount of nucleic acid target in samples 
which is known as quantitative PCR (qPCR).  These improvements are 
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engendered by the incorporation of fluorescent dyes into the PCR reaction.  
Two types of approach are used which are the incorporation of a DNA binding 
dye which will bind to any double stranded DNA and then fluoresce at a 
specific wavelength (e.g. SYBR Green), and probes labelled with reporter dye 
molecules) [207].  The former approach lacks specificity due to the dye being 
able to bind to any double stranded DNA generated in the PCR reaction, 
therefore the majority of diagnostic assays used in microbiology utilise the 
latter technique using probes labelled with fluorescent reporter dyes .  
1.6.4  TaqMan 5’ Nuclease Real-time PCR chemistry  
During the real time PCR reaction, as the temperature decreases from 95°C, the 
probe anneals to any complimentary strand of DNA at approximately 10°C 
higher than the primers.  So the probe always anneals before the primers.  The 
probe anneals to the same (anti-sense) strand of DNA as the forward primer, 
and includes two fluorescent dyes, one at either end.  One dye is a reporter dye 
or fluorophore at the 5’ end, the other a quencher fluorophore at the 3’ end.  
While the two dyes are in close proximity, the quencher dye prevents the 
reporter from emitting the majority of its fluorescence.  This is achieved by 
Fluorescence Resonance Energy Transfer (FRET).  The reporter dye molecule is 
excited by a light source in the real-time PCR platform, and emits a “virtual 
photon” which is immediately absorbed by the nearby quencher dye molecule 
[207].  However, as the primer is elongated by the Taq DNA polymerase 
enzyme it eventually encounters the end of the annealed probe.  In addition to 
its DNA polymerase activity, Taq polymerase has 5’-3’ exonuclease activity, 
meaning it breaks the bond between bases at the end of a nucleotide chain.  
Each base of the probe is broken off in turn- both broken from its neighbour and 
also separated from the strand of target DNA which allows the Taq polymerase 
to continue to extend the DNA primer.  The two dyes are therefore separated by 
this process, the reporter dye (donor) then fluoresces without being quenched, 
and this emission is detected by the real time PCR platform.  The emission 
spectrum of the donor (fluorescer) molecule needs to overlap with the 
absorption spectrum of the acceptor (quencher) molecule for FRET to occur 
[208] and thus only certain combinations of fluorescers and quenchers can be 
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used.  Each copy of DNA which is amplified causes a rise in detected 
fluorescence, and as amplification is exponential, higher numbers of target 
DNA sequences in the original sample result in earlier fluorescence.  In this 
way, real time PCR can be quantitative.  The probe adds high specificity to the 
real time PCR result, as the probe should only bind to the target DNA sought.  
1.6.5 Applications of real time PCR 
The speed of real time PCR and lack of post-PCR processing mean that it is 
often chosen over traditional PCR.  Real time PCR is used in a variety of clinical 
situations, including detecting organisms causing community acquired 
pneumonia [209-212], bacterial and viral respiratory pathogens [192], 
meningitis [213], calculating bacterial loads in diseases such as cystic fibrosis 
[214] and joint infection [215].  The utility of real time PCR can be further 
increased when it is multiplexed to allow simultaneous detection of several 
targets due to the use of multiple probe dye combinations active at different 
wavelengths.   
1.6.6  Applications of real-time multiplex PCR 
Clinical applications of multiplex real-time PCR include conditions where 
several organisms may be responsible for a single disease process or where only 
small volumes of sample are available, for example in meningitis [216].   In 
addition, laboratory time is saved in terms of sample preparation.  Other real 
time multiplex PCR assays include those for respiratory viruses [190], for 
atypical organisms causing CAP [190, 201, 217],  and other bacteria of clinical 
relevance [203, 218-221]. 
1.6.7  Disadvantages of real time multiplex PCR 
There are three main issues with real time multiplex PCR.  Firstly, due to the 
limited number of fluorescent dyes instruments can detect, only four or five 
targets can be detected in a single reaction.  This means that different panels are 
needed for each disease under consideration, and some diseases would require 
several panels.  Secondly, because PCR is a enzymatic process if two different 
targets are present in the sample in differing quantities, the target at the higher 
concentration may be amplified preferentially compared to the target at lower 
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concentration [222].  Thirdly, some samples yield a weakly positive result, 
when the fluorescence only occurs between cycles 35 and 40 [223].   In this case, 
clinicians must make a decision as to the management of the patient, based on 
the patient’s condition and the pathogen involved.  There is as yet little research 
on the distribution of cycle numbers of positive results in different infections, 
but it appears that this may be pathogen specific [187, 224].   
1.6.8 Using real-time PCR to identify respiratory commensal pathogens in the 
oral cavity   
Real-time multiplex PCR assays were suitable for the detection of respiratory 
commensal pathogens from the oral cavity.  While several multiplex PCR 
assays have been developed for use in respiratory infections [195, 201, 213, 216-
218, 225], only a few recent assays address the group of bacteria common to 
HAP, which include S. aureus  and MRSA, S. pneumoniae, H. influenzae, E. coli, 
Klebsiella pneumoniae, P. aeruginosa, A. baumannii, and other coliform bacteria 
[193, 195].  Therefore a set of novel assays were designed and multiplexed for 
this purpose. 
1.7 Aims of this work 
The overall aim of this project was to determine whether characterising the 
presence of respiratory commensal pathogens within the oral bacterial 
community in patients with lower limb fracture at the start of hospital 
admission could stratify future risk of HAP.   Individual aims are listed below.  
1. Design a multiplex real time PCR assay for common respiratory bacterial 
pathogens in hospital acquired pneumonia. 
2. Recruit a cohort of hospital in-patients with lower limb fracture and 
collect a series of oral samples over the first 14 days of admission, along 
with demographic data, plaque scores, xerostomia scores and identify 
cases of pneumonia and other complications prospectively. 
3. Analyse the oral samples using the multiplexed real-time PCR assays 
after the completion of follow up. 
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4. Describe colonisation dynamics of respiratory commensal pathogens 
within the oral cavity in hospitalised older persons. 
5. Investigate whether cases of HAP were associated with the presence of 
particular organisms or combinations of organisms within the mouth, 
oral hygiene variables, patient demography, operative factors or events 
in hospital. 
6. Make recommendations about future research in this area and about 
changes to clinical practice which should be considered as a result of this 
work. 
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1.8  Chapter 2 Materials and methods 
2.1 Bacterial isolates 
Bacterial isolates used in this study are listed in Appendix 4.  Isolates were 
kindly provided by the Health Protection Agency Public Health Laboratory 
Newcastle; Professor John Perry, Microbiology department, Freeman Hospital, 
Newcastle; and Professor Andrew Smith, Glasgow University. 
2.2 Microbiological media and molecular biological enzymes and buffers  
See Appendix A. 
2.3 Storage of bacterial cultures 
Bacterial cultures were stored at -20ºC in STGG (skimmed milk, tryptone, 
glucose and glycerine) in 2ml microtubes.   
2.4 Maintenance of working cultures 
PCR assays were validated using bacterial DNA extracted from clinical isolates 
which had been identified in the local microbiology laboratory (Freeman 
Hospital, Newcastle upon Tyne).  Bacteria were stored in STGG after 
identification.  Aerobic bacteria were cultured on Columbia blood agar (or 
chocolate agar for H. influenzae) and incubated at 37°C in aerobic conditions, 
with additional 5% CO2 for S. pneumoniae and H. influenzae.  Anaerobic bacteria 
were cultured on Columbia blood agar, placed in an anaerobic jar with a 
negative control plate (inoculated with P. aeruginosa) and a sachet of 
Anaerogen™ (Oxoid Ltd., Basingstoke, Hampshire, England), and incubated at 
37ºC for 2-5 days.    
2.5 Manual extraction of nucleic acids from bacterial cultures 
2.5.1 Gram negative bacteria 
The Qiagen DNeasy kit (Crawley, UK) was used to manually extract DNA from 
bacterial cultures (see 2.4) as per manufacturer instructions.  Extraction of 
nucleic acids was undertaken using bacteria which had been cultured for 24-36 
hours.  Bacteria were emulsified in a 2ml microtube containing 180μl of buffer 
ATL using a 1μl plastic loop.  20μl of proteinase K was added.   The suspension 
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was mixed by vortex mixer and incubated on a heating block at 56°C until the 
suspension became clear.  The sample was mixed by vortexing for 15 seconds 
and 200μl of buffer AL was added followed by further mixing by vortex.  200μl 
ethanol was added and the sample was mixed by vortex again.  The sample was 
transferred into a spin column by pipette and centrifuged at 6000xg for one 
minute.  The tube containing flow-through was discarded, and the spin column 
was placed into a new 2ml collection tube and 500μl of buffer AW1 was added 
to the column.  The sample was further centrifuged at 6000xg for one minute.  
The collection tube was discarded and the spin column placed into a new 
collection tube, and 500μl buffer AW2 was added.  The sample was then 
centrifuged at 20,000xg for three minutes to remove any residual wash buffer.  
The spin column was transferred to a clean tube and 200μl buffer AE was 
added to the column to elute DNA.  The sample was incubated at room 
temperature for one minute and then centrifuged for one minute at 6000xg to 
elute the extracted DNA off the spin column.  
2.5.2 Gram positive bacteria 
Gram positive bacteria were pre-treated with a lysis buffer containing 20mM 
Tris-Cl pH 8.0, 2mM Sodium EDTA, 1.2% Triton x100 and lysozyme 20 mg/ml.  
Bacteria were transferred to a microtube containing 180μl of the above lysis 
buffer using a 1μl loop, and incubated at 37°C on a heating block for 30 
minutes.  25μl proteinase K and 200μl buffer AL were added and the sample 
was mixed by vortex mixer and incubated for a further 30 minutes at 56°C.  
200µl ethanol was added to the sample and mixed by vortex mixer.  The sample 
was then pipetted into spin columns and the procedure was continued as in 
2.5.1. 
2.6 Automated extraction of bacterial DNA from study samples and 
bacterial isolates 
Automated DNA extraction was performed on the NucliSENS® easyMAG™ 
platform (bioMerieux, France) with off-board lysis as per manufacturer 
instructions.  Automated extraction was used for all study samples and the 
majority of the known bacterial isolates used in validation studies.  Swab 
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samples taken during the patient study were transferred manually into tubes 
containing lysis buffer using sterile forceps.  A cotton-tipped swab was used to 
transfer and emulsify bacteria cultured on agar plates (for validation studies) 
into a tube containing lysis buffer.  Samples were incubated in lysis buffer for a 
minimum of ten minutes at room temperature (21ºC), transferred into the 
instrument plastic wells by pipette and loaded onto the easyMAG instrument.   
Added to each sample were 100µl of magnetic silica beads, prepared according 
to manufacturer instructions.  The remainder of the process was carried out by 
the easyMAG instrument.  The DNA bound to the magnetic silica beads, which 
were subsequently magnetised to the side of the plastic well.  Lysis buffer at the 
bottom of the well was removed, and the magnetic silica was then released into 
guanidine thiocyanate.    This process was repeated with a second wash buffer, 
and the DNA eluted into an elution buffer.  The silica beads were magnetised 
midway up the wall of the sample well leaving a clear eluate.  The eluates were 
transferred into sterile 2ml microtubes by pipette and stored at -80°C prior to 
testing with the PCR assays. 
2.7 Amplification of DNA from bacterial isolates using standard PCR 
2.7.1 Reaction conditions   
PCR reactions were carried out in 50µl volumes and contained water, 5µl 10x 
buffer, dNTPs (0.125mM), Taq Gold polymerase (1.25 units), magnesium 
chloride (2.5mM) (Applied Biosystems, Warrington UK), primers (final 
concentration 20mM) and 5µl template DNA.  PCR amplification was carried 
out in a GeneAmp 9700 thermal cycler (Applied Biosystems, Warrington, UK).  
Thermal cycling conditions were as follows: 94ºC for 15 minutes, 40 cycles of 
94ºC for 30s, 55ºC for 30s, then 72ºC for 1 min.  Then followed one hold at 72ºC 
for 7 minutes and samples were then held at 4ºC. 
2.7.2 Gel electrophoresis for detecting PCR products 
Agarose gel electrophoresis was used to visualise PCR products.  The agarose 
gel was made by adding 100 mls of 1x Tris base/Boric acid/ EDTA 
(Ethylenediaminetetraacetic acid) buffer, (TBE buffer), to 1.2g of agarose gel 
(Microsieve 3:1, Flowgen). A solution was obtained by heating in a microwave 
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on full power (800 watts) for 90 seconds, and 10µl of 10mg/ml of ethidium 
bromide (Sigma-Aldrich laboratories, UK) was added.  The solution was 
incubated in a water bath (55 °C) for 15 minutes and poured into a gel tray.  The 
gel tray was placed into an electrophoresis bath (Amersham Pharmacia Biotech 
Inc., Sweden, via electrophoresis power supply EPS 301).  Electrophoresis 
buffer contained 600mls 1x TBE buffer and 60μl ethidium bromide.  10μl of 
DNA molecular weight marker (Superladder- Low 100bp ladder, Thermo 
Fisher Scientific, Surrey, UK) was inoculated into the two most lateral wells.  
10μl of gel loading buffer (BlueJuice from Invitrogen, Life technologies Ltd., 
Paisley, UK) was added to 10 μl of PCR products and mixed by pipetting, and 
10μl of dyed sample was loaded into the gel.  The gel was subjected to 80 volts 
for 70 minutes. 
Electrophoresed DNA was visualised under ultraviolet light (302nm) using a 
Bio-Rad Universal Hood II (Bio-Rad laboratories Hercules, California) camera 
and photographed using the Molecular Imager Gel Doc XR System and the 
Quantity One 1-D software (version 4.6.2) from the same company. 
2.8 Amplification of bacterial DNA from study samples and bacterial 
isolates using real-time PCR 
Real time PCR assays were carried out in 50µl volumes and contained Universal 
PCR master mix (Applied Biosystems, Warrington, UK), primers (final 
concentration 20µM), probe (final concentration 10µM) and 5μl of DNA 
template.   Thermal cycling and data analysis were conducted on a Taqman 
7500 instrument (Applied Biosystems).  Thermal cycling conditions were as 
follows: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15s 
then 60°C for 1 min.  Results were analysed using the auto-analysis feature. 
2.9 Positive and negative controls used in PCR reactions and bacterial DNA 
extractions  
PCR grade water (Sigma-Aldrich Company Ltd, Gillingham UK) and non 
template wells were used as negative controls for PCR reactions.  Positive 
controls included a mixture of salmon sperm DNA (0.5mg/ml, Invitrogen, 
Paisley UK), DNA extracted from all target bacteria and human DNA 
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containing the gap gene.  Approximately 20 samples of extracted DNA from 
each bacterial target were analysed using real time PCR to determine a mean Ct 
value.  The Ct values differed by the organism tested, and accordingly different 
concentrations of each target bacteria were added to the positive control mix to 
aim for a final Ct value of 30-35 for each organism included.  The same positive 
control mixture (100µl) was also used during each bacterial DNA extraction 
run, in addition to a dry swab as a negative extraction control.   
2.10 Standardisation of sample testing 
Samples were anonymised at the bedside and assigned a laboratory number at 
DNA extraction.  A standard operating procedure was developed for testing 
study samples.  The five primer and probe combinations were pre-prepared, 
and stored at -20C˚.  The assays were undertaken on two 7500 Real-time PCR 
instruments between July 2010 and April 2012, after completion of patient 
follow up.  The assays were processed by a single laboratory technician.  
Results were analysed using the Taqman auto-analysis feature and stored in a 
database (Microsoft Access, Office 2007) on the Newcastle upon Tyne Hospitals 
Trust server.  This database also contained clinical details from the study 
patients and the addition of PCR results to the database un-blinded the study.   
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Chapter 3 Development of a real time multiplex PCR assay for 
detecting oral colonisation with potential respiratory pathogens 
3.1 Introduction 
3.1.1 Detecting potential respiratory pathogens in the oral environment  
Oral colonisation with respiratory commensal pathogens may represent a risk 
factor for HAP [21, 33] in older persons.  In the hospital setting, rapid 
identification of these organisms may be beneficial in order to implement 
timely interventions e.g. improved oral hygiene, given that median time to 
HAP onset may be as early as 7-11 days [21, 22].  Standard culture techniques 
require a minimum of 48 hours for full identification, compared with PCR 
which may be able to produce results within the working day.  However, 
identifying individual pathogens within the densely populated oral 
environment requires a highly specific assay.  Compared with standard 
endpoint PCR, real-time PCR has increased specificity due to the addition of a 
probe.   Real-time PCR is therefore likely to be well suited to identifying 
organisms within a dense bacterial population, and is also frequently used in 
routine microbiology laboratories in the United Kingdom (UK).   
3.2 Methods   
3.2.1 Real-time PCR assay development: Literature review 
The commonest bacterial causes of HAP in non-ventilated patients in the 
United States (US) [11] are shown in 1.2.3 (no similar data existed for patients in 
the UK).  These bacteria first adhere to the oropharynx before aspiration or 
micro-aspiration into the lungs to cause HAP.  Therefore the commonest ten 
bacterial pathogens were chosen as real-time PCR assay targets to represent the 
majority of cases of HAP, which included S. aureus, MRSA, E. coli, P. aeruginosa, 
S. pneumoniae, H. influenzae, Acinetobacter spp., K. pneumoniae, S. marcescens and 
E. cloacae.  Satisfactory previously published assays existed for GAPDH 
(targeting the gap gene) [226] and S. aureus/MRSA assays (targeting femB and 
mecA respectively)  [227], and further literature searching was not undertaken 
for these targets. A literature review of real time and standard PCR assays 
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targeting the other organisms was conducted in October 2008 using Medline 
1950-present (criteria described in Table 9).  Iterative searching of 
bibliographies of each paper was performed until no further papers were 
found.  Papers relating to typing rather than primary identification were not 
retrieved.   Where little was found for a particular organism, an additional 
“Google” search was undertaken. The results of this search are shown in 
Appendix B.   
 
Table 9. Medline search strategy for literature search of previously published 
PCR assays for target organisms 
Target Pathogen Search Strategy Hits Papers** 
Pseudomonas 
aeruginosa 
[Pseudomonas aeruginosa OR Pseudomonas 
infections] AND Polymerase chain 
reaction(expl) 
619 24 
Klebsiella 
pneumoniae 
[Klebsiella(expl) OR Klebsiella infections] 
AND Polymerase chain reaction(expl) 
301 6 
Enterobacter spp. Enterobacter(expl) AND Polymerase 
chain reaction(expl) 
140 8 
Escherichia coli [Escherichia(expl) OR E. coli infections] 
AND Polymerase chain reaction.ti,ab.* 
2196 36 
Acinetobacter spp. [Acinetobacter(expl) OR Acinetobacter 
infections] AND Polymerase chain 
reaction(expl) 
255 10 
Haemophilus 
influenzae 
[Haemophilus influenzae OR Haemophilus 
infections] AND Polymerase chain 
reaction(expl) 
305 38 
Serratia 
marcescens 
[Serratia infections OR Serratia(expl)] 
AND Polymerase chain reaction(expl) 
86 2 
Streptococcus 
pneumoniae 
[Streptococcus pneumoniae OR 
Pneumococcal infections] AND 
Polymerase chain reaction(expl) 
563 36 
*search strategy amended as usual search gave 7122 citations. 
** excluding further papers found by bibliography searching 
 
3.2.2 Assay Design 
The literature review yielded promising candidate genes for E. coli (uidA), P. 
aeruginosa (ecfX), S. pneumoniae (cps), H. influenzae (P6), Acinetobacter spp (16s-
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23s ITS), and coliforms (16s).  Insufficient data were available on the S. 
marcescens and Enterobacter genomes in 2009 which precluded assay design.   
A table containing all assays retrieved from this search can be found in 
Appendix B.  In silico analysis of sections of shortlisted genes or primers was 
undertaken using the basic alignment search tool (BLAST) against all the 
nucleotide database in GenBank, with the aim finding conserved genes within 
species and of avoiding genes/sequences present in other target organisms, 
common oral bacteria or human DNA.   
Genes conserved within the species were found for P. aeruginosa, E. coli, H. 
influenzae and S. pneumoniae.  However none of the previously published assays 
were both suitable for the Taqman instrument and sufficiently specific for use 
on oral samples.  Therefore novel assays were designed for these targets.  No 
gene from previously published assays distinguished the closely related 
Enterobacteriaceae, and further comparative genomic searching was 
undertaken using the Comprehensive Microbial Resource database 
(http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi), but this was 
unsuccessful.  Therefore a generic coliform assay was designed targeting the 16s 
gene.  
For each target, all sequence data relating to the candidate gene were 
downloaded from GenBank and exported into Editseq software (Lasergene, 
DNA STAR incorporated, Madison, Wisconsin).  Sequences were aligned using 
MegAlign (Lasergene, DNA STAR inc., Madison, Wisconsin) using clustal W 
analysis.    Conserved regions were compared with the same gene from other 
organisms.  Automated primer design was undertaken using the consensus 
sequence in PrimerExpress software (Applied Biosystems, Warrington, UK), 
and secondary structures were checked using NetPrimer (free software, 
http://www.premierbiosoft.com/netprimer).  Primers or probes which formed 
secondary structures with –ΔG >6 were abandoned and redesigned. Specificity 
of final primers and probes was confirmed using a BLAST search against the 
nucleotide database in GenBank.  No set of primers yielded any unexpected 
matches.  The characteristics of novel assays are shown in Table 10, sequence 
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data for all assays is shown in Table 11 and function of all target genes are 
shown in Table 12.   
Primers were manufactured by Eurogentec Ltd (Southampton, UK).  Detection 
of known bacterial isolates was confirmed using endpoint PCR (see 2.7.1) and 
agarose gel electrophoresis (described in 2.7.2) prior to primer optimisation for 
real-time PCR.
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Table 10.   Locations, optimised reaction concentrations and melting temperatures of primers and probes for real time PCR assays 
designed in this study 
Target Strain (GenBank Accession no) Gene  Primer locations 
(length)          
Probe location Length 
of 
amplicon 
Primer 
concs** 
F/R 
Probe 
conc 
Tms*** of primers 
and probe 
E. coli* K12 DH10B (CP000948 1783245-
1785056) 
uidA F 1699-1714 
(16) 
R 1765-1750 
(16) 
1722-1748 
(27) 
67 0.9/0.9 0.25 F 59°C, R 58°C 
Pr 68°C 
P. aeruginosa  PA01 (AE004091.2 1409949-
1410476) 
ecfX F 410-428 (19) 
R 474-454 (21) 
Pr 431-451 
(21) 
65 0.05/0.9 0.25 F 59°C, R 59°C 
Pr 69°C 
S. pneumoniae* G54 (CP001015 303775-304674) cps A-D F 344-368 (25) 
R415-398 (18) 
Pr 374-392 
(19) 
48 0.3/0.3 0.25 F 59°C, R 58°C 
Pr 70°C 
H. influenzae  86-028NP (CP000057.2 470967-
471428) 
P6 F 309-334 (26) 
R 431-409 (23) 
Pr 336-364 
(29) 
123 0.9/09 0.25 F 59°C, R 58°C 
Pr 68°C 
Acinetobacter 
spp. 
AB 307-0294 (CP001172.1 19883-
20482) 
16s F 119-140 (22) 
R 260-267 (24) 
Pr 205-226 
(22) 
142 0.9/0.9 0.25 F 58°C, R 58°C 
Pr 69°C 
Coliform NTUH-K2044 (16108-17564) 16s   F 76-95 (20) 
R 159-139 (21) 
Pr 100-116 
(17) 
84 0.9/0.9 0.25 F 59°C, R 58°C 
Pr 69°C 
F= forward, R=reverse, *Minor groove binder probes designed       ** concs= Concentration      ***Tm= Melting temperature 
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Table 11. Primer and probe sequences for assays used in this study 
Target 
organism 
Gene 
target 
Primer sequences      Probe sequence and dye label (5’-3’) 
S. aureus  femB F GAC ATT TGA TAG TCA ACG TAA ACG TAA ACG 
TAA TAT T 
R GCT CTT CAG TTT CAC GAT ATA AAT CTA AGA 
 VIC- TCA TCA CGT TCA AGG AAT CTG ACT 
TTA ACA CCA TAG T- TAMRA 
MRSA mecA F CAT TGA TCG CAA CGT TCA ATT T 
R TGG TCT TTC TGC ATT CCT GGA 
CY5-TGG AAG TTA GAT TGG GAT CAT AGC GTC 
AT- DDQII 
E. coli   uidA F CGC GCT TTC CCA CCA A 
R CGG CCT GTG GGC ATT C 
CY5-CAA TTC CAC AGT TTT CGC GAT CCA GAC- 
DDQII 
P. aeruginosa  ecfX F GCC TGT CCC AGG TCG AAG T 
R GAT GTG CTT TTC CAC CAT GCT 
VIC-CCG AGC GCA TGG GAA TCT CCC- TAMRA 
S. 
pneumoniae  
cps F GTG TCG CTG TTT TAG CAG ATA GTG A 
R TCC CAG TCG GTG CTG TCA 
VIC- AAA ATG TTA CGC AAC TGA C-MGB 
H. influenzae  P6 F AAA CGG TAT TGT AAC GTT GTT GAA GA 
R CAG GTT CTG TAG CTG CAT TAG CA 
FAM-CAG CAA CAG AGT AAC CGC CAA AAG 
TTT GA- BHQ1 
Acinetobacter 
spp 
16s F TCA GAC CCA CCA TGA CTT TGA C 
R GGT GGA GAC TAG GAG AGT CGA ACT 
CY5-TAG AGC GCC TGC TTT GCA CGC A-DDQII 
Coliform 16s F GCG GAC GGG TGA GTA ATG TC 
R GCG ACG TTA TGC GGT ATT AGC 
FAM- AAA CTG CCT GAT GGA GG- MGB 
Human 
cells 
GAPDH F CTC CCC ACA CAC ATG CAC TTA 
R CCT AGT CCC AGG GCT TTG ATT 
VIC- AAA AGA GCT AGG AGG GAC AGG CAA 
CTT GGC TAMRA 
F=Forward R=Reverse
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 Table 12. Functions of target genes in final PCR assays 
Target  Gene target  Gene function 
S. aureus  femB Codes for fem protein.  Involved in meticillin susceptibility, impaired cell separation, formation of 
peptaglycine interpeptide bridge, cell wall turnover.  
MRSA mecA Meticillin resistance, encodes penicillin binding protein 2A 
E. coli  uidA Codes for beta-glucuronidase enzyme which cleaves  
methylumbelliferyl-β-D glucuronide (MUG) 
P. aeruginosa  ecfX  Codes for extracytoplasmic function sigma factor.  May be involved with virulence and haem 
uptake[228].   
S. pneumoniae  cps Capsular polysaccharide synthesis 
H. influenzae  P6 Codes for outer membrane protein 
Acinetobacter spp 16s-23s ITS Internal transcribed spacer (ITS) between 16s and 23s ribosomal subunits 
Coliform 16s 16s ribosomal RNA, a component of the 30s subunit of the prokaryotic ribosome, stabilises 
protein synthesis 
GAPDH gap Codes for glyceraldehyde 3-phosphate dehydrogenase, an enzyme which catalyses the 6th step in 
glycolysis. Constitutively expressed in all human cells. 
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3.2.3 Real time PCR reaction 
Real time PCR assays were carried out in 50µl volumes (as described in 2.8) and 
contained 25µl Universal PCR master mix (Applied Biosystems, Warrington, 
UK), primers (final concentration 20µM), probe (final concentration 10µM), 5μl 
of DNA template and PCR grade water.   Thermal cycling and data analysis 
were conducted on two Taqman 7500 instruments (Applied Biosystems).  
Thermal cycling conditions were as follows: 50°C for 2 minutes, 95°C for 10 
minutes, then 40 cycles of 95°C for 15s then 60°C for 1 min. 
3.2.4 Controls 
PCR grade water (Sigma-Aldrich Company Ltd, Gillingham UK) and non-
template wells were used as negative controls.  Positive controls included a 
mixture of salmon sperm DNA (0.5mg/ml (Invitrogen, Paisley UK)), all target 
bacterial DNA plus human DNA containing the gap gene (as described in 2.9).   
Approximately 20 samples of extracted DNA from each bacterial target were 
analysed using real time PCR to determine a mean Ct value.  The Ct values 
differed by the organism tested, and accordingly different concentrations of 
each target bacteria were added to the positive control mix to aim for a final Ct 
value of 30-35 for each organism included.    
3.2.5 Optimisation of primer concentrations for real time PCR 
Primer concentrations were optimised by analysing standard concentrations of 
known bacterial isolates with a checkerboard of primer concentrations as 
shown in Table 13, according to manufacturer instructions. The combination of 
concentrations which produced the highest ΔRN value (level of fluorescence) 
was chosen.   
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Table 13. Primer concentration checkerboard used for optimisation of real-
time PCR assays 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.05/0.05 
0.05/0.3 
0.05/0.9 
0.3/0.05 
0.3/0.3 
0.3/0.9 
0.9/0.05 
0.9/0.3 
0.9/0.9 
 
3.2.6 Optimisation of probe concentration for real time PCR  
Probe concentrations were optimised by analysing standard concentrations of 
known bacterial isolates with varying probe concentrations (50nM - 250nM in 
50nM increments), according to manufacturer instructions.  The concentration 
which yielded the lowest Ct value was chosen (250nM for all assays).   
3.2.7 Multiplexing the PCR assays 
Assays were initially multiplexed together in groups of three, with commonly 
identified pathogens separated to maximise sensitivity.  Combinations of single, 
duplex and triplex assays were tested, in triplicate, against three known target 
bacterial isolates (singly, in three groups of two and a group of three bacterial 
isolates).  Provided there was no increase in Ct value more than three cycles 
between each of the single assays and the triplex assay, the multiplex was 
considered satisfactory.   Data from multiplex experiments are shown in 
Appendix D.  The sensitivity of GAPDH and Acinetobacter spp assays decreased 
more than three Ct cycles after multiplexing in a variety of assay combinations, 
and therefore these were left as single assays.   
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3.2.8 Automated extraction of total nucleic acids from clinical bacterial 
isolates for sensitivity and specificity testing 
Automated extraction of total nucleic acids from clinical bacterial isolates was 
performed using a NucliSens® easyMAG™ platform (bioMerieux, France) with 
off-board lysis, according to manufacturer instructions as described in 2.6.   The 
extracted DNA samples were stored in 96-well plates at -80°C prior to analysis 
using real-time PCR. 
3.3 Results    
3.3.1 Inclusivity testing of the real-time PCR assays 
Each assay was tested against a bank of clinical bacterial isolates which had 
been identified in a local microbiology laboratory to species level.  Full results 
are available in Appendix E and a summary of results is included in Table 14.  
The assays identified the majority of clinical isolates tested.   
3.3.2 Specificity testing of multiplexed real-time PCR assays  
The multiplexed real-time PCR assays were tested against DNA extracted from 
a panel of 63 freshly cultured previously identified bacteria, including 43 oral 
bacterial species and target organisms.  Standard reaction conditions were used 
as described in 3.2.3.  The panel of bacteria are listed in Appendix E.  All assays 
had satisfactory control results and identified target organisms correctly.  When 
a threshold of Ct<27 was applied, the coliform assay correctly identified E. coli, 
K. pneumoniae, E. cloacae and S. marcescens.   However, positive coliform real-
time PCR results were also obtained when testing four of the 63 panel 
organisms (a haemolytic Streptococcus (group B), S. constellatus, Enterococcus 
faecium and S. epidermidis).  The E. coli assay cross-reacted with a haemolytic 
Streptococcus (group B), S. constellatus, and E. faecium.  The S. aureus assay 
cross-reacted with S. constellatus and a beta-haemolytic Streptococcus Group C 
(1).  
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Table 14. Inclusivity testing of final multiplex real-time PCR assays against 
known clinical isolates  
Assay Number of organisms correctly 
identified 
% correctly identified 
S. aureus  15/16 94 
MRSA 17/17 100 
E. coli* 26/30 87 
P. aeruginosa  25/28 89 
S. pneumoniae  14/14 100 
H. influenzae  16/17 94 
Acinetobacter spp* 14/14 100 
 Coliform** 8/8                 (E. coli) 
16/17             (E. cloacae) 
20/23             (K. pneumoniae) 
13/13             (S. marcescens) 
4/4                 (M. morganii) 
100 
100 
87 
100 
100 
 
*Using threshold of Ct<35 **Using threshold of Ct<27 
 
3.3.3 Detection of possible contamination of PCR reagents during testing of 
patient study samples 
A total of 816 samples of DNA extracted from tongue or throat swabs were 
tested with the multiplex real-time PCR assays described above and in 2.10, and 
no inhibition occurred.  Results from individual patients, converted from Ct 
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values to presence or absence, are shown in Appendix F.  However, during the 
testing of study samples, it was noted that some negative controls from the E. 
coli, Acinetobacter spp and coliform assays yielded positive results.   
During testing of the E. coli assay, water and non-template controls produced 
positive results, sometimes consistently within a particular PCR run and 
sometimes more sporadically, with Ct values >33.  Further testing with sterile 
plastics, an unopened batch of PCR-grade water and preparing fresh primers 
and probe from unused stock excluded these as the source of contamination.  It 
was noted that PCR runs which took place after a particular date exhibited very 
few negative controls with positive results, and one batch of universal master 
mix in particular appeared to almost eradicate the problem.  The universal 
master mix was implicated as the source.   Therefore this specific 
uncontaminated batch was used to retest samples which had been tested with 
potentially contaminated master mix (approximately half of the samples).  
Occasional sporadic positive results for water and non-template controls still 
occurred, albeit with Ct values >39.  All Ct values from negative or water 
controls were >38 and a positive detection threshold of <35 was applied to all 
results from the E. coli assay, to differentiate between negative controls with 
positive results and positive samples.  
Testing of samples with the Acinetobacter spp. assay demonstrated that only 
extraction negative controls produced positive results.  The individual swabs 
and PCR water had both tested individually as negative controls during routine 
DNA extraction initially, but both had produced positive Acinetobacter spp 
assay results, suggesting that they were not the source of contamination.  A 
previous report suggested that A. baumannii contamination of the buffer and 
line fluids from the easyMAG platform had previously been detected when 
testing HIV-1 viral load samples [229].  Buffer fluid samples from the easyMAG 
platform used in extracting study samples were tested using the Acinetobacter 
spp assay after PCR results were obtained (one year after DNA extractions were 
undertaken), but produced negative results.  Buffer fluids had been on the 
instrument for 48 hours at the time of testing, and this may have been too early 
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for contamination to have developed.  Claasen et al. noted that buffer fluids 
became contaminated after 1 week on the instrument.  Ct values of extraction 
negative controls were all >36, so a threshold of <35 was used to determine 
positive results for study samples. 
Positive results were obtained for all samples tested with the generic coliform 
assay, including all controls, with mean Ct values for negative controls of 31.26 
(standard deviation 3.20).  Retesting of samples using the less contaminated 
batch of master mix was not undertaken because it was presumed that even a  
less contaminated batch of master mix would not make sufficient difference to 
the Ct values on re-testing (given a mean Ct of 31.26) to rely on the results 
produced.  Instead, two products were investigated to determine whether they 
could eradicate contamination within reagents.   
The first was a DNA-free Taq polymerase (Moltaq 16s DNA Polymerase, 
Molzym, Bremen, Germany) which was tested using conventional PCR.  The 
primers from the generic coliform assay were used to assay nucleic acids 
extracted from Klebsiella spp. isolates and water controls.  The microtube 
containing master mix was placed in a previously frozen metal block, and DNA 
polymerase was added last.    The PCR assays were carried out in 50µl volumes 
and contained Moltaq 16s DNA polymerase (2units), primers (final 
concentration 20µM), 5µl of 10x buffer, dNTPs 0.125mM and 5μl of DNA 
template.   PCR amplification was carried out in a GeneAmp 9700 thermal 
cycler (Applied Biosystems, Warrington, UK).  Thermal cycling conditions were 
as follows: 94ºC for 15 minutes, 40 cycles of 94ºC for 30s, 55ºC for 30s, 72ºC for 1 
min.  Then followed one hold at 72ºC for seven minutes and the samples were 
then held at 4ºC as described in 2.7.1.  PCR products were separated using 
agarose gel electrophoresis, stained using ethidium bromide, and visualised 
under ultraviolet light as described in 2.7.2.  However bands consistent with 
specific Klebsiella spp product were still detected in the water controls 
indicating that Klebsiella spp was present within reagents or water.  Given the 
results detailed above, these results were consistent with Taq polymerase being 
the likeliest source of contamination.   
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The second approach investigated was the addition of 10 units of exonuclease 
III (Promega, Southampton, UK) to the real-time PCR reaction.  Cherkaoui et al. 
successfully eradicated bacterial contamination from PCR of 144 clinical 
samples from normally sterile sites using this method [230]. The enzyme was 
added to the universal master mix and incubated at 37 ºC for 30 minutes, then 
70 ºC for 20 minutes in water baths, before the addition of primers and probe.  
Thermal cycling took place in the Taqman 7500 instrument with automated 
analysis of results as described in 3.2.3.  However no amplification was detected 
on the Taqman instrument when DNA from clinical isolates was tested, 
suggesting inhibition of the PCR reaction had occured, possibly from probe 
degradation by the exonuclease.  
Both approaches to eliminate contamination from real-time PCR reactions were 
unsuccessful.  The range of results from negative controls (lowest Ct value= 
26.04) meant that a threshold could not be reliably applied to interpret study 
results from this assay.  Of 167 negative controls, 164 (97%) results showed 
Ct>30, and the three results <30 had Ct value of 0, 26.04 and 26.5.  Therefore a 
threshold of Ct<27 was used to view initial results from the coliform assay 
(available in Appendix F), but these data were not analysed further.    
3.4 Discussion 
Novel real time multiplex PCR assays were designed for five major bacterial 
respiratory pathogens.  Inclusivity and specificity testing validated these assays 
and no inhibition problems were encountered during subsequent testing on 
oral samples, suggesting that the assays performed well in this bacterially dense 
population.   Use of the Taqman probe (which binds only to the desired 
amplicon) rather SYBR-green probes (which bind to any double stranded DNA) 
led to high specificity.   
Assays for genes specific to individual bacteria were designed rather than using 
universal bacterial primers coupled with specific probes because of the 
perceived difficulties surrounding 16s PCR, particularly in the oral 
environment. In actual fact, the 16s assay designed for Acinetobacter spp,. in the 
absence of other potential gene targets, functioned well.  This suggests that real 
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time PCR is sufficiently specific even when testing bacterially rich samples 
where the target is in low copy number.  
The coliform assay demonstrated consistently positive results when testing 
water and non-template controls at high levels, which precluded its further use.   
It has been previously documented that bacterial 16s PCR assays yielded 
positive results from water and non-template controls when identifying 
ubiquitous environmental organisms, owing to non-sterility of reagents at 
manufacturing level [230-232].  In addition, E. coli is used to produce 
recombinant Taq polymerase and some components of this organism may 
remain present in the Taq polymerase [233].  Companies such as Applied 
Biosystems and others buy Taq polymerase to make Universal master mix from 
a number of other companies and differences therefore exist between batches.  
Results from the negative controls during testing with the E. coli assay were 
much improved by the use of a single less contaminated batch of master mix, 
although sporadic false positive results with Ct values>39 were still observed.  
DNA free reagents tested in this work were not effective in reducing 
contamination in water and non-template controls, and use of endonucleases 
was not compatible with the Taqman platform.  Other methods trialled have 
been use of ultraviolet light [231], DNase I [231], and ethylenediaminetetracetic 
acid (EDTA), but reductions in PCR sensitivity were observed due to inhibition.  
One group successfully used DNase I in combination with dithiothreitol (DTT) 
treatment and heat inactivation prior to PCR to remove residual DNase [234], 
however we were unable to replicate this.  Regardless, these solutions are too 
time-consuming for routine use in a clinical laboratory.  Resolving 
contamination issues at manufacturer level appears to be the most appropriate 
solution. 
Contamination with Acinetobacter spp. is likely to have occurred on the 
easyMAG extraction platform, despite negative PCR results when testing buffer 
fluids later.  A literature search revealed a previous study which described 
contamination with A. baumannii in Buffer 2 of the easyMAG system, which had 
been resolved by flushing buffer lines with 70% and storage of buffers at 
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4°C[229].  Buffer fluids were tested from the easyMAG platform used in the 
study in duplicate, albeit one year after the problems had occurred due to time 
lag between DNA extraction and PCR, but all tested negative.  Given that only 
extraction controls were positive, and so consistently throughout testing, it 
remains likely the easyMag instrument was the source of contamination.   
A small number of organisms were not detected by the E. coli, coliform and S. 
aureus assays.  These included a S. constellatus, haemolytic Streptococcus group 
B and E. faecium (common to both E. coli and coliform assays), S. epidermidis 
(coliform assay only), and S. constellatus and group C Streptococcus (S. aureus 
assay only).  There are several possible explanations for this.  The design of the 
assays relies on the DNA sequences downloaded to GenBank being sufficiently 
representative of most strains of the target organisms.  However some 
organisms (eg. S.aureus) exhibit a clonal population structure and therefore 
some strains may not have been detected, others may demonstrate a non-clonal 
population structure with frequent recombination of DNA [235],  and there may 
not be adequate descriptions of these phenomena attached to sequence data (or 
simply inadequate sequence data).  A further explanation could be that 
laboratory identification, although adequate for clinical purposes, may be 
inaccurate at a molecular level.  Given that the cross-reacting organisms were 
common to both the E. coli and coliform assays, either the organisms were 
misidentified at laboratory level (and further sequencing of these isolates could 
confirm this) or these organisms possess genetic sequences identical to 16s and 
uidA genes of E. coli.  In silico testing (BLAST) of the primers and probe from 
both assays against  GenBank’s nucleotide database did identify homology with 
some Streptococci for one of the primers or probe, but failed to identify 
streptococcal sequences for both primers and probe, even when the search was 
narrowed to include testing against only streptococcal sequences.  Sequencing 
the relevant clinical bacterial isolates would reveal whether cross-reactivity 
occurred due to similarities in genetic sequences.  
Assays could not be designed for S. marcescens or Enterobacter due to lack of 
sequence data at the time of design, which accounted for <3.7% and 4.3% of 835 
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cases of HAP respectively [11].  The pathogens covered in the designed assays 
still represent the majority of known bacterial aetiological agents, and the 
overall assay remains viable without the inclusion of these two targets.   Now 
that next generation sequencing is becoming both faster and more affordable, it 
is likely that the volume of sequence data will rise exponentially in the next few 
years, and assay design for S. marcescens and E. cloacae will be achievable.  Other 
important pathogens not sought in this study included Morhaxhella catarrhalis 
and viruses such as influenza.  M. catarrhalis is the third commonest cause of 
community acquired pneumonia (CAP) [9], and it is likely that this organism 
would have been present in the mouths of study patients.  However, it is not an 
important cause of HAP, and an assay for this organism was therefore not 
included.  Viruses are also important causes of (1-23% of cases of CAP [236]), 
and were not sought in this study.  Testing for viruses would have increased 
the cost of the project to an unacceptable level, as multiple viruses would need 
to be sought, however this could be an area for future work on the duplicate 
samples taken.   
A possible criticism of the overall aims of the assays might be that relevant (and 
possibly uncultured) pathogens may have been omitted from this assay, given 
that an aetiology was discovered in <60% cases of pneumonia in older adults in 
one study [17], and the role of uncultured bacteria in HAP is unclear.  A 
metagenomic approach could have been used instead of PCR to characterise 
oral samples, circumventing this issue.  However at the time of conception of 
this study, next generation sequencing techniques were insufficiently advanced 
to allow timely and affordable analysis of the required number of oral samples.   
However further work is needed to characterise the “normal” flora of the oral 
cavity and to assess organisms present in bronchoalveolar lavage samples in 
patients with proven HAP to identify novel pathogens in this context.  
3.4.1 Conclusions 
Multiplex real-time PCR assays were successfully designed for five major 
bacterial respiratory pathogens, and were able to identify target bacteria from 
oral samples.  Some reagent contamination issues were resolved by the 
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substitution of a particular batch of master mix, however designing bacterial 
16s assays remains problematic due to contamination of reagents at 
manufacturing level. 
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Chapter 4 
Dynamics of oral colonisation with respiratory commensal 
pathogens, oral health status and incidence of hospital acquired 
pneumonia in older patients with lower limb fracture. 
4.1  Introduction 
Hospital acquired pneumonia carries a mortality of 12-43% in older people [23, 
24, 32, 70], and is one of the commonest complications following lower limb 
fracture in older adults, with an incidence of  8.6-10% [23, 49, 50]. The majority 
of lower limb fractures in the older person requiring hospital admission affect 
the neck of the femur (hip fracture); fractures of the ankle are less common 
[237].    Currently around 70,000-75,000 people sustain a hip fracture in the UK 
annually [238], and this figure is likely to rise further with the changing 
demography of the UK population.  The crude one month mortality rate after 
hip fracture is approximately 10% and the one year mortality rate is around a 
third of patients, mainly from other illnesses or complications, rather than 
arising from the fracture itself [51].  Hospital acquired pneumonia (HAP) 
contributes significantly to the mortality of patients with hip fracture [121, 239, 
240], and has been quoted as the second most common cause of death after 
operative treatment for hip fracture [23]. The prevention of accidental falls in 
older people is multi-factorial [241], and falls resulting in hip fractures are likely 
to pose continuing demands on NHS service provision in years to come.  
Understanding risk factors for HAP may lead to improved strategies for 
prevention, which may in turn reduce mortality, length of stay in hospital, and 
may improve functional outcome at discharge in those who would have 
developed HAP.   
The most obvious modifiable risk factors to modulate the risk of HAP appear to 
be oral colonisation with respiratory commensal pathogens [21, 29, 33] and 
dental factors [29, 30, 44, 69], and both are incompletely understood as yet.  
Other risk factors such as dependence on others for feeding or managing oral 
secretions [21, 28, 30, 68], dysphagia [110], tendency to aspirate [28, 32], age [24, 
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48, 54, 67, 81, 111] and COPD [29, 30, 53, 61] may be less amenable to 
intervention.  Two successful oral hygiene intervention studies of moderate 
quality have been conducted with a view to reducing pneumonia in nursing 
home and long term care facility patients[86, 181].  However, the target of 
intervention remains unclear, and if robust large-scale interventions studies are 
to be designed, understanding whether the target of intervention is removal of 
dental or denture plaque,  eliminating colonisation of potential aetiological 
agents on dental or buccal surfaces, or tackling other issues, such as dry mouth, 
is crucial. It is assumed that colonisation with organisms associated with HAP 
begins after hospital admission, but the timing of the start of colonisation, and 
thus the optimal time to institute oral hygiene prevention measures, is unclear.    
This study sought to investigate the occurrence of HAP in a cohort of older 
patients with lower limb fracture in relation to putative risk factors, including 
dental factors such as number of teeth, oral dryness, presence of dentures, 
dental and denture plaque, and also the extent of oral colonisation with the 
seven most common respiratory pathogens, using purpose designed multiplex 
real time PCR assays.  The dynamics of oral colonisation with respiratory 
commensal pathogens were investigated.  It was hypothesised that colonisation 
events would be associated with length of stay (i.e. an epidemiological 
explanation).   “Community” pathogens such as S. pneumoniae, H. influenzae and 
S. aureus were expected to decline over time in hospital, and “hospital” 
pathogens (the remainder) were expected to increase.   
The demographics, dentition, oral microbiology and outcomes of the study 
cohort, will be described in Chapter 4 and the relationships between HAP and 
the above variables will be investigated in Chapter 5.  
4.2  Methods 
4.2.1 Patient recruitment and consent 
Patients were recruited from two orthopaedic admissions wards at Newcastle 
General Hospital between April 2009 and July 2010.  All patients with lower 
limb fracture admitted to the Newcastle Hospitals were discussed at the next 
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daily trauma meeting at 0800, and potential participants were identified here.  
Recruitment occurred preoperatively where possible, but patients were usually 
operated the day after admission, and where preoperative recruitment was not 
possible, patients were recruited on the following day.  Details of participation 
in the study were explained verbally, and potential participants were also given 
a leaflet to read.  Written consent was obtained from patients who had the 
capacity to make the decision.   Every effort was made to allow the patient to 
make their own decision including repetition of information, interviews at 
different times of day, and use of spectacles and hearing aids where needed.  
When patient consent was not possible, relatives were invited to act as personal 
consultees on behalf of the patient.  A professional consultee was sought for 
patients who could not consent who had no relatives.  Patient follow up was 
undertaken on destination wards provided they were within the Newcastle 
Upon Tyne Hospitals Trust.   
Inclusion criteria included age > 65 and lower limb fracture.  Exclusion criteria 
included recent immunosupression from chemotherapy or other 
immunosuppressive drugs (including any prescription of >=10mg 
prednisolone), acute illness, palliative care and community acquired 
pneumonia.  
4.2.2 Recording of demographic data 
Demographic data were recorded from the hospital notes by the study 
investigator (VE) or the study nurses (JB, SE) on paper study files.  Active study 
files were stored with the patient notes on the ward, and other study files were 
kept in a locked filing cabinet at the Health Protection Agency Newcastle.  Data 
were later entered into a study database, (Microsoft Access) which was held on 
the Newcastle upon Tyne Hospitals (NUTH) server to store patient data.  
Caldicott approval was granted.  
Age, gender, weight, place of residence prior to admission, comorbidities, 
prescribed drugs at admission, operative and anaesthetic details, MRSA 
admission swab results, and smoking status were noted from the admission 
documentation. Operative details recorded included time of operation, type of 
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operation performed, length of operation as defined by start and end of 
anaesthetic recorded on anaesthetic chart and peri-operative antibiotics.  All 
patients (apart from two who were treated without operation) received peri-
operative antibiotics (three doses of Cefuroxime 750mg 12 hourly until August 
2009, three doses of Teicoplanin 400mg 12 hourly thereafter).  Therefore 
approximately 20 patients received the former and 73 the latter regimens.  All 
patients received low molecular weight heparin in the form of 4500 units 
tinzaparin subcutaneously, unless already anticoagulated on warfarin.  The 
postoperative analgesia used routinely was co-codamol 30/500mg four times 
daily and any increase from this was noted.  When no weight had been 
recorded, patients were asked for their last known weight, or in 6 cases a last 
known weight was noted from the General Practitioner records.   In addition, 
presence of associated visual impairment (glasses) and hearing impairment 
(hearing aid) were recorded.  Functional scores including the Barthel index and 
the Clinical Frailty scale were calculated.  The Hierarchical Assessment of 
Balance and Mobility (HABAM) score was also calculated at the time of 
consent.  A Charlson comorbidity index was calculated from the above 
information using an online calculator found at www.medal.org.   
4.2.3 Study variables 
Ordinal and categorical variables used in the study and their definitions are 
described in Table 15.  Three functional and complementary variables were 
chosen for use in the study.  The Barthel index (scored out of 20) is recorded 
routinely in older patients in hospital in the UK, and is included in the 
admission proforma for patients with hip fracture in Newcastle upon Tyne 
Hospitals.  However this score only decreases once patients are unable to 
independently attend to an activity of daily living, e.g. toileting or grooming.  It 
does not account for earlier signs of frailty, such as fatigue, or needing help 
with higher order tasks such as shopping or dealing with money.  The clinical 
frailty scale was developed to allow the clinician to quickly and easily 
distinguish the fittest from the frailest patients using nine categories, and has 
been validated on older Canadians to predict death and move to institutional 
care [242].  This scale has three categories for fitter patients who would not yet 
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be classified as frail, and one category for borderline frailty.  While exercise 
tolerance is mentioned within the categories of the clinical frailty scale, it is not 
explicitly measured, and the independent patient who is able to walk 100 yards 
only would not necessarily be distinguished from the independent patient who 
could walk a mile.  Therefore a mobility scale was also used in the study, and 
was developed by the same group as the clinical frailty scale [243].  This score 
was highly positively correlated with the clinical frailty score in a convenience 
sample of geriatric in and out patients, and had good test-retest and inter-rater 
reliability. 
The Charlson comorbidity score is an age-weighted score of serious 
comorbidities, and its outcome predicts likelihood of ten-year survival.  Some 
advocate simply counting number of comorbidities, including visual and 
hearing impairment [244].  However, the Charlson comorbidity index has been 
widely used and validated in a number of populations, and it was included for 
this reason.
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Table 15.  Ordinal and categorical variables used in the study and their 
definitions 
Variable Explanation Orientation 
Residence 3 categories according to site of 
residence pre admission,  
1=own home 
2=institution    
3=hospital  
Barthel score Score 1-20 based on dependence 
on others for  activities of daily 
living, e.g. toileting, stairs 
High score means more 
independent.  
Clinical frailty 
scale 
Score 1-9 based on frailty 
category 
High score means more 
frail 
HABAM Mobility score based on ability 
to standing balance, transfers 
between bed and chair and 
exercise tolerance /63 
High score means more 
mobile 
Consent Two categories, able to consent 
for self (includes mild cognitive 
impairment) and unable to 
consent for self 
1= self consent     
2=help for consent 
Charlson 
comorbidity 
index 
An age weighted score of 
severity of significant illnesses; 
relates to 10 year survival 
High score means low or 
zero probability of 
survival at 10 years 
Smoking status 3 groups 1=current smoker 
2= ex-smoker 
3=never smoker 
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4.2.4 Recording of oral hygiene variables 
The PI was trained in dental examination and plaque scoring at the Dental 
Hospital, Newcastle University, and attended two dental clinics in advance of 
the start of the study.  The PI had undertaken dental plaque scoring in a 
previous study [245].  The number and position of teeth or teeth on dentures 
was recorded for each patient.  Both dental and denture plaque (full mouth) 
were scored by a single investigator (VE) using the modified Quigley Hein 
index [246, 247], described below in Figure 1.  This score was used because it 
was a visual score (and therefore did not necessitate the removal of plaque) and 
because of its ability to discriminate between larger and smaller plaque loads.   
Other possible plaque scoring systems required the use of a dental probe or did 
not distinguish between heavier loads of plaque (e.g. Silness and Loe or a 
dichotomous scoring system).   
Plaque was scored on days 1, 7 and 14 at the bedside, with the aid of a head-
torch and dental mirror.  Dentures were removed for scoring, and were not 
cleaned after scoring.  Only dentures that were being worn were scored.  At the 
start of the study, it was decided that plaque or debris between but not on 
denture “teeth” was given a score of 3.    In order to create a single plaque score 
per patient, a quartile score was assigned to each modified Quigley Hein index.   
Where scores were discordant in dentate denture wearers, the higher of the two 
quartiles was used in analysis.    Midway through the study, intra-rater (VE) 
calibration using 138 surfaces gave kappa scores of 80.9% (good).  On day 14 of 
admission, a xerostomia inventory questionnaire was undertaken [248].  This 
was a subjective measure of dry mouth using an 11 point questionnaire with 
responses increasing in frequency between “never” and “very often”.  Patients 
were questioned on their sensation of dry mouth for the preceding two weeks 
only.  No objective measures of xerostomia were taken. 
There was no specific oral hygiene policy on the orthopaedic admissions ward 
at the time of the study.  Dentures were placed in denture pots overnight, 
where available.  Those with teeth attended to their own oral hygiene.  
 82 
 
 
 
 
 
Figure 1. Diagram of modified Quigley Hein scoring system 
 
 
 
 
Table 16. Modified Quigley-Hein scoring system 
Score Description 
0 No visible plaque 
1 Plaque visible but not continuous around tooth border 
2 Plaque continuous around tooth but less that 1mm in height 
3 Plaque continuous around tooth and over 1mm but less than one 
third of tooth 
4 Plaque covers between one and two thirds of tooth surface 
5 Plaque covers more than two thirds of tooth surface 
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4.2.5 Collection of oral samples 
Dry flocked swabs (suitable for use with PCR assays [249, 250]) were used to 
sample the tongue and throat in duplicate at time points described in Figure 2.  
It was hypothesised that most changes in the structure of the oral bacterial 
community would occur within the first 5 days of admission because similar 
changes had been observed in patients after admission to intensive care [42].  In 
addition, time to HAP was quoted as up to 9 days after surgery, and 61% of 
pneumonias occurred within 5 days of operation [26].  Therefore, the sampling 
time-points were chosen to try and observe these changes over the first few 
days of admission.    
The combination of tongue and throat samples was previously shown to be the 
minimally inclusive combination achievable in those with cognitive impairment 
in detecting coliforms, Pseudomonads and S. aureus in orthopaedic patients 
[245].   The day of admission was considered to be day 0.  Where possible the 
first set of samples was taken pre-operatively (usually day 1), otherwise 
samples were taken the following morning.  Where swab collection fell on 
weekend days, the sample was taken on the nearest working day.   All samples 
were taken between 8.30am and 12 pm, or 1-4pm.  No special instructions were 
given to patients regarding food or drink prior to sample collection.  If patients 
were discharged before 14 days no further samples were taken.  
Two throat swabs were taken from right and left anterior faucial pillars, using a 
back-and-forth motion three times.  Two tongue swabs were also taken by 
rubbing three strokes posterior-anterior, then rotating the swab 180º and 
making a further three strokes in the same way.  Swab tips were transferred 
into 2ml microtubes which were labelled with the patient’s hospital number, 
date, swab and day number, and the type of swab.  The two swabs from each 
site were labelled “A” or “B” at random.  “A” swabs were used for PCR 
analysis and “B” swabs were subjected to DNA extraction and stored at -80ºC 
as a duplicate.    
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Samples were transported to the Health Protection Agency within four hours of 
collection, and stored in a single plastic specimen bag at 2-8ºC until DNA 
extraction within 48 hours.  Samples were anonymised by allocation of a 
laboratory number at DNA extraction, and stored at -80°C at Health Protection 
Agency Newcastle.  After patient follow- up was complete, extracted DNA 
samples were analysed using the multiplex real-time PCR assays (described in 
2.8 and 2.10) between September 2010 and December 2011 by a single clinical 
scientist (GE).    
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                                   Figure 2. Sampling and observation schedule for study
Sample  Sample  Sample  Sample  Sample  
Plaque 
score 
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Xerostomia 
inventory 
     0         1          2            3          4          5        6          7                                                                            14 
      
     Day of admission 
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4.2.6 Study patient follow up 
After the initial sampling period, study participants were visited three times 
per week (Monday, Wednesday, Friday) until discharge to detect complications 
and to ensure complete ascertainment of cases of HAP.  During the follow up 
visit, participants were asked an open question about general health, asked 
about presence of cough, and last recorded observations (blood pressure, pulse, 
temperature, oxygen saturation and respiratory rate) were noted.  When asking 
about cough, patients were asked to report a new cough or a change to an 
existing cough.  Glasgow Coma Score, an AVPU score (alert, alert to voice only, 
alert to pain, unresponsive) and any delirium were also noted.  Delirium was 
diagnosed clinically by VE, based on comparison with previous visits or 
conversations with relatives or nursing staff.  Complications such as new drugs, 
deep vein thrombosis, or acute illness were recorded on a weekly basis using 
case notes review.   
HAP was diagnosed when antibiotics were started for pneumonia by the 
responsible clinician after 48 hours in hospital.   Episodes of lower respiratory 
tract infection (i.e. symptoms and/or signs of respiratory tract infection without 
visible changes on chest radiograph) were also noted.  The most abnormal 
observations and blood tests in the 48 hours prior to diagnosis were recorded.  
The diagnosis of HAP was further characterised as “probable” or “possible” 
case using American Thoracic Society and British Society for Antimicrobial 
Chemotherapy (Table 17 and Table 18).  
After discharge, two sets of follow up phone calls were made at one and three 
months, firstly to the GP and secondly to the patient themselves or their care 
home to detect later cases of healthcare associated respiratory tract infection.  
Any prescriptions of antibiotics and their underlying indication were noted. 
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Table 17. Diagnostic criteria for hospital acquired pneumonia used in this 
study 
British Society for Antimicrobial 
Chemotherapy guidelines [10] 
American Thoracic Society Guidelines[19] 
New infiltrates on chest radiograph  
Plus two of: 
Purulent respiratory secretions 
Temperature >38.3ºC 
White cell count>10 or <4 
Increased oxygen requirement 
New infiltrates on chest radiograph  
Plus two of: 
Purulent respiratory secretions 
Temperature >38ºC 
Leukocytosis or leucopoenia 
 
 
 
 
Table 18. Criteria to distinguish probable and possible cases of hospital 
acquired pneumonia 
Criteria Diagnosis 
Consolidation on chest radiograph* 
plus 2 or more minor criteria 
Probable HAP 
Consolidation on chest radiograph* 
plus 1 minor criterion 
Possible HAP 
Pneumonia as 1A on death certificate  Possible HAP 
*as per report by radiologist
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4.2.7 Ethic al considerations 
Ethical approval was granted by the Newcastle and North Tyneside 2 research 
ethics committee.  The Newcastle Upon Tyne Hospitals trust agreed to act as 
sponsor for the research and Research and Development approval was granted.   
Minor amendments were granted in 2009 in order to allow five swab samples 
rather than three, to sample tongue and throat rather than just throat, and to 
use two swabs at each time point.  A second minor amendment was approved 
later in 2009, after the study had started to allow recruitment of other fracture 
types to the lower limb in order to boost recruitment numbers. 
4.2.8 Statistical analyses 
Microsoft Excel (versions 2007-2010) was used to store and manipulate 
anonymised data prior to analysis.  All analysis was undertaken in R (R: A 
language and environment for Statistical computing, Vienna, Austria).  
Generalised linear models with a binomial error structure were used to analyse 
some variables.  For repeated measures, generalised linear modelling with 
penalised quasi likelihood was used. 
4.2.9 Funding 
This project was funded by the Medical Research Council as part of a Clinical 
Research Training Fellowship in June 2008. 
4.3 Results 
4.3.1 Recruitment of study cohort 
The final study cohort consisted of 93 patients recruited between April 2009 and 
July 2010 (consort diagram shown in Figure 3).  Recruitment was difficult for 
many reasons.   Consent needed to be coordinated around anaesthetist, surgeon 
and nursing visits, and obviously the operation itself.  Patients were frequently 
in pain or scared and some were very tired.  Many refused immediately, stating 
that they didn’t wish to undertaken any extra unnecessary burdens at such a 
difficult time.  Others accepted initially, but then declined when they realised 
they needed to sign a form.   Interestingly, it was relatively easy to recruit those 
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with cognitive impairment because their relatives could appreciate the non-
intrusive nature of the research and readily agreed for their relative to take part.   
Reasons for exclusion and withdrawal are summarised in Table 19.  More 
females declined to participate than males (54% versus 42%).  The cohort 
includes three patients who withdrew but consented to have their data used, 
but these patients were excluded for analyses relating to HAP.    Two patients 
recruited did not have an operation and one patient had two admissions 
separated by three days for the same fracture which had become unstable on 
discharge.  Demographic data was taken from the first admission in this case.  
One patient could not be contacted during the post-discharge period for follow 
up, but his General practitioner was contacted.  
Recruitment varied by month and between the same month in different years 
(Figure 4) and was proportional to the numbers of patients screened for each 
month.     
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Figure 3. Consort diagram showing fates of screened patients 
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Excluded (n=49) 
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Excluded (n=6) or 
withdrew (n=3) 
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Table 19. Reasons for exclusion, withdrawal and refusal to participate in the 
study 
Non-recruitment category Reasons for non-recruitment 
Excluded at screening Community acquired pneumonia                    (n=16) 
Miscellaneous                                                      (n=14) 
Unwell, transferred to other hospital               (n=13) 
Taking oral steroids                                             (n=6) 
No consent obtained No reason stated                                                  (n=83) 
Logistical problems                                             (n=52) 
Moribund or aggressive                                      (n=35) 
Too tired or in too much pain                             (n=20) 
Withdrew or excluded 
after initial recruitment 
Community acquired pneumonia                     (n=4) 
Patient wish                                                           (n=3) 
Transfer to other hospital                                    (n=2) 
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             Figure 4. Numbers of patients screened and recruited by month during study period 
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4.3.2 Demography of the study cohort 
Of the final cohort of 93 study patients, 29 (31%) were male and 64 (69%) were 
female.  The majority of patients were admitted from their own homes (78/93, 
84%), with 11 (12%) residing in nursing or residential care prior to admission, 
and four (4%) patients being transferred from other hospitals after a fall and 
subsequent fracture.  Distributions of other demographic data are shown 
graphically in Figure 5.  
Figure 5. Distributions of demographic and functional data from study 
patients. 
 
Note: One patient had no weight recorded 
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Figure 5 describes a cohort with a mean age of 81, who were functionally 
independent (median Barthel score 20) but beginning to feel fatigued (median 
clinical frailty score of 4) and who were mobile but with some limit to their 
exercise tolerance (median HABAM score of 53).  The Charlson index ranged 
from 2-11, with a median index of 5 (a score of 5 translates to a 21% risk of 
death at 10 years). The median weight was 63 kilograms (kg) with a range from 
36 to 102 kg. 
Visual impairment was common (75/93, 81%), and hearing impairment was 
less common (27/93, 29%).  Patients were prescribed a range of 0-19 drugs at 
admission, with a median of 6 medications.  Drugs that have been previously 
associated with pneumonia were prescribed frequently to the study patients 
and are summarised in Table 82, Appendix G.   In terms of number of 
comorbidities at admission, the median number of comorbidities was 6, with a 
range from 0-15.  In total, 17 (18%) patients had chronic obstructive airways 
disease (COPD).   The majority of patients (n=76, 82%) were non-smokers at the 
time of the study which included 47 (51%) ex smokers and 31 (31%) never 
smokers.   
When patients were divided into two groups clinical frailty score (1-4=fit, 5-
9=frail), frailer patients were older (p=0.005), had a higher Charlson 
comorbidity index (p=0.003), were prescribed more drugs at admission 
(p<0.001) and were less mobile (p<0.001).  There was slight evidence that frailer 
patients had fewer teeth (p=0.058).    
4.3.3 Operative and anaesthetic data 
The majority of patients (86/93) had sustained fractures to the neck of femur, of 
which 43/87 were intracapsular, and 43/86 were intertrochanteric.  The 
remaining six patients had fractured the femoral shaft (n=2) or an ankle (n=5).   
The operations performed for each type of fracture are shown in Table 20.  One 
patient was discharged for three days but readmitted for operation when 
conservative treatment failed, and this was treated as one admission as 
described above.  One patient was operated upon but the fracture was found to 
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be old and healed and therefore was closed without procedure, and two other 
patients were managed without operation due to alignment of fracture.  
 In terms of anaesthetic type, 53% of patients (n=49) received a general 
anaesthetic with laryngeal mask airway and femoral nerve block, and 29 (31%) 
received a general anaesthetic, endotracheal tube and femoral nerve block.  Five 
patients (5%) received general anaesthetic and endotracheal intubation only, 
and seven (8%) received spinal anaesthesia.  The type of anaesthetic was 
unknown for one patient.  
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Table 20. Type of fracture and operations performed on study patients (n=90) 
Fracture type Number of 
patients 
Operation Number of patients (n=91)* 
Intracapsular neck of femur 43 Hemiarthoplasty  37 
AO** screws 4 
Exeter bipolar hemiarthoplasty 
 
2 
Intertrochanteric fracture of neck 
of femur 
 
42 Dynamic hip screw 34 
Intramedullary hip screw 8 
Femoral shaft fracture 
 
2 Open reduction and internal fixation of femur 2 
Ankle fracture 5 Open reduction and internal fixation of ankle 5 
*2 patients had stable ankle/femoral fractures which were subsequently not operated upon and 1 patient was operated upon but found 
to have a healed hip fracture, and no treatment was undertaken. 
** AO = Algemeinshaft fur osteosynthesefragen 
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4.3.4 Findings from oral health examinations 
Fifty patients possessed teeth, with a range of 0-28, median of 5, and lower and 
upper quartiles of 0 and 20 respectively.  Of these, 24 also wore removable 
dentures.  Forty-three patients had no teeth and all but one wore removable 
dentures.  In total, 66 patients wore removable dentures.  The numbers of 
plaque scores recorded by dental status are shown in Table 21.   
No statistically significant variation was seen between dental nor denture 
plaques score over the three examinations (Figure 6), nor between fitter and 
frailer patients over time.   Dental findings are summarised in Table 83, 
Appendix G.   
Table 21. Frequency of plaque scores undertaken per examination  and dental 
status 
Examination day Total (n=92*) Dentate (n=50) Denture wearing 
(n=67) 
1 92 49 60 
7 78 44 54 
14 61 33 44 
*One patient had neither teeth nor dentures 
The distribution of xerostomia inventory (XI) scores (n=58) taken on day 14 
ranged from 0-46, with median 16.5, and lower and upper quartiles 10 and 26 
respectively.  The data were non-parametric, even after logarithmic 
transformation.  Therefore a binomial value based on low XI score (0-10) and 
high score (>10) was calculated.  A score of 0-10 was chosen to represent those 
who either had responded “very often”   to only one or two questions or who 
responded less strongly to several questions (or indeed those with a score of 0, 
n=3).  High XI score (n=40) was not significantly associated with age, clinical 
frailty scale, Charlson comorbidity index, number of drugs prescribed at 
admission, nor prescription of cognitively active drugs at admission.  There was 
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a slight association between high XI score and number of comorbidities 
(p=0.055, Fisher’s exact test). 
 
Figure 6. Plots of modified Quigley Hein indices from dental and denture 
examinations of study patients on day 1, day 7 and day 14  (A= Dental 
examinations only, B=Denture examinations only) 
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4.3.5 Results from real-time PCR assays of oral samples 
A total of 816 samples of extracted nucleic acid (408=tongue swabs, 408=throat 
swabs) from 93 patients were successfully tested using the novel multiplex real-
time PCR assays.  Human DNA was found in all samples, as evidenced by 
positive GAPDH assay results.   Thresholds for positive identification of target 
pathogens are described in 3.4.3.  Distributions of Ct values for positive results 
from PCR assays are shown in Figure 1, Appendix G.  Ct values from the 
GAPDH assay were normally distributed, but the distributions of Ct values 
from the other assays were negatively skewed and zero-inflated.   
Frequencies of patients with different numbers of time points sampled are 
shown in Table 22.  Two sets of samples were taken late due to an oversight in 
recording when follow-up should occur for each patient.  Eleven patients 
missed one sample for logistical reasons or memory error; seven missed sample 
two, two missed sample three and two missed sample four.  The first sample 
was taken preoperatively in 50 patients and post-operatively in 43 patients. 
Table 22. Frequencies of patients with different numbers of time points 
sampled  
Number of time points sampled Frequency (n=93) 
5 55 
4 24 
3 5 
2 4 
1 2 
 
Mean CT values from the GAPDH assay were compared over the 5 sampling 
points using generalized linear modeling with Penalised Quasi-Likelihood ( 
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Table 23), and no significant difference was found.  This suggests differences 
seen in target organism assays over time were likely to be real. 
Table 23. Mixed effect model fitted using penalized quasi-likelihood relating 
CT values for the GAPDH assay over time in hospital 
Target Value Standard 
error 
DF T value P value 
GAPDH -0.023  0.024 722 -0.951    0.342 
(Intercept) Residual, StdDev:    2.257 2.815 
Individual patient results are shown in Appendix F.  Twenty patients had all 
negative swabs.  Of the remaining 73, 17 had transient acquisition of a single 
pathogen on one day only, and the other 56 had single (n=26) or mixed 
pathogen colonisation (n=30).  Of single pathogen colonisation, S. pneumoniae 
was most common (n=20), followed by P. aeruginosa (n=6), H. influenzae (n=4) 
and E. coli/Acinetobacter spp (both n=2).  S. aureus colonisation alone was seen 
in one patient.  Certain combinations of pathogens were seen more frequently.  
Disregarding the persistence of the organisms, the commonest combinations of 
organisms were permutations containing S. pneumoniae and H. influenzae (n=11), 
S. aureus and MRSA (n=10), E. coli and H. influenzae (n=5), and S. pneumoniae 
and P. aeruginosa (n=5). 
To examine the effect of time in hospital on prevalence of target pathogens, 
abundance of each of the target organisms at the five sampling time points was 
plotted in Figure 7 (raw numbers are shown in Table 84, Appendix G).  S. 
pneumoniae was most abundant throughout the sampling period, and appeared 
to decline over time.  H. influenzae was next common and also appeared to 
decline significantly over time in hospital.  MRSA, S. aureus, P. aeruginosa, E. coli 
and Acinetobacter spp were comparatively rare.  Fewer than 5% of samples 
overall were positive for “hospital” pathogens (MRSA, E. coli, P. aeruginosa and 
Acinetobacter spp.), and coliforms were seen in around 8% of samples.   The 
results from the coliform assay are included here for interest but will not be 
shown in later analyses. 
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Figure 7. Abundance of target organisms in all samples over time  
 
 
Note: The number of patients with samples positive for each organism at 
each sampling point is represented by the area of the shaded circles.  Several 
organisms may arise from a single patient sample.  S. pneumoniae, H. 
influenzae and coliforms were detected most commonly in all patients. 
 
 
However this plot does not take the persistence of colonisation of the organisms 
into account. For example, patients with a positive E. coli result on sample 1 or 
sample 2 may both have positive results on sample 3.  More important in terms 
of clinical relevance is when organisms were first seen.   Results from PCR 
assays from individual patients (Appendix F) were used to define when 
acquisition and colonisation first occurred.  Acquisition was defined to have 
occurred if samples were positive at one or more time points (either tongue, or 
throat or both samples positive).  Colonisation was defined as samples positive 
at two or more time points, which need not have been consecutive (tongue or 
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throat or both samples positive).  Figure 8 shows the first day of acquisition or 
colonisation of target organisms, and Figure 9 shows the first day of 
colonisation only.  Acquisition was more common than colonisation in all 
organisms apart from S. pneumoniae.  Colonisation was rare in E. coli (2%), 
MRSA (2%), P. aeruginosa (4%), Acinetobacter spp. (2%), moderately common in 
S. aureus (8%) and H. influenzae (9%), and common in the case of S. pneumoniae 
(29%).  The majority of both acquisition and colonisation began early in 
admission (day 0-3).   When considering colonisation only (Figure 9), it is even 
clearer that the first day of colonisation was within the first three days of 
admission for the majority of organisms.   Only MRSA and P. aeruginosa began 
to colonise at day 7, albeit rarely.  It is unclear from these analyses whether 
colonisation occurred as a result of events surrounding admission or whether 
these results reflected earlier colonisation in the community.  There were no 
marked differences between the incidence of positive results between patients 
whose first sample had been taken pre- versus post-operatively.
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Figure 8. First day patients acquired each of the seven target organisms (area 
of circles represents number of patients who first acquired each organism by 
swab number taken) 
 
Figure 9. First day patients became colonised with  target organisms  
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A generalised linear model with Penalised Quasi-Likelihood (GLMMPQL) was 
used to investigate changes in presence/absence of individual organisms over 
time using Ct value as a binary variable by patient (Table 24). Tongue and 
throat swabs were treated equally. 
Table 24. GLMMPQL model relating presence/absence of organism over time 
in individual patients to investigate whether changes over time in hospital 
occurred. 
Organism Coefficient Standard error DF T P value 
H. influenzae  -0.222  0.043 315 -5.123        0 
S. pneumoniae  -0.053 0.030 315 -1.759   0.080 
Coliform 0.003 0.203 315 0.017   0.986 
E. coli  -0.082  0.044 315 -1.879   0.061 
P. aeruginosa  -0.016 0.030 315 -0.541    0.589 
S. aureus  0  0 315 -13.984        0 
MRSA -0.039  0.208 315 -0.187   0.852 
Acinetobacter 
spp 
0.024 0.027    315 0.861  0.390 
DF =degrees of freedom 
Only H. influenzae was shown to decline significantly over time, with an odds 
ratio of 0.44.  Occurrence of H. influenzae declined by 20% at each sampling 
point.  There was slight evidence that S. pneumoniae and E. coli decreased with 
time.  GlmmPQL modelling  of S. aureus above produced wide standard error 
and a large negative coefficient and therefore a simple generalised linear model 
was also undertaken, the results of which were non-significant (Table 25). 
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Table 25. Generalised linear model relating presence of S. aureus over time in 
individual patients to investigate whether changes over time in hospital 
occurred. 
Organism Estimate Std. Error z value P value    
S. aureus -0.027     0.049 -0.552     0.581     
Null deviance: 198.94  on 408  degrees of freedom, Residual deviance: 198.63  on 
407  degrees of freedom, AIC: 202.63 
4.3.6 Complications during admission and length of stay  
Complications were common among the study patients (n=90), with a median 
of eight complication events per patient (range 0-50).  Aspiration events were 
observed in four patients by the study investigator (VE) at study visits.  
Cerebrovascular disease had been documented in 16 patients (18%), of which 
one of these had a witnessed aspiration event.  Post-operative cough occurred 
in 41 patients (46%).  Eight patients had one or more falls in hospital.  Despite 
receiving prophylaxis against deep vein thrombosis (in the form of once daily 
subcutaneous low molecular weight heparin), five patients (6%) developed a 
deep vein thrombosis (DVT) in hospital. Twenty patients (22%) developed one 
or more urinary tract infections.  Ten (11%) developed either a hyper- or 
hypoactive delirium.  Eight patients (9%) developed an infection, excluding 
urinary tract infection and hospital acquired pneumonia (e.g. wound infection).  
Sixteen patients (18%) developed non-infectious acute illnesses (e.g. vomiting, 
digoxin toxicity).  Other complications included new drugs being started (all 
patients were prescribed new drugs which usually included calcium and a 
bisphosphonate to reduce fractures) and complications specific to a particular 
patient.  Four patients were transferred to intensive care for escalation of 
treatment, of whom two patients developed HAP (not related to ventilation).  
All patients transferred to intensive care died.   
Length of hospital stay ranged from 4-265 days, with a median of 25 days and 
lower and upper quartiles of 14 and 53 days respectively.  Increased length of 
stay was significantly associated with the combination of increased number of 
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complications, increased clinical frailty score and presence of urinary tract 
infection during admission (Table 26). 
Table 26. Relating length of hospital stay with patient variables using Cox’s 
proportional hazards. 
Variable Coefficient Exponential 
(coefficient) 
Standard 
error 
(coefficient)       
Z value P value     
Number of 
complications 
-0.066    
 
0.936   0.016 -4.188 <0.001*** 
Clinical 
frailty score 
-0.208    0.812   0.090   -2.310 0.021 *   
Urinary tract 
infection 
-0.508    0.602   0.276 -1.838    0.066 .   
 
 
 
 
Table 27. Chi squared results from variables include in the survival analysis 
Variable Rho Chi squared P value 
Number of 
complications 
0.405  20.057 <0.001 
Clinical frailty 
score 
-0.099   
 
1.522 0.022 
Urinary tract 
infection 
0.054   0.244 0.062 
Global NA  23.625 <0.001 
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Figure 10. Survival curves of length of stay in hospital of study patients 
(Confidence intervals plotted with dashed line, solid line represents survival 
curve.  The risk of discharge declines sharply until day 50, less sharply until 
day 100 and then flattens as the vast majority of patients have no been 
discharged.) 
 
 
The proportional hazards assumption of the Cox regression were tested and the 
chi squared values associated are shown in Table 27.  The risk of discharge in 
relation to significant covariates was not proportional and increased with time 
spent in hospital (Figure 11).  
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Figure 11. Risk of discharge plotted against time in hospital and number of 
complications (Each circle represents a patient and the solid line represents 
the risk of discharge, with dotted lines representing confidence intervals 
around this) 
 
4.3.7 HAP and death during admission  
In total 10/90 (11%) patients developed HAP during the hospital admission, 
and 18/90 (20%) of patients developed HAP or LRTI at any point during the 
study period (of whom three patients developed LRTI during admission.).  
Microbiological results from patients who developed HAP are shown in Table 
85, Appendix G.  Three patients who developed HAP were found to have active 
cancer during the hospital admission (metastatic lung cancer, metastatic 
prostate cancer and high grade glioma of brain), and these patients all died 
during follow up. Two of these patients received radiotherapy during follow up 
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(but after the oral sampling period) and subsequently developed HAP.    The 
median number of days to HAP was 27 (range 2-88).  Diagnosis of HAP was 
further characterised using two definitions (British Society for Antimicrobial 
Chemotherapy, BSAC and American Thoracic Society, ATS) which were 
concordant in all 10 patients.  Seven patients were characterised as “probable 
HAP” and three more as “possible HAP”.   Two of the “possible HAP” patients 
were diagnosed from death certificate, but did not have new changes on chest 
radiograph (or did not have a chest radiograph due to severity of illness) and 
therefore did not fulfil BSAC or ATS criteria.  However these patients were 
sufficiently unwell that they were treated for HAP based on clinical findings.  
Initial antibiotics prescribed included cefuroxime and clarithromycin (n=2), 
coamoxiclav (n= 4), Piperacillin-tazobactam (n=2), doxycycline (n=1), and 
chloramphenicol (n=1, patient with S. aureus bacteraemic pneumonia).  Two 
patients were prescribed additional metronidazole to cover anaerobic causes of 
pneumonia, due to suspicion of aspiration.  Of the ten patients with HAP, five 
had two courses of antibiotics for HAP due to recurrence of symptoms after 
treatment had stopped, and one was prescribed three courses of antibiotics in 
total (patient 97).  Patients who were prescribed two or more courses of 
antibiotics were no more likely to die than those prescribed only one course of 
antibiotics.  Case vignettes of those who developed HAP are described in Table 
86 in Appendix G. 
In total, ten patients died in hospital (10.8%); six of those died from HAP, one 
from pressure sores and probable wound infection, one from acute interstitial 
pneumonitis (extensive invasive respiratory cultures negative), one from 
cardio-respiratory failure and pulmonary embolus and one died from gram-
negative bacterial sepsis secondary to catheter insertion.  HAP was therefore the 
leading cause of in-hospital death.  Length of stay before death in hospital 
ranged from 5-146 days with a median of 32.5 days.  Death after admission for 
lower limb fracture was highly significantly associated with residence in either 
institution or hospital prior to admission.  
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Table 28. Generalised linear model relating death from all causes during the 
entire study with residence in either institution or hospital prior to admission 
 Estimate  Std. Error z value P value OR (95% 
confidence 
intervals) 
Residence in 
hospital or 
institution 
2.036     0.638    3.190   0.001 ** 7.66 (2.19-
26.74) 
Null deviance: 82.175  on 92  degrees of freedom, Residual deviance: 72.314  on 
91  degrees of freedom, AIC: 76.314 
 
4.3.8 Discharge and follow up 
Ten patients died in hospital (10.8%) and the remaining 83 patients survived to 
discharge (Table 29).  The majority of these patients returned home, with eight 
patients changing from home to institution: five to residential care, and three to 
nursing care.   
Table 29. Hospital discharge destinations of study patients 
Discharge destination Number of patients (n=93) 
Died in hospital 10 
Own home 67 
Residential home 11 
Nursing home 5 
 
A further five patients died during the 90 days following discharge from non-
HAP causes, leaving 78/93 (84%) alive at 90 days after admission, or a crude 
mortality rate of 16% at 90 days.  Eight (10%) patients received antibiotics for 
lower respiratory tract infection during the 90 day follow up period.  Owing to 
lack of access to chest x-ray in the community it was not possible to determine 
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whether these patients in fact had pneumonia.  Ultimately 8/10 patients who 
had HAP during the study died (six from HAP, one possibly form HAP and the 
other from high-grade glioma), while none of the patients with HAP/LRTI 
diagnosed after discharge died.  HAP was responsible for 40% of the deaths 
during the entire study period, and 80% of patients who developed HAP died.   
4.4 Discussion 
It has been assumed that increased length of stay in hospital was associated 
with increased rates of colonisation with “hospital” type commensal pathogens, 
such as E. coli, P. aeruginosa, and Acinetobacter.  However results above suggest 
that both transient acquisition and colonisation occur for the first time within 
the first three days of admission in the majority of organisms.  Only MRSA and 
P. aeruginosa began to colonise at day 7, and these events were rare.  It is unclear 
whether detection of these organisms early in admission represented the oral 
flora acquired from the community, or whether organisms were acquired as a 
result of a combination of events surrounding the fracture, including the use of 
peri-operative antibiotics.  Studies on the oral flora of subjects receiving 
antibiotics (amoxicillin, ceftriaxone, penicillin) have reported a rapid but 
transient reduction in numbers of commensal organisms (e.g. viridans 
Streptococci) [251-253] and commensal pathogens such as S. pneumoniae, 
Branhamella (Moraxella cattarhalis) and H. influenzae [254], with restoration of 
previous flora either during therapy or after discontinuation of antibiotic 
treatment.  One study reported cefpirome had no effects on pharyngeal flora 
[255].  In our study 20 people were colonised with S. pneumoniae throughout 
admission despite peri-operative antibiotics (which included antibiotics active 
against S. pneumoniae), which suggests that the antibiotics had little effect on 
this organism, possibly due to the brevity of the course (three doses only).  
There were no great differences between the incidence of positive results 
between patients whose first sample had ben taken pre- versus post-
operatively, therefore it is likely that events proximal to the operation 
influenced the occurrence of colonisation.  It must also be noted that, given the 
small number of samples taken, the risk of two samples being colonised starting 
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on sample 3 or later must be lower as there are fewer opportunities for the 
sample to be positive.   
In general, these findings suggest that the hospital environment is not a major 
source of colonisation of target pathogens in this cohort of patients.  Even 
transient acquisition (swab positive at only one time-point) was more common 
in the first 3 days of admission.  These findings cannot be applied to patients in 
other settings such as those on general medical wards or intensive care units.  In 
practical terms, this means that the window for intervening to prevent putative 
sequelae of oral colonisation with respiratory pathogens is within 72 hours of 
admission to hospital in this cohort. 
It is difficult to compare levels of colonisation of the target pathogens with 
those found in other studies due to differences in definitions, particularly given 
this was a relatively small study.  However colonisation with respiratory 
commensal pathogens was generally relatively infrequent, apart from with S. 
pneumoniae (29%), which was high when compared with estimates of 1-13% in 
nasopharygeal samples from young adults [256].  H. influenzae has previously 
been detected from 3-19% of young adults [256].  Previous studies have 
suggested prevalence of S. aureus colonisation as ranging from 23-48% [29, 257], 
so estimates here are low, probably again due to differences in definition. 
The tongue and throat, as opposed to dental plaque, were sampled because it 
was assumed that the risk of HAP would be higher if colonising organisms 
were present anywhere in the mouth rather than specifically in dental plaque.  
A previous study identified that coliform bacteria, S. aureus and P. aeruginosa 
were more commonly identified in the oral rinse, tongue or throat samples than 
from dental or dental plaque [245].  Dental or denture plaque often only became 
positive when all other sites were also positive.  However, a study by Furrier et 
al. demonstrated that coliform positive dental plaque was likely to give rise to 
nosocomial infection whereas S. aureus infected dental plaque was not [42].  
These assumptions need to be tested further to clarify the optimal sampling 
sites for future studies. 
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It was felt to be important to include older adults with cognitive impairment in 
the study because poor cognition has been associated with higher risk of HAP 
[258], and also to aid translation of study findings to “real” populations of 
patients.  Therefore a combination of tongue and throat swabs was used to 
sample the oral microbiota, which was shown to be the minimally inclusive 
sampling combination in those with cognitive impairment in an earlier study 
[245].  The gold standard method for detecting oral microorganisms such as S. 
aureus, coliform bacteria and Pseudomonads was shown to be the oral rinse 
sample [245].  Thus results from the final assays may have missed some 
organisms which would have been detected by an oral rinse.   Nasal sampling 
was not undertaken but also may have increased yield of target micro-
organisms, especially for S. pneumoniae [259].  There were few data available 
regarding the prevalence of hospital respiratory pathogens (e.g. P. aeruginosa, E. 
coli) from nasal samples compared with oral sampling. 
The patient cohort in general was representative of a population of “well” 
persons with lower limb fracture, but some biases occurred at recruitment.  In 
particular, 20/190 patients (11%) who refused to participate cited that taking 
part would be “too much” for them suggesting a degree or strain or anxiety 
contributing to refusal.  In addition, 35/190 (18%) were moribund or deemed 
too aggressive to take part in the study.  Aggression was associated with 
dementia, and patients were often bed-bound and could or would not open 
their mouths to have swabs taken, which was taken as refusal of assent to 
participate.  The withdrawal rate was low (3/93, 3%).  Recruitment took place 
on Monday to Friday only, and patients who were admitted on either Friday 
evening or Saturday were not included.  This is unlikely to have introduced 
systematic bias in the type of patient recruited as there are presumably no 
differences between people who fall on a Thursday or a Friday.  However 
missing these patients could have introduced a difference in outcome in terms 
of the ward care received, due to lower weekend staffing levels as compared to 
weekday.  Of all the patients who potentially could have been recruited, 74% 
were female.  However, 54% of females declined, compared with 42% of males.  
The proportion of women recruited was 69%, less than the 80% expected 
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(around 80% of hip fracture patients are said to be female) but may reflect that 
proportionally more men were willing to participate.  
The rate of HAP in this study (10%) was similar to the 9% found in a previous 
UK study of hip fracture patients [23].  The cohort in this study was a “well” 
population, and patients with acute medical illness, patients who were 
moribund and patients who were aggressive or uncooperative as a result of 
moderate-severe cognitive impairment were excluded at recruitment.  In 
addition, seven patients had fractures of either ankle or femoral shaft, and were 
likely to be less frail and therefore less at risk of HAP than were the patients 
with fractured neck of femur.   
It could be argued that by ensuring complete follow up of patients in hospital, 
ascertainment bias occurred.  However the diagnosis of HAP was made by an 
orthogeriatrician independent of this study, and either a chest radiograph plus 
other signs or a death certificate diagnosis plus other signs were needed to 
verify a diagnosis.  Diagnosis of HAP is difficult because there is no gold 
standard diagnostic test.  The prospective nature of follow up is likely to have 
increased accuracy of diagnosis as compared with retrospective follow up.  
While it could be argued that including the use of death certificate data is less 
objective than a positive chest radiograph,  two patients who were clinically 
suspected to have died from HAP but were too unwell to undergo chest 
radiography would have been otherwise missed.  The above criteria represent 
the best diagnosis that can be made without invasive respiratory sampling or 
computed tomography scanning. 
Two patients underwent radiotherapy after active cancer was discovered 
during hospital admission, and subsequently developed HAP.  While chemo- 
or radio-therapy were exclusion criteria for the study, pathological fracture was 
not, and therefore these patients were included.  However their risk of HAP 
may have been greater due to both cancer and radiotherapy, and there was an 
argument for excluding these two patients from analysis.  Central to this work 
has been the attempt to make the findings as relevant to a “real” population of 
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patients as possible, in order to aid translation into everyday clinical work, and 
therefore, it was decided to include these patients in the analysis. 
Previous publications have suggested that nursing home residents with HAP 
were more likely to “present atypically”- that is with a delirium [14, 15], not 
getting out of bed (“off legs”), falls  or decreased oral intake compared to 
younger patients.  In this study, 7/10 patients fulfilled both ATS and BSAC 
criteria for pneumonia, one only had one minor criterion but had a positive 
chest radiograph and two patients were too unwell for chest radiography and 
were diagnosed by death certificate.  The criteria for ATS and BSAC diagnoses 
are slightly different in terms of temperature and white cell count thresholds, 
and also in that the BSAC guidelines include decreased oxygen saturations.  
Anecdotally, sometimes one would have to look harder to detect relevant 
clinical findings (e.g. green phlegm on nightgown in a patient not apparently 
coughing), but the typical clinical signs of pneumonia were still present in this 
older age group, and other modes of presentation were additional to, rather 
than instead of, the traditional clinical presentation of pneumonia.   
The death rate in this cohort was higher than previously suggested (60% 
compared with 18-43%), despite exclusion of the sickest patients at recruitment.  
It is unclear why the mortality rate was higher in this study than others and 
may relate to complete follow up (i.e. greater ascertainment of outcomes) or 
may be related to there being an over representation of males within the cohort, 
who are more likely to develop HAP.  Regardless, HAP was the leading cause 
of death in hospital in this cohort, and was associated with death in 40% of 
those who died during the study.  Therefore efforts to prevent HAP are 
warranted, given the scale of the problem of lower limb fractures in older 
people.  
Patients admitted from a location other than their own homes were 
approximately seven times more likely to die in hospital.  This has been 
attributed to patients in institutional care having a poorer prognosis from 
pneumonia than community dwelling persons [260].  Given the strength of this 
effect, however it may be prudent to class these patients as high risk when 
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counselling patients and families about outcomes after hip fracture.  In a 
retrospective study of 195 nursing home residents who sustained a hip fracture, 
76.9% died in the 1.4 year median follow up, and the risk of death was 70% 
greater if there had been an episode of pneumonia within six months of hip 
fracture [240].  There is no single strategy to prevent deaths in patients admitted 
from other locations, but patients transferred from other hospitals may need 
greater attention placed on their care if a full recovery is anticipated, with 
proactive management of existing conditions and shared care between other 
specialties where appropriate.  In addition, the information may help to plan 
escalation of therapy and to prepare the patient and family about possible 
outcome, if they wish for this information. 
Few patients underwent spinal anaesthesia in this study, which is commonly 
used when operating on patients with hip fracture in other centres (in Scotland 
around 60% undergo spinal anaesthesia)[261].  No airway is inserted when 
patients undergo spinal anaesthesia, although sedative drugs are given which 
may increase the risk of aspiration or respiratory depression.  While spinal 
anaesthesia is recommended in patients with hip fracture, there is no clear 
evidence of clinical benefit, though one study suggested that respiratory 
morbidity was higher after general anaesthetic in octogenarian patients [262].  It 
is possible that increased instrumentation of the airway in patients in this study 
could have increased the rate of HAP but would not be expected to account for 
increased mortality.   
Dental plaque scores were relatively high, indicating unmet oral health needs in 
older patients with lower limb fracture in hospital, but there were no significant 
differences in scores over time, or between fitter and frailer patients.  Patients 
anecdotally reported struggling to clean their teeth for a few days after 
operation because they couldn’t walk to a sink, however this observation did 
not correlate with statistically significant increase in plaque at examination on 
day 7.  However this study may have been underpowered to detect small 
differences in plaque scores (see 5.5).  The finding that there was no difference 
to plaque scores between scoring time points is in contrast with those from 
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another study  of ICU patients [42].  However, plaque scoring on day seven 
may have been too late to detect transient changes, or small changes may not 
have been detected by the modified Quigley Hein index.    
The modified Quigley Hein index was used in preference to other plaque scores 
because it was a visual score (and therefore did not necessitate the removal of 
plaque and was repeatable for inter-examiner alignment) and because of its 
ability to discriminate between larger and smaller plaque loads.  Previous 
studies indicated that some older patients have extensive denture or dental 
plaque, and it was hypothesised that these patients would be more likely to be 
colonised by respiratory commensal pathogens, if plaque was the stable 
reservoir of infection.  Other possible plaque scoring systems (e.g. Silness and 
Loe or a dichotomous scoring system) require the use of a dental probe or do 
not distinguish between heavier loads of plaque.  Disclosing tablets were not 
used, as brushing to remove the colouration could have interfered with the 
outcomes being studied, but this could have produced a greater degree of intra- 
and inter-rater variation, and potentially led to more conservative scoring.  
Indeed, neither of the two medical research nurses associated with this project 
achieved sufficiently high agreement with the PI (VE) to undertake plaque 
scoring as part of the study.  Ideally, intra-rater calibration ought to have 
occurred at several time points during the study and included more surfaces.  
Because examinations took place at the bedside, lighting was suboptimal and 
air-drying of teeth was not undertaken, which could have contributed to poorer 
detection of smaller amounts of plaque.  In retrospect, full mouth scoring may 
not have been needed [263], which would have decreased time taken for 
examinations and potentially left more time for calibration.  Three forms of bias 
have been identified when undertaking plaque scoring [263]- leniency, central 
tendency and the halo effect.  Leniency, the tendency to score all teeth similarly, 
and central tendency bias combined could have led to increased scoring of 
middle values.  The halo effect, where the general oral appearance, discrepant 
with the actual state of the teeth leads an examiner to score more or less 
leniently was more likely to have led to generally increased scores in older 
hospitalised patients.  If these biases occurred they could have contributed to a 
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lack of difference between examinations.  However because scoring was 
undertaken by a single examiner, the effects from these biases are likely to have 
been minimised, as these biases are likely to be more pronounced when 
aligning several examiners.  
The same scoring system was used for teeth and dentures, but dentures were 
removed, (and some drying will have therefore taken place) and examined in 
better light, and smaller deposits of plaque may have been seen on dentures 
because of this.  It was difficult to know how to score debris between but not on 
teeth, and it may have been better in terms of subsequent analysis to have 
scored this debris according to the height of plaque, as per the Quigley Hein 
index, rather than simply assigning a score of 3, as this would have created a 
central tendency bias, and again could have contributed to not finding a 
significant difference between scores. 
A composite plaque score was created so that all the patients could be included 
in analysis relating to plaque, and the higher of the dental or denture quartile 
score was used in analysis.  Previous studies had not shown any association 
between amount of plaque and presence of respiratory pathogens [42, 153], so 
using the higher score added strength to accepting the null hypothesis.  Overall, 
small differences between scores may have been minimised, but larger 
differences between very little plaque and large amounts of plaque were 
adequately characterised. 
Several areas highlighted in this study warrant further investigation.  Most 
clinically relevant would be to validate the risk factors for increased length of 
stay in hospital, as this could be used to plan discharge and escalation of care.  
Specifically, preventing urinary tract infections via reducing urinary catheter 
use (the commonest cause of UTI in hospital patients [264]) has the potential to 
save money by reducing patient stay.  It would also be interesting to compare 
oral colonisation dynamics of respiratory commensal pathogens with patients 
in other setting such as medical admissions wards and other surgical wards, 
and to sample for longer into the admission.  Once more bacterial genomic 
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sequencing data for other coliform bacteria becomes available, it will be 
possible to investigate the role these bacteria have in the development of HAP.   
4.4.1 Conclusions 
Oral colonisation with respiratory commensal pathogens begins predominantly 
within the first three days of admission in older patients with lower limb 
fracture, and not as a result of time spent in hospital.  If oral hygiene 
interventions are implemented with a view to modifying the oral microbiota, 
these should be undertaken at the start of hospital admission in this group of 
patients.  Patients admitted to hospital with lower limb fracture from locations 
other than home should be treated as having a high risk of death in hospital, 
and care planned accordingly.  Oral health in older patients in hospital with 
lower limb fracture is poor in some cases, with patients frequently reporting 
sensation of dry mouth.  HAP occurred in 11% of patients, with a crude 
mortality of 60%, and was the leading cause of death in hospital after lower 
limb fracture.  Efforts to understand the pathogenesis of HAP and identify 
modifiable risk factors are necessary. 
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Chapter 5  
Investigating risk factors for the development of hospital acquired 
pneumonia in older patients with lower limb fracture 
5.1 Introduction 
In order to better understand the pathogenesis of HAP in patients with lower 
limb fracture in relation to the different groups of putative risk factors,  a cohort 
of patients were followed prospectively to detect oral colonization with seven 
common  respiratory commensal pathogens, levels of dental plaque,  subjective 
sensation of oral dryness, and incidence of HAP during hospital admission.  To 
identify the most important risk factors for HAP, data on the majority of 
previously reported risk factors were collected in these patients, and correlation 
between these variables was assessed using a correlation matrix.   The cohort of 
patients in this study were a “real”, prospective population, and the study was 
approached with a clinical viewpoint, with variables utilised that are used and 
recorded in everyday clinical practice in the UK.   Univariate generalised linear 
modelling and Fisher’s exact test were used to investigate associations between 
cases of HAP and patient risk factors, which included complications occurring 
during admission.  Risk factors likely to impact on colonisation events with 
individual pathogens were then selected for inclusion in two conceptual 
models.  These models were then challenged using multivariate generalised 
linear modelling.  Infection events were investigated using individual variables 
from the models.    
5.1.1 Aims of this Chapter 
The individual aims of the Chapter are described below. 
1. Describe the extent to which patient variables interact using a correlation 
matrix 
2. Investigate whether HAP or HAP/LRTI was associated with recorded 
patient variables 
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3. Investigate whether HAP or HAP/LRTI was associated with acquisition 
or colonisation with target pathogens  
4. Investigate whether colonisation with individual target pathogens was 
associated with variables contained in the medical or dental models  
5.  Investigate whether certain combinations of pathogens or absence of 
pathogens related to either HAP or HAP/LRTI up to 3 months or other patient 
variables 
5.2 Methods 
Data collection, study variables follow up and ethical and funding are described 
in 4.2.  Three patients who withdrew were excluded from analyses in this 
Chapter because they were not followed up for HAP or LRTI after withdrawal 
(therefore n=90).    
5.2.1 Definitions of acquisition and colonisation of commensal pathogens 
Acquisition of organisms was defined as the presence of an organism at any 
point over the five sampling time points.  Seven binary variables, 
corresponding to each of the target organisms, were calculated per patient.  In 
previous studies investigating repeated microbiological samples, colonization 
by an organism was defined as two or more consecutive swabs positive for the 
same organism [265, 266].  Colonisation was thought to be important clinically, 
and was distinguished from transient carriage of that organism (single sample 
positive) which was felt to be clinically less important [35].   However it could 
be argued that non-consecutive positive swabs still constitute a risk to the 
lungs, as any simultaneous episode of aspiration could result in an increased 
risk of HAP.   Non-consecutive positive samples may represent repeated 
transient acquisition via the nose or mouth, or the waxing and waning of 
numbers of that organism, with smaller numbers not easily detected, 
particularly by culture-based methods.  Any sequelae related to carriage of 
these organisms may be proportional to number of days colonized (i.e. five 
days colonized may carry a greater risk than two days colonized).   Therefore 
analysis was also conducted using a colonization index.  The total number of 
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positive samples divided by the number of samples taken was calculated for 
each bacterium (e.g. 6/10=0.6 for S. aureus) per patient, and this value was 
known as the colonization index.  Tongue and throat samples were therefore 
considered equally.  This meant that colonisation was seen as a continuum, 
rather than a binary state, and the effect of persistent or intermittent 
colonisation could be determined. A previous group developed a colonization 
index to assist in determining when to treat intensive care patients with 
candidal colonization at risk of invasive infection [267].   However this index 
was calculated by taking the sum of the log10 of concentrations of candida 
isolated from 1ml of oropharngeal washing sample and dividing by the number 
of washings taken (maximum two).  No other colonization indices have been 
published to the best of this author’s knowledge.  Colonisation status was also 
analysed as a binomial variable, with “uncolonised” referring to the 20 patients 
with negative samples for all target organisms over all time points.   
5.2.2 Definitions of HAP and HAP/LRTI 
Two outcome variables were used in analyses in this chapter: HAP and 
HAP/LRTI.  Cases of HAP were identified when the responsible clinician 
started antibiotics for HAP, and further characterised by both British Society for 
Antimicrobial Chemotherapy (BSAC) and American Thoracic Society (ATS) 
guidelines to ensure diagnoses were robust and comparable (see 4.2.6).  
Pneumonia is distinguished from lower respiratory tract infection (a less 
serious illness) by the presence of infiltrates on chest radiograph.  In order to 
fulfil BSAC/ATS guidelines for HAP, new infiltrates were required on a chest 
radiograph reported by a radiologist.  In addition, “Pneumonia” as primary 
cause of death on death certificate was acceptable where patients were too 
unwell to tolerate chest radiography.  HAP was diagnosed during hospital stay 
only.  However, patients were followed until three months after discharge for 
episodes of pneumonia, which are now referred to as “healthcare associated 
pneumonia” [11].  Routinely UK General Practitioners (GP) do not request chest 
radiography when treating respiratory infection, and therefore it was not 
possible to determine whether these patients had pneumonia. Therefore 
episodes of lower respiratory tract infection (LRTI) were also recorded 
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throughout admission and up to three months after discharge.  Cases of LRTI 
were identified by hospital clinician or GP starting antibiotics for LRTI at any 
point during the study period; new infiltrates on chest radiograph were not 
required for diagnosis.  HAP/LRTI therefore referred to any cases of HAP 
during hospital admission, plus any cases of LRTI at any point during the study 
period. 
5.2.3 Conceptual models of the roles of patient demographics and oral health 
variables in oral colonization with respiratory commensal pathogens 
It was hypothesised that the same risk factors which caused HAP would also 
influence clinically important colonisation events with respiratory commensal 
pathogens, given that infection follows adherence and colonisation of an 
infecting organism.  In order to generate clinically relevant models to explain 
colonisation with respiratory commensal pathogens, two sets of variables were 
considered: the first from previously published studies considering HAP, and 
the second from overriding general health variables which are likely to impact 
on other variables (including two frailty scores, one mobility score and a 
comorbidity score).  These variables were later formed into two models to 
explain colonisation with respiratory commensal pathogens.  The first 
considered risk factors proximal to the site of colonisation, specifically 
involving factors of the mouth, dentition and plaque (dental model, Figure 12).  
The second involved assessing the extent to which patient demographics and 
comorbidity were risk factors for colonisation by each colonising pathogen 
(medical model, Figure 13).  These models only included variables present at 
admission, as other events could have happened at any time throughout the 
admission and not necessarily within the 14 day sampling period.  The dental 
model was smaller to allow any effects from the dental variables to be seen, as 
fewer patients could be included in this analysis (e.g. only a proportion wore 
dentures), and only pertinent non-dental demographic variables were included.  
Overriding health variables such as age, gender, functional indices and 
comorbidity index were included in both models.  The effects of tobacco smoke 
on colonisation with respiratory commensal pathogens is unknown, but is 
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known to be associated with combined obstructive pulmonary disease (COPD, 
see below) and to influence oral conditions such as periodontitis, and it seemed 
prudent to include this variable in both models.  All dental variables other than 
xerostomia index were included in the dental model, and plaque scores at day 7 
and day 14 were substituted for admission plaque score when testing models.  
The relationship between colonisation with individual respiratory commensal 
pathogens and xerostomia score was analysed separately, due to number of 
missing values.   
 Deprivation has not been tested in relation to HAP or colonisation with 
respiratory pathogens, and was included in both models to generate further 
hypotheses.  Cerebrovascular disease, a common cause of dysphagia, is 
included in the medical model, as pneumonia is a common complication after 
stroke.  COPD was included in the model because again pneumonia is common 
in patients with COPD, antibiotic use is often frequent (which in turn may be a 
risk factor for colonisation with non-oral bacteria) and some of the drugs 
prescribed commonly for COPD such as oral steroids or inhaled steroids may 
also increase the risk of pneumonia.   Dementia, ability to self consent and place 
of residence were included in the medical model, as pneumonia is common in 
nursing home residents, who in turn have a high prevalence of dementia and 
cognitive impairment.  Diagnoses of dementia were sometimes made during 
admission, usually where cognitive impairment was milder, and inability to self 
consent was a simple method of detecting all persons with significant cognitive 
impairment.  Aspiration was not included in the models because there was no 
biological explanation for an effect on oral colonisation.  Nasogastric tubes were 
inserted in two patients after the sampling period had finished and therefore 
were not included in the models. 
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Figure 12. Patient variables used in dental model 
Age + Gender+ Clinical frailty score +Barthel index + Charlson index + 
Residence + Number of Teeth + Dentures + Admission plaque score + 
Deprivation score*+Smoking 
*UK indices of multiple deprivation 
Figure 13. Patient variables used in medical model 
Age+Gender+COPD+Antibiotics pre admission + Ability to self-consent + 
Residence + Barthel index + Weight + Number of teeth + Admission plaque 
score + Clinical frailty score +HABAM score + Smoking + Charlson index + 
Cerebrovascular disease + Dementia 
5.2.4 Data analysis 
The list of putative risk factors contained variables that were potentially related.  
Therefore the extent of the association between variables was investigated using 
correlation matrices. Correlation matrices were constructed in R using the 
polycor package, with Pearson correlation coefficients calculated for continuous 
variables.   Where data types were categorical or ordinal, polycoric correlation 
was used to assess associations.  Correlations of either greater that 0.2 or lower 
than -0.2 were considered noteworthy in terms of explaining clinically relevant 
colinearity between variables (rather than significant associations per se).  
While correlation coefficients of >0.8 are usually considered significant, here 
understanding weaker colinearity between variables potentially helped to 
explain significant results obtained in multivariate analyses relating carriage of 
organisms with patient characterstics. 
Generalised linear modeling with a binomial error structure was undertaken to 
investigate HAP/LRTI and colonisation with individual organisms in relation 
to uni- and multi-variate explanatory variables respectively.  During 
multivariate analysis, stepwise removal of non-significant variables in the two 
models was undertaken until only significant variables remained.  Fisher’s 
exact test was also used to investigate the relationships between HAP and 
explanatory variables where there were proportionally few cases compared to 
controls.  Although covariates such as Barthel index and Clinical Frailty Score 
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were categorical, given the number of categories (minimum 9), they were 
considered as continuous variables.   
Canonical correspondence analysis (CCA) was used to investigate relationships 
between colonisation patterns amongst patients and patient demographics.  
CCA is based on correspondence analysis (CA). CA is an iterative matrix 
approach which, in this case, seeks to investigate and separate the main trends 
in variation in an individual by a measured characteristics data matrix. To 
achieve this the correlations between individual patients and their colonisation 
status are maximised, such that patients with similar statuses have similar 
‘scores’ on what are analogous to principle component axes. Scores for an 
individual patient on one axis are the weighted average of a set of 
complementary scores for the individual colonising agents for the same axis (as 
in a principal components analysis). The scores for patients are therefore 
derivable from the scores of the colonization variable present for the patient 
and vice versa.  CCA was undertaken using the Vegan package in R.  Patient 
variables which had been found to be significantly associated with colonization 
with individual organisms in generalized linear models were included as 
covariates, along with HAP as an outcome variable.  An organism by patient 
matrix was used to assess likely dependence between patient co-variates and 
colonization with target organisms.  The raw data matrix was subjected to CCA 
with patient demographic information used as covariates to explain the 
patterns of colonization amongst patients.  Two patients were excluded from 
the CCA as one had no plaque score (patient with no teeth or dentures) and the 
other had no weight recorded.  
5.3 Results 
5.3.1 Investigating the extent of correlation between key variables used in the 
study 
Results from the correlation analyses are shown in Table 30, and standard 
errors for the analyses are shown in Table 87, Appendix H.  Correlations of 
either greater that 0.2 or lower than -0.2 were considered noteworthy 
(coefficients of >0.205 or <0.205, significant at 5% level with 90 degrees of 
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freedom), and are typed in boldface.  Deprivation was associated with 
increased weight, fewer teeth, increased tendency to wear complete dentures, 
and being a current smoker.  There were slight (0.19) correlations between 
deprivation and increased clinical frailty score and increased plaque score at 
admission.  Smoking was associated with increased age, increased number of 
teeth, increased likelihood of dementia, and decreased likelihood of wearing 
complete dentures.  Dementia was associated with increased age, decreased 
Barthel index, increased Clinical Frailty Score, Decreased HABAM (mobility) 
score and increased Charlson index.  Increased Charlson index (increased 
number and severity of illnesses) was in turn associated with increased age, 
being male, a decreased Barthel index, increased Clinical Frailty score and 
decreased HABAM score.  Increased HABAM score (better mobility) was 
associated with lower age, being female, home-living, increased Barthel index 
(more independent) and decreased Clinical frailty score.  Increased Clinical 
frailty score was associated with increased age, being male, residence in 
institution or hospital prior to admission, and lower Barthel index (less 
independent).  An increased Barthel index (more independent) was associated 
with lower age, being female, and home-living.  Residence in a location other 
than home was associated with increased age.  Increased weight was associated 
with home-living.   
Inability to sign the consent form oneself was associated with increased age, 
residence somewhere other than home, decreased Barthel index (less 
independent), increased clinical frailty score, decreased HABAM (mobility) 
score, increased likelihood of dementia, and decreased likelihood of combined 
obstructive respiratory disease (COPD).  COPD was associated with lower age, 
being female, not having dementia and current smoking.  Having been 
prescribed antibiotics within three months prior to admission was associated 
with decreased Barthel index, increased likelihood of having dementia, ex- or 
never smoking and inability to sign the consent form oneself.   
Presence of complete dentures was associated with increased age, decreased 
number of teeth, increased clinical frailty score and decreased HABAM score.  
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Increased tooth number was associated with lower age.  Increased plaque at 
admission was associated with decreased Barthel score (less independent), 
decreased number of teeth, increased likelihood of having dementia and 
increased likelihood of wearing complete dentures.  
Given the degree of interaction between covariates, outcome variables were 
subjected to multivariate analysis where possible. 
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Table 30. Correlation matrix of patient variables used in the study 
 
Age Female Residence Barthel Weight Teeth Frailty HABAM Charlson Dementia Dentures Smoking Plaque1 IMD COPD Consent Antibiotics 
Age 1.00 Polyserial Pearson Pearson Pearson Pearson Pearson Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Female -0.21 1.00 Polyserial Polyserial Polyserial Polyserial Polyserial Polyserial Polyserial Polychoric Polyserial Polyserial Polyserial Polyserial Polychoric Polyserial Polychoric 
Residence 0.30 -0.17 1.00 Pearson Pearson Pearson Pearson Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Barthel -0.31 0.20 -0.38 1.00 Pearson Pearson Pearson Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Weight -0.14 -0.19 -0.29 -0.02 1.00 Pearson Pearson Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Teeth  -0.24 0.07 0.03 0.13 0.00 1.00 Pearson Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Frailty 0.33 -0.42 0.38 -0.54 -0.08 -0.23 1.00 Pearson Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
HABAM -0.39 0.24 -0.39 0.52 0.05 0.22 -0.74 1.00 Pearson Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Charlson 0.43 -0.35 0.15 -0.40 0.18 -0.11 0.35 -0.38 1.00 Polyserial Pearson Pearson Pearson Pearson Polyserial Pearson Polyserial 
Dementia 0.23 -0.15 0.17 -0.41 -0.11 0.06 0.38 -0.28 0.20 1.00 Polyserial Polyserial Polyserial Polyserial Polychoric Polyserial Polychoric 
Dentures 0.23 -0.20 0.02 -0.19 0.06 -0.87 0.20 -0.22 0.05 -0.03 1.00 Pearson Pearson Pearson Polyserial Pearson Polyserial 
Smoking 0.20 0.19 -0.03 -0.02 0.06 0.22 -0.13 0.04 0.08 0.31 -0.22 1.00 Pearson Pearson Polyserial Pearson Polyserial 
Plaque1 -0.03 0.15 -0.10 -0.20 -0.02 -0.32 0.11 -0.03 0.07 0.58 0.30 -0.10 1.00 Pearson Polyserial Pearson Polyserial 
IMD -0.02 -0.18 -0.09 -0.19 0.18 -0.28 0.20 -0.18 0.11 0.13 0.27 -0.31 0.22 1.00 Polyserial Pearson Polyserial 
COPD -0.23 0.37 -0.11 0.07 -0.06 -0.11 -0.06 0.05 -0.04 -0.67 0.03 -0.31 -0.12 0.13 1.00 Polyserial Polychoric 
consent 0.38 0.08 0.39 -0.49 -0.20 -0.15 0.31 -0.38 0.17 0.43 0.14 0.03 0.08 0.12 -0.21 1.00 Polyserial 
Antibiotics 0.14 0.03 0.11 -0.24 -0.06 0.17 0.20 -0.10 0.19 0.29 -0.13 0.28 0.02 -0.16 0.18 0.21 1.00 
 
Barthel=Barthel index, Teeth=number of teeth, Frailty=Clinical frailty score, Charlson=Charlson index, Plaque1=Admission plaque 
quartile score, IMD= Indices of multiple deprivation score, COPD=Combined obstructive respiratory disease, Consent= ability to sign 
consent for oneself, Antibiotics=Prescribed antibiotics within three months prior to hospital admission 
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5.3.2 Investigating associations between HAP or HAP/LRTI and patient 
demographic factors 
Univariate generalised linear models were used to investigate associations 
between HAP/LRTI and patient factors during the whole study period (cases 
n=18).  Where number of cases was low (HAP n=10), associations between HAP 
and explanatory variables were analysed using Fisher’s exact test.   
HAP was not significantly associated with any patient demographic variables 
tested, however there was slight evidence of associations with age (p=0.06), 
Charlson index (p=0.07) and increased deprivation score (p= 0.06).  Full results 
are shown in Table 88, Appendix H.  HAP/LRTI up to 3 months after discharge 
were significantly associated with increased Charlson comorbidity index, 
increased clinical frailty score, and decreased HABAM (mobility) score (Table 
31).  Interestingly HAP/LRTI was not associated with increased age. 
Table 31. Relating HAP/LRTI  and patient factors  using univariate 
generalised linear modelling (significant variables shown only) 
Variable Estimate Standar
d error 
Z 
value 
P value Residual 
deviance 
Odds ratio 
(95% 
confidence 
intervals) 
Clinical 
frailty 
scale 
0.527      0.196 2.68 <0.01** 81.648  on 
88 
1.69 (1.15-
2.49) 
Mobility 
(HABAM) 
-0.047     0.023 -2.064    0.04 * 85.788  on 
88 
0.95 (0.91-
1.00) 
Charlson 
index 
0.389     0.119    3.267   <0.01** 78.302  on 
88 
1.48 (1.17-
1.86) 
Null deviance =90.072  on 89 
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5.3.3 Investigating associations between HAP or HAP/LRTI and oral 
colonisation with respiratory commensal pathogens 
HAP was significantly associated with persistent colonisation with E. coli both 
using Fisher’s exact test (p=0.036) and using generalised linear modelling (Table 
32).  The model was somewhat underdispersed and the lower confidence 
interval for the odds ratio was zero.  
Table 32. Univariate generalised linear model relating HAP and oral 
colonisation index with E. coli 
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% confidence 
intervals) 
E. coli 0.503      0.2561    1.963    0.050 1.65 (1.00-2.73) 
Null deviance: 62.79  on 89  degrees of freedom 
Residual deviance: 57.80  on 87  degrees of freedom 
AIC: 63.8  
HAP was not associated with being either colonised with any or uncolonised by 
all pathogens.  HAP was not associated with acquisition of any individual 
pathogen.  HAP was not associated with a positive PCR assay (coliform assay 
not included) with any organism at admission only.  In addition, neither death 
due to any cause nor cough were associated with a positive PCR assay result at 
admission. 
HAP/LRTI was significantly associated with persistent S. aureus colonisation 
(Table 33).  There was slight evidence that persistent colonisation with MRSA 
was also associated with HAP/LRTI (Table 34).  Analyses of HAP with S. 
aureus and HAP/LRTI with E. coli are included from completeness in Tables 94-
96, Appendix H.  However, these results need to be interpreted in light of the 
power of the study (see 5.4). 
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Table 33. Univariate generalised linear model relating HAP/LRTI and oral 
colonisation index with S. aureus 
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% confidence 
intervals) 
S. aureus 0.426      0.181    2.357    0.018 * 1.53 (1.07-2.18) 
Null deviance: 90.072  on 89  degrees of freedom 
Residual deviance: 82.835  on 87  degrees of freedom 
AIC: 88.835 
 
Table 34. Univariate generalised linear model relating HAP/LRTI and oral 
colonisation index with MRSA 
HAP/LRTI Estimate Standard error Z value P value 
MRSA 0.546      0.305    1.793     0.073 . 
Null deviance: 90.072  on 89  degrees of freedom 
Residual deviance: 84.483  on 87  degrees of freedom 
AIC: 90.483 
Absence of cough was significantly associated with absence of detection of 
respiratory commensal pathogens on any sample (p= 0.002, Odds ratio= 5.75 
95% confidence intervals 1.67- 25.75). However cough was not associated with 
positive PCR assays at admission only.   
5.3.4 Investigating associations between HAP or HAP/LRTI and oral health 
variables 
Neither HAP nor HAP/LRTI were more common in dentate patients, those 
who wore dentures, those with increased number of teeth, or with higher 
plaque quartile scores at admission, day 7 or day 14.  HAP and HAP/LRTI 
were not associated with increased denture plaque indices at days 1, 7 or 14.  In 
dentate patients only, HAP and HAP/LRTI were not associated with increased 
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modified Quigley Hein scores.  HAP and HAP/LRTI were not commoner in 
those with a high xerostomia score.   
5.3.5 Investigating associations between HAP or HAP/LRTI and in-hospital 
events and outcomes 
Table 35 and Table 36 show postoperative delirium, witnessed aspiration 
episodes, and falls during hospital admission were all significantly more 
common in patients who developed HAP or HAP/LRTI.  Two of the three 
aspiration episodes in patients who subsequently developed HAP occurred 
prior to the episode of HAP, and one was simultaneous.  HAP was also 
associated with cough.  HAP was not associated with length of operation, time 
to operation, or type of anaesthetic.  There was no association between HAP or 
HAP/LRTI and pre-operative albumin levels.  Full results are shown in Tables 
89-90, Appendix H. 
 
Table 35. Associations between HAP and significant in hospital events using 
Fisher’s exact test 
Variable HAP 
(N=10) 
No HAP 
(n=80) 
P value Odds ratio (95% 
confidence intervals) 
Aspiration  3/10 1/80 <0.01 30.88 (2.18 -1773.08) 
Delirium 4/10 6/80 0.01 7.89 (1.28-46.31) 
Fall 3/10 5/80 0.04 6.21 (0.80-41.00) 
Cough 9/10 32/80 <0.01 13.17 (1.69 -601.85) 
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Table 36. Univariate generalised linear models relating HAP/LRTI at any 
point and significant in-hospital events 
Variable Estimate Standard 
error 
Z 
value 
P value Residual 
deviance 
(df) 
Odds ratio (95% 
confidence 
intervals) 
Aspiration 2.653      1.189    2.231    0.026  84.104  
on 88   
14.20 (1.38-
146.06) 
Delirium 1.640      0.701    2.338    0.019  84.870  
on 88 
5.15 (1.30-20.37) 
Fall 2.180      0.790    2.758   0.006  82.292  
on 88 
8.85 (1.88-41.65) 
Null deviance= 90.072  on 89 degrees of freedom 
 
Both HAP (p< 0.001, Fisher’s exact test) and HAP/LRTI were associated with 
increased number of complications during hospital stay (Table 37), though the 
effect size was small.  
 
Table 37. Univariate generalised linear model relating HAP/LRTI with 
number of complications during hospital admission 
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% 
confidence intervals) 
Number of 
complications 
0.100     0.030    3.291 <0.001 *** 1.10 (1.04-1.17) 
Null deviance: 90.072  on 89  degrees of freedom 
Residual deviance: 76.628  on 88  degrees of freedom 
AIC: 80.628 
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Death from any cause was strongly associated with both HAP and HAP/LRTI, 
but more so with HAP.  Death was still associated with prior HAP when 
patients with pneumonia and active cancer were not included (P= 0.001 , odds 
ratio= 17.23, 95% confidence intervals= 2.44-203.26, Fishers exact test), as shown 
in Table 40 
. 
Table 38. Univariate generalised linear model relating death from all causes 
and HAP  
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% 
confidence intervals) 
HAP 3.731      0.884    4.220 <0.001 *** 41.71 (7.37-235.95) 
Null deviance: 81.101  on 89  degrees of freedom, Residual deviance: 57.482  on 
88  degrees of freedom, AIC: 61.482 
 
 
Table 39. Univariate generalised linear model relating death from all causes 
and HAP/LRTI at any point during the study 
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% confidence 
intervals) 
HAP/LRTI 2.005      0.619    3.239   0.001 7.43 (2.21- 24.99) 
Null deviance: 81.101  on 89  degrees of freedom, Residual deviance: 70.657  on 
88  degrees of freedom, AIC: 74.657 
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Table 40. Univariate generalised linear model relating death from any cause 
and HAP in persons without active cancer 
Variable Estimate Standard 
error 
Z value P value Odds ratio (95% confidence 
intervals) 
HAP 2.904      0.902    3.220   0.001 
** 
18.25 (3.11- 106.95) 
Null deviance: 81.101  on 89  degrees of freedom, Residual deviance: 69.445  on 
88  degrees of freedom, AIC: 73.445 
5.3.6 Oral colonisation with respiratory commensal pathogens and patient 
factors  
Acquisition of any organism was associated with decreased Barthel index, 
prescription of a cognitively active drug at admission and post-operative cough 
(Tables 98-99, Appendix H).  Multivariate generalised linear modelling was 
used to investigate the associations between colonisation with individual 
organisms and patient factors using both the medical model (Table 41) and the 
dental model (Table 42).  Multivariate models were generated for all seven 
target organisms.  However the final models for E. coli and Acinetobacter using 
the medical model were underdispersed, which was likely due to the paucity of 
positive results from these two assays (21/816 or fewer) and are not shown in 
Table 41.  Full results are shown in Tables 117-125, Appendix H. 
Univariate analysis was also undertaken and results are shown in Tables 108-
116, Appendix H (models for S. pneumoniae and H. influenzae were somewhat 
overdispersed, while models of Acinetobacter were underdispersed).  
Colonisation rather than acquisition was used to investigate associations with 
patient factors, as HAP or HAP/LRTI were associated only with increased oral 
colonisation index of S. aureus and E. coli.    However significant results from 
relating acquisition of target organisms with patient factors using multivariate 
analysis are shown in Tables 100-107, Appendix H for completeness. 
Models of S. aureus indicated that being male, being prescribed antibiotics in the 
three months prior to sampling, increased Charlson index, being fitter 
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(increased Barthel or decreased Clinical frailty score), decreased weight and 
current smoking were associatied with increased colonisation indices.  In 
addition, colonisation with S. aureus was associated with both dementia and 
inability to self consent in the medical model.  Factors that were included in 
both models but only appeared significantly in one model included low 
deprivation score (dental model) and number of teeth (medical model) . 
The models explaining MRSA colonisation resulted in broadly concordant 
results for both models and included recent use of antibiotics, current or history 
of smoking, higher Barthel index (more independent), higher Charlson index 
(more serious illnesses).  Number of teeth was included in both models as a 
variable but was only significant in the medical model.   
Colonisation with E. coli was explained using the dental model only, and 
significant variables included being male, possessing few teeth but not wearing 
dentures, current smoking and lower Barthel index (less independent). 
Neither model contained significant risk factors for P. aeruginosa colonisation.  
There were 16 patients with positive samples for P. aeruginosa, but only nine 
with more than one sample positive and the highest index was 0.4 (in only 1 
patient).  Being female, increased Charlson index and increased clinical frailty 
score were significant risk factors using the medical model initially, but became 
insignificant during stepwise removal of non-significant variables.   
Colonisation with S. pneumoniae was explained by being female, possessing 
increased number of teeth, current or history of smoking, lower Charlson index 
(fewer serious illnesses) and increased HABAM (mobility) score.  Variables 
included in both models but significant in only one model were decreased 
clinical frailty score, and lower deprivation score (dental model), and decreased 
plaque score at admission and no use of recent antibiotics (medical model). 
H. influenzae colonisation was explained by being female, having combined 
obstructive pulmonary disease (COPD) and decreased Barthel score (less 
independent).  Of variables included in both models but only significantly 
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associated with H. influenzae colonisation in one were increased deprivation 
score and lower age (dental model), and current smoking, presence of dementia 
and decreased number of teeth (medical model). 
Colonisation with Acinetobacter spp was not associated with any variable tested 
in either model.  In the above models, there was discordance between the 
significance of some variables included in both models.  However the 
correlation analysis above demonstrated extensive correlation between risk 
factors, and this is considered further in the discussion. 
Colonisation with S. pneumoniae was not associated with a significant decrease 
the colonisation indices of S. aureus or E. coli (univariate generalised linear 
modelling).
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Table 41. Multivariate generalised linear models relating oral colonisation index of target organisms with patient factors using the  
medical model  
Organism Positive risks Negative risks 
S. aureus  Male* Recent antibiotics*** Charlson index*** 
Dementia*** Unable to self-consent* 
Weight* Teeth number* Frailty score* Ex** or never 
smoker*** 
MRSA Recent antibiotics*** Barthel** Charlson index** Ever 
smoked*** 
Teeth number**  
P. aeruginosa  Nil significant Nil significant 
S. pneumoniae  Female**  Teeth number***  HABAM***   Can’t self-
consent * Current/Ex smoker* 
Plaque score quartile at admission* Recent antibiotics** 
Charlson index** 
H. influenzae  Female*  COPD** Current smoker*  Dementia*** Barthel*  Number of teeth**   
*p<0.05, **p<0.01, ***p<0.001 
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Table 42.  Multivariate generalised linear models relating oral colonisation with target organisms against patient and dental factors 
using the dental model 
Organism Positive risks Negative risks 
S. aureus  Charlson index**    Admission plaque*      
Barthel index*    Male**    
Current smoking** 
Low deprivation score 
 
MRSA Age*       Charlson index* 
Current or ex smoker*     Barthel index (less frail)* 
N/A 
E. coli  No dentures*    Male***     Current smoking***  
 
Few teeth**       Barthel index (more frail)*** 
P. aeruginosa  Nil significant Nil significant 
S. pneumoniae  Female*    More teeth***     Current smoking*** Clinical frailty score (less frail)*     Charlson index (fewer serious 
illnesses)* 
Deprivation score (less deprived) 
H. influenzae  Dentures (complete) **    Female** 
Deprivation score (more deprived)** 
Age (younger)**      Barthel score (more frail)*** 
Acinetobacter 
spp 
Nil significant Nil significant 
*p<0.05, **p<0.01, ***p<0.001 
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5.3.7 Oral colonisation with S. aureus and xerostomia  
The binomial xerostomia score was not entered into either the full medical or 
simple dental model due to number of missing values, and is therefore 
considered separately.  Increased colonisation with S. aureus was related to a 
high xerostomia score (Table 43).     
Table 43. Generalised linear model relating S. aureus colonisation with 
xerostomia (binary variable)  
Variable Estimate Standard 
error 
Z value P 
value 
Odds ratio 
(95%Confidence 
intervals) 
S. aureus  2.488      
  
1.023    2.432 0.015*   12.04 (1.62- 89.40) 
Null deviance: 99.919  on 57  degrees of freedom 
Residual deviance: 86.836  on 56  degrees of freedom 
  (32 observations deleted due to missingness) 
AIC: 115.26 
5.3.8 Multivariate analysis: Canonical correspondence plots of pathogens, 
patients and patient variables 
Patient variables entered into the CCA included age, Barthel score, clinical 
frailty score, Charlson index, dementia, number of teeth, plaque quartile score 
at admission, weight, presence of HAP and presence of HAP/LRTI, along with 
colonisation indices per organisms and per patient.  In the CCA plot (Figure 14) 
the first axis appears to represent a trend from (positive scores) frail individuals 
to those with teeth (negative scores), which probably represents a spectrum of 
frailty, with fitter patients possessing more teeth.   The second (y) axis was less 
clear, although the Barthel and Charlson indices were closest to being parallel 
to this axis. This implies that high Charlson scores were associated with low 
(negative) second axis scores.  
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S. pneumoniae colonisation was associated with increased number of teeth and 
increased independence, as found previously in this Chapter.  S. pneumoniae 
and S. aureus co-colonisation were associated with higher Barthel score 
(meaning more independent persons).  Increased frailty (measured by the 
clinical frailty score) and increased Charlson comorbidity index were associated 
with co-colonisation with MRSA, Acineobacter spp and P. aeruginosa.   
Interestingly, H. influenzae and E. coli co-colonisation were seen in a number of 
patients.  The results from multivariate GLMs earlier in the chapter showed that 
both E. coli and H. influenzae were associated with increased frailty.  H. 
influenzae was geographically distant from MRSA.  Patients colonised with 
MRSA were typically community dwelling and less frail, whereas the reverse 
was true of patients colonised with H. influenzae, which may account for the 
plotted distance between these variables.  In summary, the CCA reiterates what 
has already been found using multivariate GLMs, but adds that certain bacteria 
co-colonise recurrently, and in association with defined patient characteristics. 
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Figure 14. Canonical 
correspondence 
analysis 
demonstrating 
relationships 
between 
colonisation indices 
of target bacteria 
and demographic  
variables in study 
patients  
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5.4 Discussion 
The covariates with the greatest effect size on HAP were in-hospital events such 
as aspiration, falls, post-operative cough, presence of delirium.  Falls and 
delirium either preceded or occurred simultaneously with HAP, and may have 
been associated with the presentation of HAP itself rather than risk factors per 
se.  It should be noted that apart from falls, the other three variables were 
observed and noted by the primary investigator at times of study visits, and 
were not measured objectively.  The effect sizes of significantly associated 
covariates in this study, such as Charlson comorbidity index or Clinical frailty 
score were small.   
Aspiration and function of swallow were not objectively tested as the aim of the 
study was not to record aspiration pneumonia.  Rather aspiration episodes 
were observed and recorded by the study investigator as part of routine follow 
up. Thus the strength of effect of aspiration on HAP is likely to be 
overestimated in this study, and needs further research in this population.  
However assessment of swallowing function by speech and language therapists 
or other trained personnel may identify patients at higher risk of HAP.  
Similarly the primary reason for noting both cough and delirium was as 
evidence that HAP was absent, rather than the reverse.   These results may 
suggest that the simple (and free) bedside test of simply asking the patient if 
they have a cough might be a predictor of subsequent HAP, in keeping with a 
previous study [56], and warrants further investigation.  
 The association between HAP and witnessed aspiration episodes begs the 
question whether the cases of HAP were in fact aspiration pneumonia.  The 
other important question is whether there is any value dividing the two 
conditions.  Aspiration pneumonia is diagnosed by clinical suspicion of 
dysphagia or impaired cough reflex in a patient with pneumonia [105], but does 
not have an associated objective diagnostic criteria, and the episodes of 
aspiration are usually unwitnessed.  The three patients who developed HAP at 
the same time as, or after, a witnessed aspiration episode would therefore be 
defined as having aspiration pneumonia.  Marik argues that pneumonia 
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secondary to aspiration of oropharyngeal contents should be considered 
separately to both community and hospital acquired pneumonia [105], despite 
acknowledging that all respiratory pathogens must be aspirated into the lungs 
to cause pneumonia of any type, and that aspiration occurs during sleep in 
healthy subjects [132].  Aspiration of oropharyngeal contents can lead to CAP as 
well as HAP in older persons [268], and the underlying insult , clinical 
syndrome and treatment are the same whether “aspiration” has taken place or 
not.   Careful studies of underlying aetiology in patients with aspiration 
pneumonia revealed that the most frequent bacterial causes were S. pneumoniae, 
S. aureus, H. influenzae and Enterobactericae [104, 269], and anaerobic bacteria 
(Streptococci) were isolated in only two patients (though antibiotics had already 
been given).  Aspiration of orophayngeal contents may be better treated as a 
risk factor for pneumonia, rather than considering aspiration pneumonia as a 
separate entity.  Risks for aspiration include decreased conscious level, 
dysphagia and intestinal obstruction [269].  However, presence of nasogastric 
tube or endotracheal tube ought also to be included as risk factors for 
aspiration, in that biofilms develop on both [118, 135], facilitating  the 
transmission of bacteria to the lungs.   However aspiration of acid, oils, 
vomitus, food or other foreign body are more likely to cause a chemical 
pneumonia or aspiration pneumonitis, and these conditions would be better 
served by being defined as a separate condition, because infection is less likely 
to be present.     The presence of a nasogastric tube is an important risk factor in 
this regard, but  data on nasogastric tube insertion was incomplete in this study 
and were therefore not analysed.  However both patients who had nasogastric 
tubes inserted developed HAP, one before and one after nasogastric tube 
insertion.  Nasogastric tube insertion indicates a person at risk of aspiration (the 
indication for a tube is either due to dysphagia or bowel obstruction) and also 
provides a reservoir of oropharyngeal bacteria to the tracheal entrance.  
Therefore even nasogastric tube insertion after HAP has occurred identifies 
aspiration as a risk factor for HAP. 
HAP was associated with more persistent colonization of E. coli, in keeping 
with a previous study conducted in intensive care patients which found E. coli 
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in dental plaque to be associated with nosocomial infections [42].  HAP/LRTI 
was associated with increased colonization with S. aureus, and there was slight 
evidence of an association with persistent colonisation with MRSA.  A previous 
culture-based study identified salivary colonisation with S. aureus as a risk 
factor for aspiration pneumonia [101].  Terpenning et al. found that aspiration 
pneumonia was associated with increased number of teeth, S. sobrinus or S. 
aureus in saliva and P. gingivalis in dental plaque [29].  However these results 
need to be interpreted in light of the sample size, as is discussed below. 
Neither HAP nor HAP/LRTI was associated with acquisition of respiratory 
commensal pathogens.  Colonisation is thought to be more significant than 
acquisition as adherence suggests evasion of host immune defences (although 
this assumes that the body recognises the bacterium as a pathogen rather than a 
commensal).  The main disadvantage of using the colonization index was that 
geographical repetition (tongue and throat positive) was considered equally 
with temporal repetition (sample 1 tongue and sample 2 tongue).   However, 
wider geographical distribution of the organism may constitute greater load 
and it was decided that tongue and throat samples should be considered 
separately rather than combining the two sets of results.  A similar approach 
was also used in the Candida colonization index [267]. 
In contrast with two previous studies which found a relationship between 
plaque score and respiratory infection in dentate institutionalised older persons 
[44, 45], in this study HAP was not associated with any measured dental 
variables.   Abe et al. only included 62/81 patients within the analysis, for 
reasons which were unclear [45].  Mojon et al. used only clinical findings to 
diagnose pneumonia, with follow up time of 1 year [44], which may have 
increased the proportion of patients diagnosed as pneumonia.   
Factors associated with oral colonization with respiratory commensal 
pathogens appeared to be pathogen specific.  S. pneumoniae colonization 
occurred in generally fitter individuals, whereas H. influenzae colonization 
appeared commoner in frailer patients.  H. influenzae colonization was 
associated with COPD which would be expected given that H. influenzae 
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infections are so common in patients with COPD.   COPD in turn was 
associated with lower age (in the correlation matrix) which explains why H. 
influenzae was simultaneously associated with lower age and increased Barthel 
index.    Despite S. pneumoniae being one of the commonest causes of 
pneumonia, increased colonization was neither associated with HAP nor with 
frailty factors.  One study suggested that biofilm formation necessary for 
establishing colonization is enhanced by the lack of the capsule, a major 
determinant of virulence [270].  Where there is a strong antibody response to a 
commensal organism, it is usually cleared, but S. pneumoniae is known to persist 
for 2-4 weeks in healthy adults [256].  Antibody response to an organism may 
be generated by colonization without infection [271]. However it is unclear 
whether there was a benefit to patients being colonised with S. pneumoniae, and 
it is more likely that colonization was related to epidemiological contacts. 
 It is unclear why S. pneumoniae was associated with increased numbers of teeth 
(and correspondingly why H. influenzae was associated with fewer teeth) and it 
seems likely that number of teeth is a confounder for health status, rather than 
being causally associated.  There is no other literature suggesting an association 
between these organisms and tooth number.  The correlation matrix showed 
that having fewer teeth was associated with increased age, but not the 
individual functional scores.  These observations require further investigation. 
Data on previous vaccination against S. pneumoniae were not collected, and this 
might be an important variable to investigate in future to explain some of the 
variation seen. 
Colonisation with P. aeruginosa and Acinetobacter spp were not explained by any 
of the variables in either model.  This is unlikely to be due to these organisms 
being infrequent  colonizers (4% and 2% of study patients respectively), as E. 
coli only colonized 2% of study patients, and was found to be associated with 
several study variables.    VAP due to P. aeruginosa has been associated with 
increased length of mechanical ventilation, increased age, use of antibiotics at 
admission and transfer form a medical unit or ICU [272].  In one study of 
intensive care patients, Acinetobacter colonization only occurred after spending 
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two weeks on intensive care [266]. Previously identified risk factors for 
nosocomial Acinetobacter infection include increased length of stay, increased 
bed transfers, increased duration and number of antibiotics, prior colonization 
with A. baumannii, use of central venous catheters,  mechanical ventilation and 
cardiovascular or respiratory failure [266, 273].  It may be that patients in this 
study did not frequently exhibit these findings during the sampling period, or 
that variables important in determining colonization with these organisms were 
not collected in this study, perhaps such as changes in the structure of the oral 
microbiota or changes at a cellular immunity level.  In addition, in the case of 
Acinetobacter spp., the assay may have detected non-pathogenic species, which 
could have contributed to non-significant analysis with patient factors.  In the 
CCA, co-colonisation with Acinetobacter spp, P. aeruginosa and MRSA appeared 
to be associated with increased frailty, suggesting a common underlying set of 
risk factors.   
Colonisation with S. aureus and MRSA was explained by similar risk factors, as 
would be expected given their genetic similarities, which included current 
smoking, male sex, increased Charlson score and recent antibiotics use.  The 
latter two risk factors indicate likely prior contact with healthcare settings.  
Interestingly though, both the CCA and the multivariate GLM (dental model) 
indicated that both MRSA and S. aureus were more frequently seen in home 
dwelling patients rather than those from institutions or transferred from 
hospital.  It is unclear why males would be more susceptible to S. aureus 
colonization than females.  Colonisation with S. aureus was associated with 
fewer teeth (in the medical model), and increased dental plaque (in the dental 
model), though both variables were included in both models.   In addition 
MRSA was also associated with fewer teeth in the medical model only.  There 
appeared to be conflict between explaining S. aureus colonization using the 
medical and dental models for variables relating to frailty.  In the medical 
model, dementia and inability to self-consent were significant, but in the dental 
model, higher Barthel index (more independent) was significantly associated.  
The reasons for this are unclear, and it may be that several groups of persons 
are at risk of S. aureus colonization (given that it is a commensal even in healthy 
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adults).  Structural equation modeling might help understand better the 
relationships between S. aureus/MRSA colonization and these variables.  
Colonisation with S. pneumoniae did not inhibit colonization with other 
organisms such as S. aureus and E. coli.  In previous studies of colonization in 
children, S. pneumoniae has been shown to decrease the colonization rate of S. 
aureus [274], and in turn, increased pneumococcal vaccine uptake has been 
associated with an increase in otitis media caused by S. aureus infection in 
children, with co-colonisation with non-vaccine type S. pneumoniae [275].  
Mouse models suggested that antibodies to S. pneumoniae cross-reacted with S. 
aureus and inhibited its ability to colonise [274].  However, given that antibody 
production and function appears to decline with age [276], these effects may be 
less pronounced in older patients. 
Colonisation with S. aureus, MRSA, S. pneumoniae, H. influenzae and E. coli was 
associated with current and/or previous smoking, in keeping with previous 
studies [43, 277-279], and suggests a common underlying mechanism.   
However one study suggested that cigarette smoke inhibited growth of S. 
pneumoniae and S. aureus, rather promoting growth of Klebsiella, Enterobacter 
and Pseudomonas [280].   Underlying mechanisms contributing to altered 
bacterial community structure are likely to be multifactorial.  One study found 
an initial pro-inflammatory host response to colonization with respiratory 
commensal pathogens specifically in smokers [277].  Other mechanisms may 
include decreased mucociliary clearance by respiratory epithelial cells and 
increased adherence to respiratory epithelial cells in smokers [281, 282].  Both 
bacterial and viral infections  are also commoner in smokers or those exposed to 
tobacco smoke, which may relate to impaired cellular and humoral immunity, 
and changes to epithelial cells in the respiratory tract [281, 282].  Pulmonary 
defences against H. influenzae specifically may be impaired in smokers [283].  
Smokers also appear to exhibit altered oral bacterial communities in general, 
with changes found including fewer alpha-haemolytic Streptococci [284], a 
more diverse and anaerobic flora [285] and increased prevalence of bacteria 
belonging to Socransky’s “red” and “orange” group bacteria [286].   Another 
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interesting finding has been that all the pathogens tested for in this study have 
been identified from cigarettes themselves using 16s PCR [287]. 
It was interesting to note that S. pneumoniae and S. aureus appeared to be 
associated with less deprived persons and H. influenzae with more deprived 
persons.  Previously colonization with both S. pneumoniae and H. influenzae has 
been associated with deprivation in children [256].  Again this may be a 
confounding effect, given that H. influenzae was associated with COPD which is 
in turn associated with smoking, a factor correlated with deprivation.   H. 
influenzae was also associated with denture wearing, and denture wearing was 
in turn correlated with increased deprivation.  Respiratory pathogens have 
previously been shown to colonise dentures [288], but denture wearing in 
general was not strongly associated with colonisation with other pathogens.  It 
is unclear whether denture wearing was a confounder for deprivation or 
whether there was a direct association between denture wearing and H. 
influenzae colonisation.    
In the dental model, only oral colonisation with S. aureus was associated with 
higher admission plaque scores.  Given that the pathogens were identified from 
tongue and throat rather than dental plaque, it was not possible to determine 
whether S. aureus was associated with mature plaque or whether both are 
confounders for poor general health, and this is an area for future research.  
This work attempted to stratify patient risk of HAP by the extent of oral 
colonization with respiratory commensal pathogens, and sampling tongue and 
throat yielded more target pathogens than did sampling dental or denture 
plaque [245].  While respiratory pathogens have previously been identified in 
dental plaque [140, 153, 289], two studies found no link between dental plaque 
index and colonisation of dental plaque with respiratory pathogens [42, 153].  
There are several possible reasons for this.  First, dental plaque may not 
influence the development of pneumonia by being the stable source of 
respiratory pathogens but may indirectly affect the risk of HAP by other means.  
Second, it may be that adherence to dental plaque is pathogen dependent.   
Fourrier et al. found that S. aureus in dental plaque was not linked to 
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subsequent VAP, while colonisation with gram negative rods was “highly 
predictive” of VAP [42].   HAP has been found more commonly in dentate 
persons [44, 101], and if these findings can be believed (studies have not been 
powered by numbers of edentate persons), the underlying reasons remain 
unclear. 
One of the major limitations of this study is that caries was not included as a 
covariate.  Aspiration pneumonia has been significantly associated with 
number of decayed teeth in two studies [30, 101].  Nor did we test for caries 
related organisms which have previously been associated with aspiration 
pneumonia [101].  Future research investigating the role of plaque in 
determining colonisation of S. aureus would need to examine these variables.  
Data were collected on blood transfusion, but this data was not analysed 
because it was discovered during follow up that the recording of transfusion 
varied in location (between notes, fluid charts, anaesthetic charts, and nursing 
documentation), and it could not be determined whether patients already 
included in the study actually had received blood products.  Poor filing of loose 
charts and nursing documentation precluded an effective retrospective search 
for these data. 
It should be noted that the colonization index data were zero inflated and 
therefore there is a possibility of over-predicting the significance of patient 
factors where colonization index was larger than zero.  A zero could either 
represent genuine absence of colonization, or that a particular organism could 
colonise that patient but other factors (measured or unmeasured) in the 
environment preclude this.  Nasopharyngeal sampling was not undertaken in 
this study, which would have been likely to increase the yield of S. pneumoniae 
in particular and possibly H. influenzae also [259].  However another study 
showed that oropharyngeal sampling of S. pneumoniae and H. influenzae in 
adults was comparable to nasopharyngeal sampling [290].   In addition, an 
organism could have been present on days not sampled.  A zero could also 
mean a bacterial species which has a single nucleotide polymorphism (SNP) in 
either primer or probe locations was not detected.  During validation of the 
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PCR assays, it was noted that a small number of bacteria previously identified 
in a microbiology laboratory by biochemical means were not detected by the 
PCR assays (see 3.4.2).  A zero result depends on the sensitivity and efficiency 
of the PCR assays.  While PCR assays can technically detect a single copy of an 
organism, this is not always the case if PCR efficiency is less than 100%. 
However PCR is more sensitive than culture.  
An assumption has been made that the organisms detected by real time PCR 
are potentially pathogenic.  It is known that both H. influenzae and S. aureus 
have a clonal population structure and only certain clones cause disease, while 
others may be non-pathogenic [235].  Assays for organisms tested in this study 
were designed using all sequence data available rather than only sequence data 
from known pathogenic clones which may mean that non-pathogenic 
organisms have been detected.  However, the assays were tested against clinical 
isolates (i.e bacteria which had been isolated from an infected site) and 
performed well.  However non-pathogenic species could have been identified 
by the assays. 
Some cross-reactivity could have occurred in the S. aureus and E. coli assays 
(which also therefore affected results of the MRSA assay), as described in 3.4.2, 
which could have produced false positive results.  The S. aureus assay detected 
two organisms from the specificity panel (S. constellatus and a group C β-
haemolytic Streptococcus), and the E. coli assay detected S. constellatus, E. 
facecium and a haemolytic Streptococcus group B.  These issues occured despite 
in silico testing using BLAST (Basic Local Alignment Search Tool), and this 
demonstrates the difficulties in designing molecular assays for bacteria-rich 
environments.  Only 14/93 (15%) patients in this study were colonised by S. 
aureus, which is lower than prevalence estimates from previous studies (23-
48%) [257].  In addition, the prevalence of group C streptococci in a study of 
1796 hospital in-patients was only 0.3% [291] and S. constellatus was detected in 
1/65 persons in another study [292], suggesting that the majority of S. aureus 
detected in this study were likely to be true positives.  Sequencing the false-
positive strains detected is the only way of knowing whether genuine cross-
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reactivity occurred or whether transformation of genes form other bacteria has 
occurred.   
This was a relatively small study, and is insufficiently powered to detect some 
results found.  Recruitment rate of the study was limited mainly by the number 
of patients refusing to participate or who could not be consented for logistic 
reasons (see 4.3.1).  However given the number of variables collected, the 
prolonged and intensive nature of follow up, the time needed for DNA 
extraction of samples, and the concomitant development of the multiplex PCR 
assays, it would have been difficult to accommodate more study patients.  
While the sample size was relatively small, the quality of study design and 
implementation was high.  
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Figure 15 shows the sample sizes needed to detect a series of odds ratio in 
binomial logistic regression with 80% power and a 5% significance level [293].   
This study was adequately powered to distinguish between variables where the 
odds ratio was just under 4, but insufficiently powered to determine smaller 
differences than this.  This includes the findings relating HAP and HAP/LRTI 
with E. coli and S. aureus colonization (whose odds ratios were 1.65 and 1.53 
respectively).  Therefore these findings need to be corroborated in a larger 
study. 
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Figure 15. Range of sample sizes required to detect given effect sizes (odds 
ratios) with 80% power and at 5% significance level 
 
Spinal anaesthesia was only used in 8% of study patients, as is the practice in 
Newcastle upon Tyne Foundation Hospitals, while in other hospitals spinal 
anaesthesia would be the norm when operating on hip fractures in particular.  
No airway manipulation is undertaken with spinal anaesthesia which may 
reduce the risk of HAP.  Medically unwell patients were excluded so results are 
not generalisable to this group.  This study only sampled patients for the first 14 
days after admission, and oral bacterial communities may have changed after 
this time, affecting the risk of HAP at a later point in the patient’s admission.  
Data on time to ambulation after surgery were not recorded.  One study 
suggested that increased time to ambulation was associated with post operative 
pneumonia and delirium [294]. 
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The findings from this study suggest that future studies should focus on 
establishing if dentate persons are at higher risk of HAP and identifying 
underlying mechanisms, in order to inform intervention studies.  Future oral 
hygiene intervention studies to prevent HAP should not be targeted only 
towards those people with heavier plaque.  In addition, next generation 
identification methods could be used to identify changes in microbial 
communities and identify as yet unknown pathogens, given that the 
aetiological agent is found in less than 60% of cases of HAP in older people [17].   
5.4.1 Conclusions 
This is a relatively small study but is one of the few which combines medical, 
dental and microbiological findings with HAP defined with chest radiograph as 
an outcome.  Colonisation with respiratory commensal pathogens is likely to be 
both a confounder (between frailty/illness and HAP) and the source of 
infecting organism(s).  The risk of HAP is therefore likely to be determined by 
the balance between overarching patient factors (which affect the oral flora and 
increase the risk of HAP) and the risk of aspiration.  The relationships between 
OCRP, oral hygiene and HAP are clearly complex.  Given that S. aureus was 
associated with dental/denture plaque and also with HAP, further research 
into the relationships between these variables, and into oral hygiene as an 
intervention in pneumonia appear warranted. 
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Chapter 6 Discussion 
Hospital acquired pneumonia (HAP) is a common and frequently fatal 
complication after lower limb fracture in UK patients, and currently no 
strategies for prevention are routinely employed in UK hospitals in patients on 
orthopaedic or other general hospital wards.  In this study, the incidence of 
HAP and HAP/LRTI were 11% and 20% respectively, and 60% of deaths in 
hospital and 40% of deaths over the whole study period were preceeded by 
HAP.  Of the 70-75,000 patients who fracture a hip annually then [51], 
approximately 7,500 will develop HAP and 15,000 will develop HAP/LRTI.  
Taking a more conservative estimate of 40% mortality, this would translate to 
3,000 deaths from HAP after hip fracture, which would account for 12% of the 
25,696 pneumonia deaths in England and Wales in 2011. 
The most striking finding in this study is that oral carriage of “hospital” type 
bacteria begins, in the most part, within 72 hours of hospital admission, 
challenging the idea that these organisms are hospital-acquired.  While results 
from this study cannot discern whether the organisms were simply acquired 
early in admission or were present in the community, these findings suggest 
that further study of oral carriage of potential respiratory pathogens is needed, 
perhaps in elective surgical patients. Results from this study suggest that 
certain patient characteristics seem to encourage carriage with particular 
organisms or combinations of organisms, and this is upheld by patients from 
settings such as nursing homes or with underlying disease tending to be 
infected by “hospital” type bacteria.  It is possible that while the environment 
remains important, the host is the key determinant of the nature of colonizing 
organisms.  This concept challenges current thinking about the origin of 
hospital acquired infection.  In order to reduce the risk of infection in 
hospitalized patients in the future, we need to better understand the 
composition and dynamics of colonization at “entry sites” and how these are 
affected by illness, immune function and other external factors.  One could 
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hypothesise that manipulation of organisms or immunity in the mouth could 
lower the risk of a variety of infections, both in the hospital and in the 
community.  
In this study, HAP was associated with host frailty and prior oral colonisation 
with respiratory commensal pathogens, but the strongest determinants for the 
development of HAP were witnessed aspiration episodes and post-operative 
cough.  These findings imply that interventions to prevent HAP should be 
directed toward patients with the above risk factors.  Overall the results suggest 
that colonising respiratory bacteria only act as pathogens when permitted to do 
so by breaches in host defences. However, colonisation with respiratory 
bacteria was also associated with pathogen specific host factors, inferring that 
adverse health of the host promoted both colonisation and subsequent 
respiratory infection with respiratory pathogens.  Figure 1 shows a diagram 
demonstrating these relationships.  Thus colonising respiratory commensal 
pathogens were simultaneously both confounders for frailty associated host 
factors and risk factors for HAP. 
 159 
 
Figure 16. Relationships between patient factors, in-hospital events and respiratory tract infection in older patients with lower limb 
fracture  
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HAP was associated only with colonisation (and not acquisition) of respiratory 
commensal pathogens, in keeping with established dogma.  Colonisation 
occurred early within the sampling period and is likely to represent flora 
acquired in the community rather than in the hospital.  However, given that the 
sampling period was only 14 days, it is not possible to comment on late 
acquisition of respiratory commensal pathogens.  The median onset of HAP 
was later than quoted in other studies (27 days compared with 7-11 days in 
other studies [21, 22, 26]) and a longer sampling period may have revealed late 
colonisation with respiratory commensal pathogens in some patients.  
Events that facilitate the delivery of potential pathogens to the lungs appears to 
be key risk factors for the development of HAP, and are common to the groups 
of patients at particular risk of HAP (e.g. patients on intensive care, stroke 
patients). However, given that all pneumonias involve aspiration to some 
degree [105], the concept of aspiration pneumonia perhaps ought to be 
discarded, and aspiration considered simply as a risk factor for pneumonia.  
Few previous studies have undertaken objective measures of aspiration, and 
further research is needed to correlate the risk of HAP with the degree of 
aspiration in order to stratify patients without clinically obvious aspiration risk.  
Delirium was also associated with HAP, and changes in conscious level are 
central to the diagnosis of delirium.  It was not possible to determine whether 
delirium contributed to an increased risk of aspiration, leading to HAP, or 
whether aspiration occurred independently which gave rise to HAP which then 
led to delirium.  The truth may be a combination of both of these, with delirium 
resulting in further aspiration, and increased and continual inoculum of oral 
bacteria transmitted to the lungs, however the sample size was too small to 
disaggregate these risk factors.   
HAP was the most prevalent healthcare associated infection in the 2011 English 
National Point Prevalence Survey of Healthcare Associated Infection [20], and 
nationally coordinated efforts to prevent the occurrence of HAP are needed. 
Given the mortality associated with HAP in this and other studies, investigating 
the efficacy of putative interventions such as disinfection of oral surfaces, 
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management of xerostomia and removal of denture and dental plaque appear 
warranted in non-ventilated patients.  The MRSA decolonisation protocols 
already in place in many NHS hospitals may offer a starting place for such 
interventions, given the importance of S.aureus in the development of 
subsequent HAP/LRTI.  While such interventions are primarily directed 
towards S. aureus, it is likely that they would be equally effective in preventing 
colonisation of E. coli and other respiratory pathogens in those at risk of HAP, 
due to the inclusion of chlorhexidine 0.12% mouthwash.  Interventions to 
prevent HAP may also be usefully investigated in other settings such as nursing 
homes, stroke units and colorectal and upper abdominal surgical wards, all of 
whom have relatively high rates of HAP.  Managing xerostomia would need to 
be addressed separately, and a further study is needed to verify the association 
with S. aureus, and to trial therapies such as rehydration, avoidance of certain 
drugs, and use of lubricants such as oxygenated glycerol triesters [295], with S. 
aureus colonisation and subjective assessment of xerostomia as endpoints.   
Other approaches which have not been adequately trialled in non-ventilated 
patients include the use of probiotics [296], or the introduction of specific 
bacteria which can inhibit the colonisation of others, known as bacterial 
interference [297].  Iwase et al. found that the introduction of Staphylococcus 
epidermidis which possessed the serine protease “Esp” was able to inhibit 
colonisation with S. aureus and destroy previous biofilm formation [298].  
Antibodies to S. pneumoniae have been shown to cross-react with S. aureus, 
decreasing nasal colonisation with the latter [274].  Introduction of non-
pathogenic E. coli into the intestines of patients with ulcerative colitis have been 
shown to prolong the maintenance phase, when combined with mesalazine 
treatment [299]. It is likely that as we begin to understand how bacterial 
communities interact using next generation sequencing techniques, our ability 
to manipulate the resident flora on body surfaces will no longer be limited 
simply to eradication.   
HAP was not directly associated with dental factors in this group, though 
colonisation with individual respiratory pathogens were significantly 
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associated with number of teeth, amount of dental and denture plaque at 
admission and sensation of xerostomia during hospital admission.  Thus HAP 
may be indirectly related to the presence of certain dental factors via 
colonisation of putative aetiological pathogens.  Given that HAP has also been 
previously associated with number of decayed teeth and presence of P. 
gingivalis [29, 30], further research is needed to understand these relationships 
better.  The exclusion of caries and P. gingivalis identification, which are 
potentially important risk factors, is one of the important limitations of this 
study. P. gingivalis has been found to modify both commensal oral flora and 
the local host immune function to promote periodontal disease[143], and may 
also prove to be important in the development of HAP.  Further work is needed 
to understand the relationships between dentition, dental and denture plaque, 
caries and the oral microbiota in more detail. 
Perhaps the major limitation to this study is its size, in part due to fewer 
patients than expected presenting with hip fracture during the study period, 
and the study was not powered to make some of the associations drawn from 
the results.  However the detail involved in follow up of this study would 
perhaps be too great for a larger or multi-centre trial.  Now that several studies 
have made similar conclusions regarding significant patient risk factors, follow 
up in future studies could be simplified to include only important risk factors. 
Yield of respiratory commensal pathogens from sampling the oral microbiota 
could have been increased by either taking an oral rinse sample or by the 
addition of nasopharyngeal samples [245, 259, 300].  However the former would 
have necessitated the exclusion of patients with moderate to severe dementia 
and the latter may have been less acceptable to patients (nasopharyngeal 
samples are uncomfortable).  A compromise would be to add a simple nasal 
swab, accepting that the yield of some bacteria would probably be lower. 
It is known that influenza and other viruses such as respiratory syncytial virus 
may facilitate infection by S. pneumoniae [75, 76, 301, 302] and that HAP may be 
caused by viruses [303]. By not testing samples for viruses, important factors in 
the development of colonisation with respiratory commensal pathogens and 
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HAP may have been overlooked.  However both cost and time played a factor 
in the decision not to analyse samples for viruses, and this is an area which 
could be addressed in the future using duplicate samples taken during the 
study.  In addition, the local oral immune response, was not assessed in relation 
to colonising pathogens.  It is likely that immunosenescence plays a prominent 
part in determining whether both colonisation and infection are successful in 
older patients, and much work is needed in this area.  Another important risk 
factor which was not assessed was alcohol intake.  Pneumonia is known to be 
more common in those with higher alcohol intake [304].  There was insufficient 
information in patient admission documentation to ensure complete 
ascertainment of this risk factor, and future studies of colonisation with 
respiratory commensal pathogens should include this risk factor. 
Though the real time multiplex PCR assays designed for this study coped well 
with bacterially rich samples, manufacturer contamination of reagents meant 
that only strongly positive results were accepted, which may have led to the 
exclusion of true weak positive results in some patients.  In addition, there is a 
risk that cross-reactivity occurred between both the S. aureus and E. coli assays 
and certain Streptococcal samples.  Without sequencing the relevant samples, it 
is not possible to determine whether any cross-reacitvity may have occurred 
during testing of study samples, but given the relatively small numbers of 
patients who had positive tests with these assays, any effects from cross-
reactivity are likely to be small.  A number of patients appeared to be colonised 
by a non-E. coli coliform (Appendix F), however these results could not be 
analysed in relation to patient factors due to significant contamination of 
reagents seen in water and non-template samples.  In addition, lack of whole 
genome sequence data precluded design of assays for Klebsiella pneumoniae, 
Serratia marcescens and Enterobacter cloacae.  While the latter two organisms are 
not common causes of HAP, K. pneumoniae is, and its exclusion may have meant 
clinically important results were not seen.  As better software facilitating the 
comparison of entire genomes becomes available, it is likely that assays will be 
designed to identify specific Enterobactericeae, and similar studies as this will 
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be needed to assess the dynamics of colonisation with these organisms, with 
particular emphasis on frailty.   
This study is among the first to investigate HAP in relation to the risk of 
aspiration episodes, S. aureus colonisation and increased frailty and 
comorbidity simultaneously and prospectively.  While several groups have 
investigated HAP in surgical patients or nursing home residents, few have 
investigated HAP in patients with lower limb fracture, and risk factors common 
to both the former groups were identified in the latter.  Studies investigating 
factors associated with colonisation rather than infection are also rare in non-
ventilated patients, and the combination of respiratory pathogens investigated 
in this study is novel in this group.  Important risk factors for colonisation with 
S. aureus have been identified in this work, which may lead to the design of 
more robust and effective intervention protocols. In addition, this study is 
unique in identifying colonisation with E. coli as important in non-ventilated 
patients. 
Another strength of this study was that a single geriatric medicine trained 
clinician conducted the majority of patient follow up, and the observation of 
aspiration episodes in particular was opportunistic and probably related to the 
time spent on each study visit.  Importantly, diagnosis of HAP was robust and 
independent of the study.   The investigator was blinded to oral sample results 
due to anonymisation and analysis of samples after patient follow up was 
complete.  Adequate sampling was ensured by the inclusion of the GAPDH 
assay, meaning that all samples negative for respiratory pathogens had a 
positive test for human DNA . 
While patient factors were more important than the components of the oral 
microbiota in determining whether HAP occurred, understanding how the oral 
microbiota changes in response to the presence of respiratory commensal 
pathogens, or indeed the reverse, may be crucial in understanding how to 
manipulate the oral flora without the use of disinfection.  Recognition of 
changes in the oral microbiota could potentially be used as biomarkers for 
HAP, and the duplicate samples taken during this study will be analysed to this 
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end.  While there do not appear to be adverse effects from disinfectants such as 
chlorhexidine, there may be advantages in the longer term in artificially 
manipulating the oral microbiota using other commensal bacteria to promote 
health.  Next generation sequencing technology is now able to determine the 
composition of bacterially rich samples rapidly and accurately, to genus level, 
and investigation of oral samples is currently being undertaken as part of the 
Human Microbiome Project [305].  This technology has allowed researchers to 
redefine the “core” oral flora, and is likely to lead to the identification of novel 
organisms, some of which may be implicated in disease.  Further studies of 
bronchoalveolar lavage samples using this technology are also likely to explain 
the aetiology of pneumonia in those patients in whom no causative organism is 
found (estimated at 40% [17]).  
Further research is also needed to better understand the pathogenesis of the 
clinical syndrome of pneumonia at a tissue and molecular level, to enable 
accurate gold standard diagnosis of pneumonia clinically.  Currently, invasive 
respiratory sampling in conjunction with chest radiography is needed to make 
the best diagnosis [10, 19].  However invasive sampling is rarely undertaken in 
older people on general hospital wards, and may be considered inappropriate 
in the UK in these patients due to frailty.    Meanwhile, a consensus statement 
on the diagnostic criteria which should be used in research trials in non-
ventilated patients is needed.  More standardised terminology or subject 
headings would also improve retrieval rates when searching for articles on 
nosocomial pneumonia in older people and potentially improve design of 
future trials by allowing researchers to assess more of the relevant literature. 
Perhaps another important next step is to raise awareness among clinicians of 
risk factors, the importance of prompt treatment and likely outcomes in HAP.  
It may also be useful to translate published risk factors into a clinical tool to 
facilitate teaching about and assessing those with this condition.  In patients in 
locations at high risk of HAP, assessing their risk of HAP at admission may be 
useful in planning care.  Cluster randomised intervention trials are needed to 
assess the efficacy of interventions discussed above.   
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In studies of older people in hospital, it is standard practice to assess variables 
at the start of admission and observe how these variables relate to an event later 
in admission.  However this method may be flawed because it assumes that the 
baseline characteristics and health state of the patient remain the same, when in 
fact sequential events over the course of admission may modulate the risk 
profile of the patient either positively or negatively.  Complications such as 
infection, pain, falls with or without head injury, dehydration, delirium, drug 
toxicity, urinary retention, acute renal failure, prescription of new drugs, blood 
transfusions and other events occur commonly in these patients during 
admissions to hospital. In addition, the psychological state of the patient may 
change, and anxiety and depression are commonly experienced by hospital 
patients [306, 307], and both of these, along with alcohol withdrawal and 
bereavement reactions were present in the patients in this study. Psychological 
stress has been shown to increase the rate of upper respiratory tract infections 
[308], and presumably also impacts on other medical conditions.  In this group 
of patients, of whom a third are likely to die within one year, psychological 
factors may be just as important as the occurrence of physical illnesses in 
determining outcome (for example when facing necessary transition to a 
residential or nursing home from previously dwelling at home).  Equally, 
patients may recover, and risk factors noted at admission may have improved 
with time.  Structural equation modelling may be one method of analysing 
complex and dynamic longitudinal data in future work.   
5.5 Conclusions 
HAP was a significant clinical problem in the group studied, and was 
associated with host frailty, oral colonisation with specific respiratory 
commensal pathogens, witnessed aspiration episodes and post-operative 
cough.  In turn, colonisation with respiratory commensal pathogens was 
associated with oral and dental risk factors, in addition to host frailty factors.  
These risk factors identify patients at high risk of HAP and suggest E. coli, S. 
aureus, dental plaque and dry mouth as possible targets for future intervention 
studies.  Further studies are needed to determine whether organisms causing 
HAP are hospital or in fact community acquired commensal pathogens.
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Chapter 7  Appendices 
7.1 Appendix A.   
7.1.1 Columbia blood agar 
Columbia agar base ( Oxoid Ltd, UK) containing horse blood. 
7.1.2 Skimmed milk, tryptone, glucose glycerol (STGG)  
Made at Freeman Hospital Microbiology laboratory.  STGG was made by 
dissolving 10ml glycerol, 0.5g glucose, 3.0g oxoid tryptone soy broth and 2.0g of 
skimmed milk powder into 100ml distilled water.  Aliquots of 1ml of STGG 
were added to sterile 2ml microtubes. 
7.1.3 Chocolate agar Made at Freeman Hospital Microbiology laboratory. 
7.1.4 Amplitaq Gold DNA Polymerase  
(containing 250U of 5U/μl Amplitaq Gold) with GeneAmp 10x PCR Gold 
buffer (containing 150mM Tris-HCL, pH8.0, 500mM KCl) and 25 mM 
magnesium chloride solution (Applied Biosystems). 
7.1.5 Tris Borate EDTA (TBE) Buffer 
100ml TBE buffer 10x solution (Severn Biotech Ltd, UK) was added to 900ml 
deionised water and 100µl of ethidium bromide added to make 1 litre of TBE 
buffer with ethidium bromide concentration 0.5μl/ml. 
7.1.6 Agarose gel electrophoresis loading buffer  
BlueJuiceTM 10x Gel loading buffer which contained 65% (w/v) sucrose, 10mM 
Tris-HCl (pH 7.5), 10mM EDTA, and 0.3% (w/v) Bromophenol blue.  The 
recommended concentration was 2x (one part buffer with 4 parts sample). 
(Invitrogen, Life Technologies Ltd, Paisley , UK) 
7.1.7 Agarose 
Microsieve (3:1) for DNA 500-1500bp was used to create agarose gels for 
electrophoresis (Flowgen Bioscience Ltd, UK). 
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7.1.8 DNA ladder 
Superladder low 100bp ladder 100μg/ml (Thermo Fisher Scientific, Surrey, 
UK). 
7.1.9 PCR water 
Sigma-Aldrich Company Ltd, UK 
7.1.10 Deoxynucleotide triphosphate bases  
For PCR 10mM mix with dTTP (Applied Biosystems, Warrington, UK) 
containing 2.5mM of each dATP, dCTP,dGDP and dTTP. 
7.1.11 Ethanol 
7.1.12 DNeasy blood and tissue kit  
For purification of DNA from bacteria was obtained from Qiagen UK Ltd. 
7.1.13 Ethidium Bromide  
10mg/ml, Invitrogen, Life Technologies Ltd, Paisley , UK 
7.1.14 Tris-EDTA buffer  
Contains 1.0M Tris HCl and 0.1M EDTA (Sigma-Aldrich Company Ltd, UK) 
7.1.15 Triton X  
Made by Sigma-Aldrich Company Ltd, UK 100x. 
7.1.16 Lysozyme 
From chicken egg white 100mg/ml, made by Sigma-Aldrich Company Ltd, UK 
7.1.17 Taqman® Universal PCR Master mix 
Applied Biosystems (Warrington, UK) 
7.1.18 Probes 
5’FAM, 3’Deep dark quencher II and 5’CY5-3’Black hole quencher 1 probes 
from Eurogentec Ltd (Southampton, UK) 
Taqman VIC-TAMRA probe from Applied Biosystems (Warrington, UK) 
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7.1.19 Oligonucleotide primers 
Oligold oligonucleotide primers were manufactured by Eurogentec Ltd, 
Southampton, UK 
7.1.20 Salmon sperm DNA 10mg/ml 
Invitrogen, Life Technologies Ltd, Paisley , UK 
7.1.21 Moltaq 16s DNA Polymerase 
Molzym, VH-bio Ltd, Gateshead, UK 
7.1.22 Exonuclease III  
Promega UK, Southampton, UK 
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7.2 Appendix B.  PCR assays targeted towards organisms causing HAP retrieved from Medline search (October 2008) 
 
Target organism Gene target Primers/Probe Comments Reference 
P. aeruginosa 16s RNA Forward 480 GTT ACC AAC AGA ATA AGC 
Reverse 1240 TTG TAC CGA CCA TTG TAG 
Probe 640     AGC TCA GTA GCT TTT GGA 
 [309] 
P. aeruginosa 16S RNA Forward GTG CCT GCA GCC GCG GTA AT 
Reverse  TGC GCC ACT AAG ATC TCA AG 
 [200] 
P. aeruginosa oprL PAL1 ATG GAA ATG CTG AAA TTC GGC 
PAL2 CTT CTT CAG CTC GAC GCG ACG 
 [219] 
P. aeruginosa OprL PAL1 ATG GAA ATG CTG AAA TTC GGC 
PAL2 CTT CTT CAG CTC GAC GCG ACG 
OprL-FL TGC GAT CAC CAC CTT CTA CTT CGA GT 
OprL-LC CGA CAG CTC CGA CCT GAA G 
 [310] 
P. aeruginosa 16S rRNA 
/oprL 
oprL 
PAL1 ATG GAA ATG CTG AAA TTC GGC 
PAL2 CTT CTT CAG CTC GAC GCG ACG 
 
16s rRNA  
Forward GAG GAA GGT GGG GAT GAC GT 
Reverse  AGC CCC GGG AAC GTA TTC AC 
 
 [311] 
P. aeruginosa exoS, exoT, 
exoU, exoY 
Exo S  
MP5 GCG AGG TCA GCA GAG TAT CG 
MP3  TTC GGC GTC ACT GTG GAT GC 
 
exoT 
 [312] 
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Target organism Gene target Primers/Probe Comments Reference 
MP5 AAT CGC CGT CCA ACT GCA TGC G 
MP5 TGT TCG CCG AGG TAC TGC TC 
 
exoU  
MP5 CCG TTG TGG TGC CGT TGA AG 
MP3 CCA GAT GTT CAC CGA CTC GC 
 
exoY  
MP5 CGG ATT CTA TGG CAG GGA GG 
MP3 GCC CTT GAT GCA CTC GAC CA 
P. aeruginosa ALGd GDP 
Mannose 
dehydrogenase 
VIC1 TTC CCT CGC AGA GAA AAC ATC 
VIC2 CCT GGT TGA TCA GGT CGA TCT 
 [218] 
Pseudomonas 
sp 
16s rDNA PA-GS-F GAC GGG TGA GTA ATG CCT A 
PA-GS-R CAC TGG TGT TCC TTC CTA TA 
 [313] 
P. aeruginosa 16s rDNA PA-SS-F GGG GGA TCT TCG GAC CTC A 
PA-SS-R TCC TTA GAG TGC CCA CCC G 
 [313] 
P. aeruginosa 23s rRNA PaFP TCC AAG TTT AAG GTG GTA GGC TG 
PARP CTT TTC TTG GAA GCA TGG CAT C 
Probe- PA23FAM 
AGG TAA ATC CGG GGT TTC AAG GCC 
 [314] 
P. aeruginosa gyrB gyrB-398 CCT GAC CAT CCG TCG CCA CAA C 
gyrB-620 CGC AGC AGG ATG CCG ACG CC 
Probe: SYBR green  
 [315] 
P. aeruginosa ecfx ECF1 ATG GAT GAG CGC TTC CGT G 
ECF2  TCA TCC TTC GCC TCC CTG 
 [228] 
P. aeruginosa ETA ETA1 GAC AAC GCC CTC AGC ATC ACC AGC  [316] 
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Target organism Gene target Primers/Probe Comments Reference 
ETA2 CGC TGG CCC ATT CGC TCC AGC GCT 
Probe 
ETA3 AGC CAC ATG TCG CCG ATC TAC ACC 
P. aeruginosa algD, nested Initially 
PAL1 GAC AGG TTG AGC TTG TGG 
PAL3 GAA TTC CTC CGC GAG AGC 
Then 
PAL 2 CGA ACT GGA CAA GCA GAC 
PAL4  GCA GAT CAC GTC CAT CAC 
 [317] 
Pseudomonas 
sp 
groES  Forward ATG AAG CTT CGT CCT CTG CAT 
Reverse GTC TTT CAG CTC GAT 
Heat shock protein  
P. aeruginosa  16s rDNA 
F CGG YCC AGA CTC CTA CGG G 
R TTA CCG CGG CTG CTG GCA C 
GyrB 
F CCT GAC CAT CCG TCG CCA CAA C 
R CGC AGC AGG ATG CCG ACG CC 
ETA 
F GAC AAC GCC CTC AGC ATC ACC AGC 
R CGC TGG CCC ATT CGC TCC AGC GCT 
AlgD 
F TTC CCT CGC AGA GAA AAC ATC 
R CCT GGT TGA TCA GGT CGA TCT 
Oprl 
F GCT CTG GCT CTG GCT GCT 
R AGG GCA CGC TCG TTA GCC 
Compared a variety 
of assays with gold 
standard 
[214] 
P. aeruginosa Exotoxin A ETA1 GACAAC GCC CTC AGC ATC ACC AGC  [318] 
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Target organism Gene target Primers/Probe Comments Reference 
ETA2 CGC TGG CCC ATT CGC TCC AGC GCT 
Pseudomonas 
sp 
16S RNA F GGT CTG AGA GGA TGA TCA GT 
R TTA GCT CCA CCT CGC GGC 
 [319] 
P. aeruginosa oprI F ATG AAC AAC GTT CTG AAA TTC TCT GCT 
R CTT GCG GCT GGC TTT TTC CAG 
PCR –Elisa [320] 
P. aeruginosa FliC  F GCC TGC AGA TCG CCA ACC 
R GGC AGC TGG TTG GCC TG 
 [321] 
P. aeruginosa 16s r RNA  
 
F1 GGCAGT AAG TTA ATA CCT TGC T 
R1 CCT TAG AGT GCC CAC CCG AG 
F2 GCG CGC GTA AGT GGT TCA GC 
In ovine fleece 
washings. 
2nd primer for nested 
PCR with R1 
[322] 
Enterobacter sp.   No papers retrieved- 
only ones found 
related to Enterbacter 
sakazakii or ESBL 
genes or typing- but 
see below 
 
Serratia 
marcescens 
16s rRNA  
 
F GGT GAC CTT AAT ACG TTC ATC AAT TG (435-
460) 
R GCA GTT CCC AGG TTG AGC C (595-613) 
 
P TGC GCT TTA CGC CCA GTA ATT CCG A (534-558) 
Real time- also 
included resistance 
genes 
[323] 
Serratia 
marcescens, 
Klebsiella, 
Enterobacter 
16s RNA in 
. 
 
 
Universal forward primer 
GGC GGC AGG CCT AAC 
 
Universal reverse primer 
CAG GCA GTT TCC CAG ACA TTA CT 
Taqman assay 
Probes but not 
primers specific to 
sequences 
[324] 
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Target organism Gene target Primers/Probe Comments Reference 
 
Probe 
FAM- AGC AAG CTC TCT GTG CTA CCG CTC GA-
TAMRA 
Acinetobacter 
baumannii 
16s-23s ITS F CAT TAT CAC GGT AAT TAG TG 
R AGA GCA CTG TGC ACT TAA G 
 
recA gene 
F CCT GAA TCT TCT GGT AAA AC 
R GTT TCT GGG CTG CCA AAC ATT AC 
 [325] 
Acinetobacter 
baumannii 
16s-23s 
 
FGAG TTT GAT CCT GGC TCA 
R CCG GTC CTC TCG TAC 
PCR plus restriction 
analysis 
[326] 
Acinetobacter 
baumannii 
16s-23s ITS AGT GTG ATC TGA CGA AGA CAC ATT AAC T Oligonucleotide 
probe for 
hybridisation not 
primers 
 
[327] 
Klebsiella 
pneumoniae 
16srRNA 
 
EMBL accession no X93214 126bp target sequence 44-
170 
K16SF 15-mer position 44-58 
K16SR 16-mer position 155-170 
 
Real time 
From blood culture 
bottles 
[328] 
Klebsiella 
pneumoniae 
Haemolysin 
gene  
EMBL accession no AF293352 
 
No primers 
described- “PCR 
performed as 
described 
elsewhere… 
[329] 
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Target organism Gene target Primers/Probe Comments Reference 
unpublished work” 
Klebsiella 
pneumoniae 
gyrA Genbank accession AJ292307 
 Sense primer 219 CTT TTC TGT TCA GAC CTG CG 
238 
Antisense primer 182 TAG CCC CTA ACG TCG ATC 
AT 163 
 
Sense probe  273 AAT ACG GTT TAT TCA TGG CG 
254 
Antisense probe 141 GCT TCG AAT TGG CGA TTT CA 
160 
 [330] 
Escherichia coli 16s rRNA, ITS, 
23s r RNA 
UP CAA TTT TCG TGT CCC CTT CG 
DN GTT AAT GAT AGT GTG TCG AAA C 
 
Used SYBR green [331] 
Escherichia coli  Various see paper Cdt genes- 
Primers generated 
non-specific products 
and were not suitable 
for typing 
[332] 
Escherichia coli 
(and group B 
Streptococcus 
and Listeria 
monocytogenes) 
16s rDNA 
 
F AAC TGG AGG AAG GTG GGG AT 
R AGG AGG TGA TCC AAC CGC A 
Not species specific [333] 
Escherichia coli SfmD 
 
F ACT GGA ATA CTT CGG ATT CAG ATA CGT 
R ATC CCT ACA GAT TCA TTC CAC GAA A 
6-FAM CAG CAG CTG GGT TGG CAT CAG TTA TTC 
Real time arm 
Good 
sensitivity/specificity 
[334] 
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Target organism Gene target Primers/Probe Comments Reference 
G-TAMRA 
In Opticon 2  
 
Escherichia coli 16s, B-
galactosidase 
 
16S 
F TCT CCA GAA CAT CAT CCT G 
R GAG CTT GAC AAA GTG GTC GT 
B-Galactosidase 
F CTT GCC TGG TTT CCG GCA CCA GAA 
R AAC CAC CGC ACG ATA GAG ATT CGG G 
Not specific enough [335] 
Escherichia coli lamb 
 
 
F GGA TAT TTC TGG TCC TGG TGC CG 
R ACT TGG TGC CGT TGT CGT TAT CC 
 
Biotin labelled probe 
TGC GTG ATA ACT ATC GTC TGG 
PCR-ELISA 
Primers from Bej et 
al. 1990 
[336] 
Escherichia coli 16s rRNA F ACA CGG TCC AGA ACT CCT ACG  
R GCC GGT GCT TCT TCT GCG GGT AAC GTC A 
SYBR Green used to quantify 
 [337] 
Escherichia coli 16s rRNA F CAT GCA AGT CGA ACG GTA ACA G 
R GCG ACG TTA TGC GGT ATT AGC  
PROBE TGC TTT GCT GAC GAG TGG CGG A 
 [338] 
Escherichia coli lacZ  
 
No primers described From Kane et al. [339] 
Escherichia coli 5s rRNA F TGC CTG GCG GCC GTA GCG CG 
R ATG CCT GGC AGT TCC CTA CT 
 [340] 
Escherichia coli gfp F CAG TGG AGA GGG TGA AGG TG 
R AAA GGG CAG ATT GTG TGG AC 
 [341] 
Escherichia coli B- F CTT TGC CTG GTT TCC GGC ACC AGA A  [342] 
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Target organism Gene target Primers/Probe Comments Reference 
galacatosidase R ACC CAC CGC ACG ATA GAG ATT CGG G 
Escherichia coli 16s 
 
F GCT AAT ACC GCA TAA CGT TCG  (168-187) 
R AAC GCT TGC ACC CTC CGT A (552-527) 
 [343] 
Escherichia coli Uid, lacZ 
 
lacZ  
F ATG AAA GCT GGC TAC AGG AAG GCC 
R GGT TTA TGC AGC AAC GAG ACG TCA 
 
Uid 
F TGT TAC GTC CTG TAG AAA GCC C 
R AAA ACT GCC TGG CAC AGC AAT T 
Lindow man 
From Fricker 1994 
[344] 
Escherichia coli cnf F CGC TTG GAC TGG GGA TAA TT 
R CTT CAT AGT AGA TGC CGC TC 
 [345] 
Escherichia coli malB 
 
F TCG CCA CAC GCT GAC GCT GAC CA 
R TTA CAT GAC CTC GGT TTA GTT CAC AGA 
Also detects Shigella [346] 
Escherichia coli uidA or 16s 
rRNA 
F AAA ACG GCA AGA AAA AGC AG 
R ACG CGT GGT TAC AGT CTT GCG 
 [347] 
Escherichia coli* lacZ and uidA lacZ 
F ATG AAA GCT GGC TAC AGG AAG GCC 
R GGT TTA TGC AGC AAC GAG ACG TCA 
uidA  
F AAA ACG GCA AGA AAA AGC AG 
R ACG CGT GGT TAC AGT CTT GCG 
 [203] 
Escherichia coli GroEL 
 
F TGA AAC GYG GTA TCG ACA AA 
R CTG CAT ACC TTC AAC MAC GTC C 
Probe 
6-FAM CCT TCT TTA CCG ACT TTI TCC ATC GCT T 
TAMRA 
Reverse transcript 
real time PCR 
[215] 
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Target organism Gene target Primers/Probe Comments Reference 
Escherichia coli uidA  
 
Inititally 
F ATC ACC GTG GTG ACG CAT GTC GC 
R CAC CAC GAT GCC ATG TTC ATC TGC 
Then 
F TAT GAA CTG TGC GTC ACA GCC 
R CAT CAG CAC GTT ATC GAA TCC 
 
Nested [348] 
Escherichia coli UidA   
 
 Based on Jefferson et 
al., another by Blanco 
et al. 
Used oligonucleotide 
gene probes 
[203] 
Escherichia coli lacZ, lamb 
 
  [203] 
Escherichia coli uidA 
 
 Used Bej et al. 1991 
primers 
[349] 
Escherichia coli malB 
 
Not listed As per Furrer et al. 
and Candrian et al. 
Were seeking 
toxigenic strains. 
 
meyer 
Escherichia coli 16s rRNA   [205] 
Escherichia coli lacZ F- CTT TGC CTG GTT TCC GGG ACC AGA A 
R- ACC CAC CGC ACG ATA GAG ATT CGG G 
 [350] 
Escherichia coli B- 
galactosidase 
 
F- CTT TGC CTG GTT TCC GGC ACC AGA A 
R- AAC CAC CGC ACG ATA GAG ATT CGG G 
Same primers as 
above. 
Kane 
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Target organism Gene target Primers/Probe Comments Reference 
S. pneumoniae  lytA GGA AAG ACC CAG AAT TAG GT 
GTC TGA GTG GTT GTT TGG TT 
308BP 
Comparing different 
swab types 
[351] 
S. pneumoniae lytA,  LytA-F ACG CAA TCT AGC AGA TGA AGC 
LytA-R TGT TTG GTT GGT TAT TCG TGC 
Probe  FAM- TTT GCC GAA AAC GCT TGA TAC 
AGG G- TAMRA 
Real time [352] 
S. pneumoniae lytA  No primers listed in article. Real time multiplex 
PCR from Sheppard 
et al. 
 
[353] 
S. pneumoniae lytA versus 
Ply. 
 
Ply 
F ACG TGA CAA TGT AGT T 
R CCG GTA CAC TCT CTA AT 
FL GGA AGT CTT GAC TCC TAG G-FLU 
640 TGG GAC AGA AAT GGG C 
 
LytA 
F CAG CGG TTG AAC TGA TTG A 
R TGG TTG GTT ATT CGT GCA A 
FL GAA AAC GCT TGA TAC AGG GAG TT 
640 AGC TGG AAT TAA AAC GCA CGA G 
Real time, lytA was 
more sensitive 
[354] 
S. pneumoniae  No primers listed in paper Real time, clinical 
study, from sputum, 
primers from Kais et 
al. 
[210] 
S. pneumoniae ply GenBank accession m17717 Multiplex reverse [330] 
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Target organism Gene target Primers/Probe Comments Reference 
Antisense primer 552 CCA CTT GGA GAA AGC TAT 
CGC T 531 
Sense primer 558 CCC AGC AAT TCA AGT GTT CG 
557 
 
Sense probe 465 CCC ACT CTT CTT GCG GTT GA 484 
Antisense probe 673 TGA GCC GTT ATT TTT TCA 
TAC TG 651 
 
 
line blot 
hybridisation of 
bacterial respiratory 
pathogens- S 
Pneumoniae, S. 
pyogenes, S. aureus, 
H. influenzae, 
Bordetella, Klebsiella, 
Legionella and 
others. 
S.pneumoniae lytA versus 
pneumolysin 
 
Pneumolysin M17717 
F CTA CCA ACG ACA GTC GCC TCT A (397-418) 
R ATT ATT CTC TAA CAA GGT CTC ATC CAC TAC 
(464-435) 
Probe FAM CCT GGA GCA CTT CT MGB 
(420-433) 
 
LytA  
F ACG CAA TCT AGC AGA TGA AGC (306-326) 
R TGT TTG GTT GGT TAT TCG TGC (386-406) 
Probe FAM TTT GCC GAA AAC GCT TGA TAC AGG 
G TAMRA (330-354) 
 
Real time [355] 
S. pneumoniae ply gene  No primers listed in this paper. Real time, from 
Corless et al. 
[356] 
S. pneumoniae Compared 
lytA ply, psaS 
LytA AE005672 nuc pos F1841014, R 1840961 P 1840985  
F ACG CAA TCT AGC AGA TGA AGC A 
Real time [357] 
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Target organism Gene target Primers/Probe Comments Reference 
 R TCG TGC GTT TTA ATT CCA GCT 
FAM GCC GAA AAC GCT TGA TAC AGG GAG- 
BHQ1 
 
PsaA U53509 F166, R 279 P 219 
F GCC CTA ATA AAT TGG AGG ATC TAA TGA 
R GAC CAG AAG TTG TAT CTT TTT TCC G 
HEX CTA GCA CAT GCT ACA AGA ATG ATT GCA 
GAA AGA AA PHOS 
 
Ply  AE008539 F 721 R 798 P 742 
F GCT TAT GGG CGC CAA GTC TA 
R CAA AGC TTC AAA AGC AGC CTC TA 
FAM-CTC AAG TTG GAA ACC ACG AGT AAG AGT 
GAT GAA PHOS 
S.  pneumoniae  16s  Not useful to this study  [358] 
S.  pneumoniae  No primers listed in this paper. Used PCR technique 
from Pai et al.   
[359] 
S.  pneumoniae ply F AGC GAT AGC TTT CTC CAA GTG G (531-552) 
R CTT AGC CAA CAA ATC GTT TAC CG (603-583) 
P ACC CCA GCA ATT CAA GTG TTC GCG (556-580) 
From Walker et al., 
real time, direct from 
sputum. 
[211] 
S.  pneumoniae ply No primers listed in this paper. From Saukkoriipi et 
al. 
[360] 
S. pneumoniae ply F TGC AGA GCG TCC TTT GGT CTA T 
R CTC TTA CTC GTG GTT TCC AAC TTG A 
Amplicon 80 bp 
From Corless et al. 
which was based on 
Walker et al. 1987 
[361] 
S. pneumoniae ply  LytA 429 bp From Corless et al.   [362] 
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Target organism Gene target Primers/Probe Comments Reference 
F AAC CAT ATA GGC AAG TAC AC 
R ATC ATG CTT AAA CTG CTC AC 
 
Ply 81 bp 
F TGC AGA GCG TCC TTT GGT CTA T 
R CTC TTA CTC GTG GTT TCC AAC TTG A 
S. pneumoniae Compared ply 
lytA  
lytA 308 bp from Nagai et al. 2001 
sense CAA CCG TAC AGA ATG AAG CGC 
anti-sense TTA TTC GTG CAA TAC TCG TGC G 
 
ply 329 bp from Salo et al. 1995 
sense  ATT TCT GTA ACA GCT ACC AAC GA 
antisense GAA TTC CCT GTC TTT TCA AAG TC 
 
spn9802 162 bp Suzuki et al. 2005 
143F CAA GTC GTT CCA AGG TAA CAA GTC T 
304R CTA AAC CAA CTC GAC CAC CTC TTT 
 
Spn9828 227bp Suzuki et al. 2005 
19F GGC ATT GTG AAT GGA TTG ATT G 
245R TCA TGT GCA TCC CAA GCT ACA   
 
With primers used to 
be highly specific- 
spn9802 and spn9828 
[363] 
S. pneumoniae lytA La5_Ext and La3_Ext from Obregon et al . Used primers from 
Salo et al., nested 
PCR 
[364] 
S.  pneumoniae  ply 208bp 
OUTER 
 [365] 
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Target organism Gene target Primers/Probe Comments Reference 
F ATT TCT GTA ACA GCT ACC AAC GA 
R GAA TTC CCT GTC TTT TCA AGT C 
INNER 
F CCC ACT TCT TCT TGC GGT TGA 
R TGA GCC GTT ATT TTT TCA TAC TG 
S. pneumoniae 
 
lytA,  No primers listed in this paper Multiplex PCR from 
Stralin et al. 2005 
[191] 
S. pneumoniae ply  From Saukkoriipi et al. 2002 
Ply 
F ACT CTT CTT GCG GTT GAT CG 
R TGA GCC GTT ATT TTT TCA TAC TG 
P TCT CCA AGT GGA AGA CCC CAG CAA 
640 CAA GTG TTC GCG GAG CGG TAA AC 
Compares Real time 
PCR for ply, 
conventional PCR 
and other tests. 
[366] 
S. pneumoniae 
 
lytA  No primers listed in this paper. Serotyping outer 
primers only from 
Messmer et al 
[221] 
S. pneumoniae Unclear No primers listed in this paper. PCR as per McAvin 
et al. 2001 
[367] 
S.  pneumoniae ply  No primers listed in this paper. Real time, direct on 
sputum, based on 
Greiner et al. 2001 
[368] 
S. pneumoniae 
 
ply  F TGC AGA GCG TCC TTT GGT CTA T 
R CTC TTA CTC GTG GTT TCC AAC TTG A 
Multiplex based on 
Corless 2001 
[369] 
S. pneumoniae Compared ply, 
lytA  
No primers listed in this paper. (outer primers only ) 
and psaA for 
specificity from 
Messmer 1997, 
[370] 
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Target organism Gene target Primers/Probe Comments Reference 
Morrison et al 2000 
S. pneumoniae ply F ACT CTT CTT GCG GTT GAT CG 
R TGA GCC GTT ATT TTT TCA TAC TG 
640 CAA TTG TTC GCG GAG CGG TAA AC 
P TCT CCA AGT GGA AGA CCC CAG CAA 
Real time, compared 
with culture in 
children. Based on 
pneumolysin 
sequence from 
Walker et al., using 
modified version of 
primers from Salo et 
al. 
 
[188] 
S. pneumoniae lytA  Genbank AF345846 173 bp 
F CAG CGG TTG AAC TGA TTG A 
R TGG TTG GTT ATT CGT GCA A 
Donor probe  GAA AAC GCT TGA TAC AGG GAG TT 
Acceptor probe AGC TGG AAT TAA AAC GCA CGA 
G 
 [371] 
S. pneumoniae 16s  Not relevant to this study.  [372] 
S. pneumoniae lytA Prototype sequence 94813 191-454 
F GGA GTA GAA TAT GGA AAT TAA TGT 
R GCT GCA TAG GTC TCA GCA TTC CAA 
 [373] 
S. pneumoniae 16s  Not relevant to this study. Simultaneous 
detection of 
meningitis pathogens  
[374] 
S. pneumoniae ply  Sense TTT CTG TAA CAG CTA CCA ACG A 
Anti sense GAA TTC CCT GTC TTT TCA AAG TC 
From Salo/ Toikka et 
al. 
[375] 
S. pneumoniae ply Primers not relevant to this study or previously Used broad range [376] 
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Target organism Gene target Primers/Probe Comments Reference 
described. and more specific 
primers then 
confirmed using ply 
by Corless et al 
S. pneumoniae 
 
 lytA  Primers above. From Gillespie et al. [377] 
S. pneumoniae unclear  SP1 ATC GAA ATT AAT GTG AGT A 
SP2 AGC TCT CAG CAT TCC A 
From Hassan-King et 
al.  
[378] 
S. pneumoniae ply  Sp sense  GAC AAT ACA GAA GTG AAG GCG G 
Sp antisense ATA GGC ACC ACT ATG ATC CAG C 
Sp d1 TCG GCA AGC CTG GAT GAT CTG CTG T 
FLUOR 
SPA1 640- AGC GAC TGC CTT CTT GAA TCA AGT 
CCT CTA -P 
 [379] 
S. pneumoniae PBP2 No primers listed in this paper. From Dowson et al. [380] 
S. pneumoniae ply, lytA,  Ply , outer 
1006-1032 AAT GCA CTG TTA CAT CAA CGC TGG 
AAA 
1047-1073 GAT ACA ACT CTG ATT CCA ATG TCG 
AAT 
Inner  
424-450 AAT AAT GTC CCA GAT AGA ATG CAG 
TAT 
473-499 TGG AAC AAC TCA AGG TCA AGT TTG 
GTT 
 
LytA Outer 
Nested PCR [381] 
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599-627 AAA ATC AAT GGC ACT TGG TAC TAC TTT 
634-660 TAT ATG CTT GCA GAC CGC TGG AGG 
AAG 
 
Inner 
107-133 AGA ATG AAG CGG ATT ATC ACT GGC 
GGA 
172-198 AAC GGT TGC ATC ATG CAG GTA GGA 
CCT 
S. pneumoniae lytA LYTA  
F CGG ACT ACC GCC TTT ATA TCG 
R GTT TCA ATC GTC AAG CCG TT 
 [382] 
S. pneumoniae ply and atpA  ply  
F AGC GAT AGC TTT CTC CAA GTG G (531-552) 
R CTT AGC CAA CAA ATC GTT TAC CG (583-605) 
 
AptA  
F CGC TAA TTT ACA GTA TGA C (783-801) 
R TAA ATC CAC GAC GAC GAA C (847-865) 
 [209] 
S. pneumoniae lytA  No primers listed Based on Garcia et al. 
1986 
 
[383] 
S. pneumoniae Unclear No primers listed in this paper. Based on Garcia et al. 
1986 
[384] 
S. pneumoniae 16S F AGT CGG TGA GGT AAC CGT AAG 
R AGG AGG TGA TCC AAC CGC A 
 [385] 
S. pneumoniae ply  F TGC AGA GCG TCC TTT GGT CTA T (894-915) Based on Walker et [216] 
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R CTC TTA CTC GTG GTT TCC AAC TTG A (974-950) 
P VIC- TGG CGC CCA TAA GCA ACA CTC GAA 
(941-918) 
al. 1987. 
S. pneumoniae 16s Lower primer (r) Genbank X58312 
CTA CGC ATT TCA CCG CTA CAC (567-587) 
 
Upper primer 
AAG GTG CAC TTG CAT CAC TAC C (106-127) 
 
 [386] 
H. influenzae gyrB GenBank accession U32738 
Sense primer  
5974 GAA TAT CCA CAG GAA TCC CG 5993 
Antisense primer  
6028 GAT GAT AAT TCT GTA TCG GTG CAA 6005 
 
Sense probe 
5926 GAA GCA CAG TCA TAA TAA CTT CTG CT 
5951 
Antisense probe 
6159 GTC CTG GTA TGT ATA TCG G 6138 
Multiplex reverse 
line blot 
hybridisation of 
bacterial respiratory 
pathogens 
[330] 
H. influenzae  bex   Not relevant to this study as only type b included. Multiplex from 
Corless et al. 
[369] 
H. influenzae bexA  No primers listed in this paper. Multiplex from 
Corless et al. 
[387, 2007 #992] 
H. influenzae 16s  16s rRNA -538bp 
F TCC TAA GAA GAG CTC AGA GAT 
R TGA TCC AAC CGC AGG TTC C 
Multiplex with H. 
influenzae 
[382] 
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Target organism Gene target Primers/Probe Comments Reference 
 
 
H. influenzae 
 
frdB F ATC GAA AGT TTA GAG GCA A (328-348) 
R TTC TTT CGA TGG ATG TGG TT (392-412) 
 [209] 
H. influenzae 
 
bexA  No primers listed in this paper. As per Falla et al. 
1994 
[383] 
H. influenzae 
 
16s rRNA then 
P6 
No primers listed in this paper. As per Stralin et al. 
2005 
[191] 
H. influenzae 
 
16a No primers listed in this paper. Nested PCR based on 
Radstrom et al. 
[388] 
H. influenzae 
 
16s rRNA then 
P6 
16s rRNA (538 bp) 
F TCC TAA GAA GAG CTC AGA GAT (4800-4820) 
R TGA TCC AAC CGC AGG TTC C (5337-5319) 
 
P6 (296 bp) 
F TTG GCG GWT ACT CTG TTG CT (174-193) 
R TGC AGG TTT TTC TTC ACC GT ( 469-449) 
 [201] 
H. influenzae 
 
 
23s then 
specific 
primers 
23s 
F GCG ATT TCY GAA YGG GGR AAC CC 
R TTC GCC TTT CCC TCA CGG TAC T 
( where Y is  C or T and R is A or G) 
 
Specific 
F GTG AGG AGA ATG TGT TGG GAA G 
R GGT TGT AGG ACT GCA ATG TGG ACT C 
Real time, used SYBR 
green some primers 
from Anthony et al. 
2000 
[389] 
H. influenzae  
 
Unclear   No primers listed in this paper. Based on Falla et al. [384] 
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H. influenzae Hel encoding 
P4 outer 
membrane 
protein.   
F GAT CCG AAT TCC TTA AAA GGA AT 
R ATT AAA TAT TGG ATC CAG TAA AAA CTG 
AAC 
 
Internal probe from Sambrook et al. deduced from 
previously published sequence of hel (Green et al 1991). 
Gcg acg tca atc tcg tgc ggt tcg ggg tgc gg 
Based on Reidl and 
Mekalaanos 1996. 
[390] 
H. influenzae  16s rRNA  
then specific 
primers 
F GG AGT GGG TTG TAC CAG AAG TAG 
R AGG AGG TGA TCC AAC CGC A 
 [385] 
H. influenzae 
 
bexA  F GGC GAA ATG GTG CTG GTA A (142-160) 
R GGC CAA GAG ATA CTC ATA GAA CGT T (241-
217) 
P TET-CAC CAC TCA TCA AAC GAA TGA GCG TGG 
(189-163) 
Based on Kroll et al. 
1988 
[216] 
H. influenzae 16s  F CGT ATT ATC GGA AGA TGA AAG TGC (177-200) 
R CTA CGC ATT TCA CCG CTA CAC (682-702) 
Modification of prev 
PCR designed by 
Hendolin et al. 
[220] 
H. influenzae 
 
16s Oligonucleotide probe 
H inf GGA GTG GGT TGT ACC AGA ATA GAT 
 
 
Universal primers, 
amplicon cloned into 
E. coli then 
hybridised and 
sequenced 
[391] 
H. influenzae 
 
16s then 
species specific  
F CCT AAG AAG AGC TCA GAG 
 
R AAG GAG GTG ATC CAY CCG CAM MTT C 
Y=G OR A  
 [392] 
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M=G OR C 
H. influenzae 16s Lower primer (R) GENBANK accession no M35019 
CTA CGC ATT TCA CCG CTA CAC (679-699) 
 
Upper primer (F) 
CGT ATT ATC GGA AGA TGA AAG TGC (177-200) 
 
 [386] 
H. influenzae 
 
 Not relevant to this study (type b only)  {Hassan-King, 
1996 #1019 
H. influenzae 
 
P6  F AAC TTT TGG CGG TTA CTC TG 
R CTA ACA CTG CAC GAC GGT TT 
 
P TAA ATA TGA CAT TCA TGG TG 
Based on Hotomi et 
al. and specific 
internal probe  
[393] 
H. influenzae 
 
16s  Not relevant to this study.  [374] 
H. influenzae-  
 
 Not relevant to this study (type b only)  [394] 
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7.3 Appendix C  Optimising primers and probes 
 
Table 44. Primer optimisation for P. aeruginosa real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 RN Rep 4 Mean 
value RN  
1. 0.05/0.05 2.00 2.06 2.10 2.10 2.07 
2. 0.05/0.3 n/a 3.51 3.55 3.57 3.54 
3. 0.05/0.9 n/a 3.56 3.62 3.64 3.61 
4. 0.3/0.05 1.49 1.48 1.46 1.47 1.48 
5. 0.3/0.3 3.21 3.22 3.19 3.19 3.20 
6. 0.3/0.9 3.54 3.54 3.52 3.49 3.52 
7. 0.9/0.05 1.50 1.50 1.52 1.52 1.51 
8. 0.9/0.3 3.07 3.01 3.03 3.02 3.03 
9. 0.9/0.9 3.46 3.44 3.40 3.38 3.42 
RN= level of fluorescence 
 
 
 
Table 45. Mean RN values by primer concentration for P. aeruginosa real-
time PCR assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
2.07 
3.54 
3.61* 
1.48 
3.20 
3.52 
1.51 
3.03 
3.42 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 46. Primer optimisation assay for Acinetobacter spp. real-
time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 
1 
RN Rep 
2 
RN Rep 
3 
RN Rep 
4 
Mean 
RN  
1. 0.05/0.05 0.36 0.36 0.36 0.36 0.36 
2. 0.05/0.30 0.97 0.96 1.00 1.05 1.00 
3. 0.05/0.9 1.14 1.17 1.21 1.28 1.20 
4. 0.3/0.05 0.49 0.49 n/a n/a 0.49 
5. 0.3/0.3 1.11 1.11 1.17 1.16 1.14 
6. 0.3/0.9 1.31 1.34 1.33 1.33 1.33 
7. 0.9/0.05 0.51 0.49 0.49 0.49 0.50 
8. 0.9/0.3 1.16 1.14 n/a 1.10 1.13 
9. 0.9/0.9 1.42 1.37 1.36 1.32 1.37 
RN= level of fluorescence 
 
 
Table 47. Mean RN values by primer concentration for 
Acinetobacter spp. real-time PCR assay 
 
 
 
Reverse 
Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.36 
1.00 
1.20 
0.49 
1.14 
1.33 
0.50 
1.13 
1.37* 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 48. Primer optimisation assays for E. coli real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 RN Rep 4 Mean RN  
1. 0.05/0.05 0.07 0.07 0.07 0.07 0.07 
2. 0.05/0.30 0.13 0.12 0.13 0.12 0.13 
3. 0.05/0.9 0.18 0.15 0.17 0.17 0.17 
4. 0.3/0.05 0.13 0.13 0.13 0.14 0.13 
5. 0.3/0.3 0.22 0.22 0.22 0.23 0.22 
6. 0.3/0.9 0.27 0.25 0.25 0.23 0.25 
7. 0.9/0.05 0.15 0.17 0.17 0.18 0.17 
8. 0.9/0.3 0.27 0.28 0.30 0.31 0.29 
9. 0.9/0.9 0.31 0.30 0.32 0.34 0.32 
RN= level of fluorescence 
 
 
 
 
Table 49. Mean RN values by primer concentration for E coli real-time PCR 
assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.07 
0.13 
0.17 
0.13 
0.22 
0.25 
0.17 
0.29 
0.32* 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 50. Primer optimisation assays for H. influenzae real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 RN Rep 4 Mean RN  
1. 0.05/0.05 0.46 0.46 0.45 0.45 0.46 
2. 0.05/0.30 0.78 0.79 0.80 0.78 0.79 
3. 0.05/0.9 0.75 0.76 0.77 0.76 0.76 
4. 0.3/0.05 0.84 0.82 0.82 0.83 0.83 
5. 0.3/0.3 1.30 1.30 1.30 1.31 1.30 
6. 0.3/0.9 1.98 1.94 1.93 1.93 1.95 
7. 0.9/0.05 3.34 3.23 3.31 n/a 3.29 
8. 0.9/0.3 2.31 2.29 2.33 2.36 2.32 
9. 0.9/0.9 2.80 2.81 2.80 2.78 2.80 
RN= level of fluorescence 
 
 
Table 51. Mean RN values by primer concentration for H. influenzae real-time 
PCR assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.46 
0.79 
0.76 
0.83 
1.30 
1.95 
3.29* 
2.32 
2.80 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 52. Primer optimisation assays for S. pneumoniae real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 Mean RN 
1. 0.05/0.05 0.26 0.28 0.29 0.27 
2. 0.05/0.30 0.56 0.56 0.57 0.56 
3. 0.05/0.9 0.58 0.58 0.58 0.58 
4. 0.3/0.05 0.77 0.76 0.75 0.76 
5. 0.3/0.3 1.31 1.33 1.30 1.31 
6. 0.3/0.9 0.58 0.70 0.73 0.67 
7. 0.9/0.05 0.74 0.74 0.77 0.75 
8. 0.9/0.3 1.35 1.27 1.20 1.27 
9. 0.9/0.9 1.28 1.16 1.06 1.17 
RN= level of fluorescence 
 
 
Table 53. Mean RN values by primer concentration for S. pneumoniae real-
time PCR assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.27 
0.56 
0.58 
0.76 
1.31* 
0.67 
0.75 
1.27 
1.17 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 54. Primer optimisation assays for S. aureus real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 Mean RN  
1. 0.05/0.05 0.01 0.02 0.00 0.01 
2. 0.05/0.30 0.35 0.37 0.37 0.36 
3. 0.05/0.9 0.55 0.58 0.57 0.56 
4. 0.3/0.05 0.06 0.04 0.05 0.05 
5. 0.3/0.3 0.53 0.54 0.54 0.54 
6. 0.3/0.9 1.04 1.03 1.03 1.03 
7. 0.9/0.05 0.06 0.06 0.04 0.05 
8. 0.9/0.3 0.54 0.51 0.54 0.53 
9. 0.9/0.9 1.22 1.24 1.21 1.22 
RN= level of fluorescence 
 
 
Table 55. Mean RN values by primer concentration for S. aureus real-time 
PCR assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.01 
0.36 
0.56 
0.05 
0.54 
1.03 
0.05 
0.53 
1.22* 
*Number in bold indicates highest RN (level of fluorescence).  
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Table 56. Primer optimisation assays for MRSA real-time PCR assay 
Primer 
concentrations 
(μM) 
RN Rep 1 RN Rep 2 RN Rep 3 Mean RN  
1. 0.05/0.05 0.29 0.23 0.22 0.25 
2. 0.05/0.30 0.50 0.52 0.51 0.51 
3. 0.05/0.9 0.56 0.59 0.50 0.55 
4. 0.3/0.05 0.18 0.17 0.17 0.17 
5. 0.3/0.3 0.54 0.60 n/a 0.57 
6. 0.3/0.9 0.66 0.65 0.66 0.66 
7. 0.9/0.05 0.18 0.20 0.17 0.18 
8. 0.9/0.3 0.51 0.52 0.54 0.52 
9. 0.9/0.9 0.68 0.67 0.72 0.69 
RN= level of fluorescence 
 
 
Table 57. Mean RN values by primer concentration for MRSA real-time PCR 
assay 
 
 
 
Reverse Primer 
(μM) 
 Forward Primer        (μM) 
0.05                       0.3                        0.9 
 
0.05 
0.3 
0.9 
0.25 
0.51 
0.55 
0.17 
0.57 
0.66 
0.18 
0.52 
0.69* 
*Number in bold indicates highest RN (level of fluorescence).  
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7.4 Appendix E Multiplex experiments 
Table 58. Comparing Ct results between single and multiplex assays for 
detection of S. aureus (in triplicate) 
Mastermix SA SA/MRSA SA/MRSA 
DNA SA SA SA/MRSA* 
1  26.5852 26.3493 Not tested 
2  26.6317 26.5689 Not tested 
3  26.4555 26.5343 Not tested 
Mean Ct 26.557 26.484 n/a 
 
 
 
Table 59. Comparing Ct results between single and multiplex assays for 
detection of MRSA (in triplicate) 
Mastermix MRSA SA/MRSA SA/MRSA 
DNA MRSA MRSA SA/MRSA* 
1  24.4962 27.1405 Not tested 
2  24. 5869 27.7436 Not tested 
3  24. 6082 24.6371 Not tested 
Mean Ct  24.564 27.507 n/a 
 
 
*Note that MRSA samples should generate a positive S. aureus assay, therefore a 
mix of MRSA and S. aureus was not tested
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Table 60. Comparing Ct values between single, duplex and triplex assays for the detection of H. influenzae (in triplicate) 
Mastermix HI HI/PA  HI/PA  HI/EC  HI/EC  HI/EC/PA  HI/EC/PA HI/EC/PA HI/EC/PA 
DNA HI HI HI/PA HI HI/EC HI HI/PA HI/EC HI/EC/PA 
1  36.487 38.6307 30.6829 35.2364 32.5103 37.0809 31.3183 35.3651 undetected 
2  37.2918 37.1985 30.6882 35.7509 33.1181 36.8125 31.3995 35.7525 Undetected 
3  36.5912 37.6238 30.6249 36.1353 33.3209 35.4145 31.8521 35.589 Undetected 
Mean Ct  36.79 37.818 30.665 35.708 32.983 36.436 31.523 35.569 n/a 
 
 
Table 61. Comparing Ct values between single, duplex and triplex assays for the detection of E. coli (in triplicate) 
Mastermix EC PA/EC  PA/EC HI/EC  HI/EC  HI/EC/PA  HI/EC/PA HI/EC/PA HI/EC/PA 
DNA EC EC PA/EC EC HI/EC EC PA/EC HI/EC HI/EC/PA 
1  30.1247 30.6819 28.6078 29.6558 26.1065 30.6125 28.9384 27.1936 29.0775 
2  31.0637 30.2209 28.3917 28.5439 26.4113 28.4829 29.2493 28.1229 28.9725 
3  31.3854 30.1572 27.6238 28.3862 26.4236 27.8717 29.6509 28.1686 28.1986 
Mean Ct  30.858 30.353 28.208 28.862 26.314 28.989 29.280 27.828 28.750 
 
 
Table 62. Comparing Ct values between single, duplex and triplex assays for the detection of P. aeruginosa (in triplicate) 
Mastermix PA PA/EC  PA/EC HI/PA HI/PA HI/EC/PA  HI/EC/PA HI/EC/PA HI/EC/PA 
DNA PA PA PA/EC PA HI/PA PA PA/EC HI/PA HI/EC/PA 
1  30.5769 31.2838 24.6422 31.7001 24.3825 32.7515 25.4427 24.8215 24.7829 
2  31.4181 31.0338 24.799 32 24.4466 33.0158 25.4372 24.7689 24.6309 
3  31.2252 31.2442 24.6588 31.4659 24.5328 32.3955 25.4817 24.8649 25.0388 
Mean Ct  31.073 31.187 24.7 31.722 24.454 32.721 25.454 24.818 24.818 
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Table 63. Comparing Ct values between single, duplex and triplex assays for the detection of S. pneumoniae (in triplicate, 
unsuccessful) 
Mastermix SPN SPN/AC SPN/AC SpN/KP SpN/KP SpN/AC/KP  SpN/AC/KP SP/AC/KP SP/AC/KP 
DNA SPN SPN SPN/AC SPN SPN/KP SPN SPN/AC SPN/KP SP/AC/KP 
1  26.1805 25.5667 26.5304 26.1961 26.5942 26.1439 26.8811 27.2794 27.2641 
2  25.6963 25.732 26.5491 26.1679 26.6463 26.1959 27.0135 27.2067 27.6847 
3  25.7144 25.7508 26.4554 26.1389 26.7246 26.1749 27.1426 27.2423 28.4039 
Mean Ct 25.864 25.683 26.512 26.168 26.655 26.172 27.012 27.243 27.784 
 
Table 64. Comparing Ct values between single, duplex and triplex assays for the detection of Acinetobacter spp. (in triplicate, 
unsuccessful) 
Mastermix AC SPN/AC SPN/AC AC/KP AC/KP SpN/AC/KP  SpN/AC/KP SP/AC/KP SP/AC/KP 
DNA AC AC SPN/AC AC AC/KP AC SPN/AC AC/KP SP/AC/KP 
1  24.3764 27.8862 32.3168 24.8689 24.4955 30.6591 - - - 
2  24.449 28.1899 30.2157 24.8053 24.7093 30.2648 - - - 
3  24.4683 28.0207 29.8046 24.9128 24.6608 29.7077 - - - 
Mean Ct  24.431 28.032 30.779 24.862 24.622 30.211    
 
Table 65. Comparing Ct values between single, duplex and triplex assays for the detection of and K. pneumoniae (in triplicate, 
unsuccessful) 
Mastermix KP AC/KP AC/KP SpN/KP SpN/KP SpN/AC/KP  SpN/AC/KP SP/AC/KP SP/AC/KP 
DNA KP KP AC/KP KP SPN/KP KP AC/KP SPN/KP SP/AC/KP 
1  23.0732 22.8747 22.6586 23.3086 23.4017 23.336 23.217 23.3877 23.2491 
2  23.1504 22.841 22.6435 23.2129 23.3701 23.3115 23.1483 23.3631 23.4117 
3  23.2129 23.6007 22.6454 23.4278 23.3219 23.2583 23.144 23.2812 23.5127 
Mean Ct  23.146 23.105 22.649 23.316 23.365 23.302 23.170 23.344 23.391 
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Table 66. Comparing Ct values between single and duplex assays for the 
detection of human DNA (in triplicate, unsuccessful)  
Mastermix GAPDH GAPDH/AC GAPDH/AC 
DNA GAPDH GAPDH GAPDH/AC 
1  33.6427 33.6085 Undetected 
2  34.0986 33.5802 Undetected 
3  33.6439 34.1632 Undetected 
Mean Ct 33.795 33.784 - 
 
 
 
 
Table 67. Comparing Ct values between single and duplex assays for the 
detection of Acinetobacter spp. (in triplicate, unsuccessful)  
Mastermix AC GAPDH/AC GAPDH/AC 
DNA AC AC GAPDH/AC 
1  24.8246 24.5818 23.0684 
2  24.8249 24.603 23.175 
3 24.393 24.5648 23.1462 
Mean Ct 24.681 24.583 23.130 
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Table 68. Comparing Ct values between single and duplex assays for the 
detection of MRSA (in triplicate, unsuccessful)  
 
Mastermix MRSA MRSA/CPS MRSA/CPS 
DNA MRSA MRSA MRSA/CPS 
1  24.9438 35.668 Undetected 
2 25.7939 36.535 Undetected 
3  25.5241 37.8119 Undetected 
Mean Ct  25.4206 36.67163 - 
 
 
 
 
Table 69. Comparing Ct values between single and duplex assays for the 
detection of S. pneumoniae (in triplicate, unsuccessful)  
 
Mastermix CPS MRSA/CPS MRSA/CPS 
DNA CPS CPS MRSA/CPS 
1  27.518 28.0828 27.0539 
2  27.7417 28.177 26.6535 
3  27.5532 28.1275 26.6862 
Mean Ct  27.6043 28.1291 26.79787 
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Table 70. Comparing Ct values between single and duplex assays for the detection of E. coli (in triplicate, unsuccessful).  
Mastermix EC EC/CPS EC/CPS EC/KP EC/KP EC/CPS/KP  EC/CPS/KP EC/CPS/KP EC/CPS/KP 
DNA EC EC EC/CPS EC EC/KP EC EC/CPS EC/KP EC/CPS/KP 
1  25.1294 28.7024 32.9775 29.0949 30.6719 - - - - 
2  24.8923 28.9511 34.2371 29.9062 29.8771 - - - - 
3  24.7652 29.2655 32.2764 29.716 30.707 - - - - 
Mean Ct 24.929 28.973 33.164 29.572 30.419 - - - - 
 
 
Table 71. Comparing Ct values between single and duplex assays for the detection of S. pneumoniae (in triplicate, unsuccessful).  
 
Mastermix CPS EC/CPS EC/CPS CPS/KP CPS/KP EC/CPS/KP EC/CPS/KP EC/CPS/KP EC/CPS/KP 
DNA CPS CPS EC/CPS CPS CPS/KP CPS EC/CPS CPS/KP EC/CPS/KP 
1  26.6306 26.1481 26.2846 26.4499 26.1913 26.4099 32.9567 26.1636 37.1052 
2  26.6465 26.1992 26.0974 26.4767 26.1955 25.8513 32.6769 26.1496 38.4368 
3  26.6428 26.1286 26.1092 26.483 26.2324 26.3295 34.0337 26.0725 - 
Mean Ct  26.640 26.158 26.164 26.470 26.206 26.197 33.222 26.129 37.771 
 
 
Table 72. Comparing Ct values between single and duplex assays for the detection of K. pneumoniae (in triplicate, unsuccessful).  
 
Mastermix KP EC/KP EC/KP CPS/KP CPS/KP EC/CPS/KP EC/CPS/KP EC/CPS/KP EC/CPS/KP 
DNA KP KP EC/KP KP CPS/KP KP EC/KP CPS/KP EC/CPS/KP 
1  23.7908 23.3899 18.1262 24.0414 23.4762 24.0313 18.4347 23.2428 18.3136 
2  23.7054 23.386 18.1056 24.4812 23.5007 24.0307 18.6057 23.1998 18.4107 
3  23.692 23.4714 17.9184 24.3407 23.3383 23.9806 18.3493 23.108 18.4531 
Mean Ct 23.729 23.416 18.050 24.288 23.438 24.014 18.463 23.184 18.392 
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7.5 Appendix D Inclusivity and specificity testing   
 
Table 73.  Species tested against Acinetobacter spp. assay for inclusivity 
Organism Organism code CT value 
Acinetobacter junii B139 34.9 
Acinetobacter haemolyticus B105 39.3 
Acinetobacter lwoffii B106 36.3 
Acinetobacter lwoffii B114 37.0 
Acinetobacter baumannii BC56 35.3 
Acinetobacter lwoffii BC57 36.4 
Acinetobacter junii BC59 34.0 
Acinetobacter lwoffii BC69 36.8 
Acinetobacter lwoffii BC70 34.7 
Acinetobacter baumannii BC68 20.9 
Acinetobacter baumannii BC99 20.5 
Acinetobacter junii M031 33.6 
Acinetobacter sp. M029 20.4 
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Table 74. Species tested against S. pneumoniae assay for inclusivity 
Organism Organism code CT value 
Streptococcus pneumoniae  B116 22.00 
Streptococcus pneumoniae  BC20 22.75 
Streptococcus pneumoniae  BC132 20.82 
Streptococcus pneumoniae  BC21 21.85 
Streptococcus pneumoniae  BC22 22.24 
Streptococcus pneumoniae  E003 23.23 
Streptococcus pneumoniae  E004 24.09 
Streptococcus pneumoniae  E006 22.68 
Streptococcus pneumoniae  E007 23.14 
Streptococcus pneumoniae  E008 23.28 
Streptococcus pneumoniae  SPN clin 1 24.41 
Streptococcus pneumoniae  SPN clin 2 24.52 
Streptococcus pneumoniae  E001 22.1 
Streptococcus pneumoniae  E002 22.6 
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Table 75. Species tested for inclusivity against P. aeruginosa assay 
Organism n=28 Organism code CT value 
Pseudomonas aeruginosa C056 17.2 
Pseudomonas aeruginosa  C057 17.4 
Pseudomonas aeruginosa  C058 16.6 
Pseudomonas aeruginosa   C060 18.3 
Pseudomonas aeruginosa  C062 18.0 
Pseudomonas aeruginosa  C063 17.0 
Pseudomonas aeruginosa  C080 18.1 
Pseudomonas aeruginosa  C092 17.8 
Pseudomonas aeruginosa  C096 17.3 
Pseudomonas aeruginosa  C094 17.4 
Pseudomonas aeruginosa  B130 Not detected 
Pseudomonas aeruginosa  B036 17.7 
Pseudomonas aeruginosa  B037 17.2 
Pseudomonas aeruginosa  B047 Not detected 
Pseudomonas aeruginosa  B049 Not detected 
Pseudomonas aeruginosa  B071 17.1 
Pseudomonas aeruginosa  BC15 17.8 
Pseudomonas aeruginosa  BC16 17.2 
Pseudomonas aeruginosa  BC17 17.1 
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Pseudomonas aeruginosa  B076 18.3 
Pseudomonas aeruginosa  BC18 17.6 
Pseudomonas aeruginosa  BC19 17.3 
Pseudomonas aeruginosa  BC48 18.7 
Pseudomonas aeruginosa  BC49 17.3 
Pseudomonas aeruginosa  BC65 16.9 
Pseudomonas aeruginosa  B013 14.6 
Pseudomonas aeruginosa  B121 15.2 
Pseudomonas aeruginosa  B024 15.4 
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Table 76. Species tested against H. influenzae assay for inclusivity 
Organism n=17 Organism code CT value 
Haemophilus influenzae  JP1 19.5 
Haemophilus influenzae  JP2 19.2 
Haemophilus influenzae  JP3 20.3 
Haemophilus influenzae  JP4 19.9 
Haemophilus influenzae  JP5 19.2 
Haemophilus influenzae  JP6 19.2 
Haemophilus influenzae  JP7 20.2 
Haemophilus influenzae  JP8 21.3 
Haemophilus influenzae  JP9 Not detected 
Haemophilus influenzae  JP10 20.1 
Haemophilus influenzae  JP11 20.2 
Haemophilus influenzae  JP12 20.5 
Haemophilus influenzae  JP13 19.4 
Haemophilus influenzae  JP14 19.7 
Haemophilus influenzae  JP15 19.7 
Haemophilus influenzae  JP16 21.6 
Haemophilus influenzae  C081 20.3 
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Table 77. Species tested against S. aureus assay for inclusivity 
Organism n=16 Organism code CT value 
Staphylococcus aureus  C001 28.62 
Staphylococcus aureus  C002 27.68 
Staphylococcus aureus  C003 27.60 
Staphylococcus aureus  C004 26.59 
Staphylococcus aureus  C006 26.87 
Staphylococcus aureus  C007 26.37 
Staphylococcus aureus  C008 25.14 
Staphylococcus aureus  C009 26.64 
Staphylococcus aureus  C012 31.31 
Staphylococcus aureus  B021 24.85 
Staphylococcus aureus  B025 29.54 
Staphylococcus aureus  B039 29.89 
Staphylococcus aureus  B049 28.51 
Staphylococcus aureus  B063 27.50 
Staphylococcus aureus  B073 Not detected 
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Table 78. Species tested against MRSA assay for inclusivity 
Organism n=17 Organism code CT value 
MRSA C010 27.70 
MRSA C011 26.63 
MRSA C021 24.59 
MRSA C043 26.32 
MRSA C049 23.92 
MRSA C050 26.23 
MRSA C051 23.58 
MRSA C052 24.78 
MRSA C053 26.60 
MRSA C054 25.21 
MRSA B006 24.87 
MRSA B017 23.52 
MRSA M023 24.37 
MRSA M024 25.33 
MRSA M020 25.60 
MRSA M022 23.17 
MRSA BC71 26.20 
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Table 79. Species tested against E. coli assay for inclusivity 
Organism n=30 Organism code CT value 
Escherichia coli C065 24.4 
Escherichia coli C066 24.6 
Escherichia coli C067 24.2 
Escherichia coli C068 24.2 
Escherichia coli C069 24.3 
Escherichia coli C070 24.2 
Escherichia coli C073 23.5 
Escherichia coli C074 24.4 
Escherichia coli C075 24.2 
Escherichia coli C076 24.1 
Escherichia coli C093 23.6 
Escherichia coli B001 24.8 
Escherichia coli B023 24.1 
Escherichia coli B031 23.7 
Escherichia coli B032 23.7 
Escherichia coli B038 23.8 
Escherichia coli B040 26.1 
Escherichia coli B045 25.1 
Escherichia coli B061 Not detected 
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Escherichia coli B066 Not detected 
Escherichia coli B070 24.3 
Escherichia coli B072 Not detected 
Escherichia coli B075 Not detected 
Escherichia coli NCTC 9001 23.0 
Escherichia coli NCTC 12900 23.6 
Escherichia coli NCTC10418 24.1 
Escherichia coli NCTC 12923 23.1 
Escherichia coli NCTC 13167 24.0 
Escherichia coli NCTC 13216 24.4 
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Table 80. Panel of bacteria tested against final multiplexed assays for specificity, showing CT values from testing 
 
Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Streptococcus 
oralis 
11427        37.75 
Streptococcus 
salivarius 
AS214        37.53 
Streptococcus 
mutans 
10449        35.53 
Streptococcus 
mitis 
AS148        37.17 
Streptococcus 
oralis 
A23        38.17 
Streptococcus 
sanguis 
AS218        36.63 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Streptococcus 
mitis  
12261         
Streptococcus 
salivarius 
8606        36.81 
Streptococcus 
gordonii 
10231        37.17 
Streptococcus 
sanguis 
7865        36.71 
Streptococcus 
oralis 
11427        37.24 
Actinomyces 
israelii 
01/30        36.50 
Streptococcus 
constellatus 
11325        37.14 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Streptococcus 
salivarius 
8618        37.11 
Corynebacteria 01/0509        36.99 
Streptococcus 
sanguis 
7863        36.47 
Streptococcus 
mutans 
R471        35.98 
Streptococcus 
mitis 
BC30        36.80 
Streptococcus 
agalactiae 
B107        36.90 
Streptococcus 
constellatus 
BC38        38.11 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Alpha-
haemolytic 
streptococcus 
BC51        39.12 
Streptococcus 
oralis 
B095        35.92 
Alpha- 
haemolytic 
streptococcus 
B123        37.33 
Haemolytic 
Streptococcus 
group B 
B065   28.96     16.65 
Lactobacillus B147        35.54 
Streptococcus 
anginosus 
B145        34.91 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Streptococcus 
constellatus 
B079   23.72     15.96 
Streptococcus 
constellatus 
B086 25.68       34.34 
Alpha-
haemolytic 
streptococcus 
B027        33.48 
Streptococcus 
agalactiae 
B010        34.85 
Beta-
haemolytic 
Streptococcus 
group C 
B037 26.60       37.80 
Haemolytic 
Streptococcus 
B002        35.49 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
group B 
Streptococcus 
sanguis x 
B012        36.23 
Enterococcus 
faecalis  
B034        35.86 
Enterococcus 
faecium  
B060   21.83     15.78 
Streptococcus 
species 
B011        36.03 
Enterococcus 
faecium  
B059        34.83 
Staphylococcus 
epidermidis  
B051        36.78 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Staphylococcus 
epidermidis 
B056        14.12 
Staphylococcus 
epidermidis 
B046        13.66 
Alpha-
haemolytic 
Streptococcus  
B022        33.10 
Streptococcus 
hominis 
B053        33.28 
Staphylococcus 
aureus 
C001 28.40       37.35 
MRSA C010  22.41      37.15 
Acinetobacter 
baumannii 
BC56       30.00 37.10 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Acinetobacter 
haemolyticus 
B105       34.77 37.10 
Acinetobacter 
lwoffii 
B106       30.27 37.56 
Klebsiella 
pneumoniae 
B043        13.99 
Klebsiella 
oxytoca  
B111        13.99 
Escherichia coli C095   21.89     14.30 
Pseudomonas 
aeruginosa 
BC16    16.58     
Enterobacter 
clocae  
B141        13.14 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
Serratia 
marcescens 
B118        13.34 
Bacillus fragilis  ATCC 
25285 
       23.87 
Lactococcus  No code        36.38 
Streptococcus 
pneumoniae 
E003     15.06    
Streptococcus 
pneumoniae 
E006     14.89   37.69 
Haemophilus 
influenzae 
918386      ND  37.72 
Haemophilus 
influenzae 
918366c      14.00  38.02 
Haemophilus NCTC      14.44  37.13 
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Organism Code S. aureus MRSA E. coli P. aeruginosa S. pneumoniae H. influenzae Acinetobacter 
spp 
Coliform 
influenzae 11931 
 
ND= Not detected. GAPDH assay negative for all bacteria tested. 
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7.6 Appendix F  Multiplex real-time PCR results by patient  
 
Note: Patients who developed HAP are highlighted in green text 
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ID:2 Day 0-2 
 
3 
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ID:3 Day 0-2 
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ID:4 Day 0-2 
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MRSA 
          
 
E. coli     
  
        
  
 
P. aeruginosa 
          
 
H. influenzae     
        
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform     
  
            
 
 
  
           
 
ID:5 Day 1 
 
3 
 
5 
 
7 
 
14 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S.aureus 
          
 
MRSA 
          
 
E. coli 
    
    
    
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
 
  
  
            
 
Acinetobacter  
          
 
Coliform 
    
    
     
 
  
226 
ID:6 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
   
  
      
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
  
    
      
 
Coliform   
 
    
       
 
ID:7 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae                     
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
227 
ID:8 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae   
         
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
   
  
     
  
 
 
ID:9 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
  
  
        
 
 
  
228 
ID:10 Day 0-2 
 
3 
 
4-6 
 
7-9 
   
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
 
  
        
 
S. pneumoniae 
    
  
     
 
Acinetobacter  
          
 
Coliform 
      
  
    
 
ID:11 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
  
  
       
 
H. influenzae 
          
 
S. pneumoniae             
  
    
 
Acinetobacter  
          
 
Coliform   
 
  
 
    
  
    
 
 
 
  
229 
ID:12 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
        
    
 
H. influenzae 
 
  
        
 
S. pneumoniae 
         
  
 
Acinetobacter  
          
 
Coliform 
    
            
 
 
ID:13 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform     
  
            
 
 
 
  
230 
ID:14 Day 0-2 
 
3 
 
4-6 
 
7-9 
   
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa   
         
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:16 Day 0-2 
 
3 
 
4-6 
 
7-9 
   
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus     
        
 
MRSA   
         
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
  
231 
ID:18 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
     
  
    
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
     
  
     
 
ID:21 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae       
 
  
 
        
 
Acinetobacter  
          
 
Coliform 
           
 
  
232 
ID:25 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae   
 
  
       
 
Acinetobacter  
          
 
Coliform 
           
 
ID:28 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
        
  
 
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
        
    
 
 
 
 
  
233 
ID:29 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
        
  
 
 
Coliform 
        
    
 
 
ID:30 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
   
  
      
 
H. influenzae               
 
    
 
S. pneumoniae 
          
 
Acinetobacter  
     
  
    
 
Coliform 
           
 
 
  
234 
ID:32 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
  
    
      
 
MRSA 
  
    
      
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
        
    
 
 
ID:33 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae     
        
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
  
235 
ID:34 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
  
  
        
 
ID:35 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae                 
  
 
Acinetobacter  
          
 
Coliform 
           
 
  
236 
ID:37 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
 
  
        
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:38 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
    
  
     
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
237 
ID:39 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
    
  
     
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:40 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
 
  
        
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
238 
ID:43 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
    
            
 
MRSA 
      
    
 
  
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter    
         
 
Coliform 
           
 
 
ID:44 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
  
  
       
 
MRSA 
  
  
       
 
E. coli 
  
  
       
 
P. aeruginosa   
   
  
     
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
  
  
     
  
 
 
Coliform 
           
 
  
239 
ID:45 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter    
      
  
  
 
Coliform 
           
 
ID:46 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
         
  
 
S. pneumoniae 
        
    
 
Acinetobacter  
  
  
       
 
Coliform 
           
 
  
240 
ID:47 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
   
  
      
 
H. influenzae 
    
    
    
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
    
    
  
  
  
 
 
 
ID:48 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae                 
  
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
241 
ID:49 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae                     
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:50 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
 
  
 
              
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
242 
ID:51 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae   
         
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:52 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae       
 
  
 
  
 
  
 
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
243 
ID:53 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
         
  
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
ID:54 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
       
  
 
  
 
H. influenzae   
         
 
S. pneumoniae   
  
  
      
 
Acinetobacter  
          
 
Coliform 
           
 
  
244 
ID:57 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae                 
  
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:58 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
    
  
 
  
   
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
245 
ID:59 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae     
  
  
     
 
S. pneumoniae     
  
  
   
    
 
Acinetobacter  
        
  
 
 
Coliform 
           
 
 
ID:61 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
   
  
      
 
P. aeruginosa 
          
 
H. influenzae 
      
    
  
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
  
246 
ID:63 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae           
     
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:64 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus     
        
 
MRSA     
        
 
E. coli 
          
 
P. aeruginosa   
  
      
  
  
 
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
247 
ID:65 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae     
  
  
 
        
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
ID:70 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae       
 
          
 
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
  
248 
ID:71 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus   
         
 
MRSA   
         
 
E. coli   
         
 
P. aeruginosa 
          
 
H. influenzae       
 
  
 
    
  
 
S. pneumoniae 
          
 
Acinetobacter  
      
  
   
 
Coliform   
          
 
 
 
ID:72 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae   
 
  
       
 
S. pneumoniae       
 
    
  
    
 
Acinetobacter  
          
 
Coliform 
           
 
  
249 
ID:73 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
        
    
 
H. influenzae 
          
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
           
 
 
 
ID:74 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
  
  
       
 
H. influenzae 
          
 
S. pneumoniae   
         
 
Acinetobacter  
          
 
Coliform 
           
 
  
250 
ID:76 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus   
   
  
 
  
   
 
MRSA   
         
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae 
     
  
    
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:77 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
          
 
S. pneumoniae             
    
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
251 
ID:78 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
  
      
     
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
    
  
     
 
S. pneumoniae 
 
                
 
 
Acinetobacter  
          
 
Coliform 
           
 
 
ID:79 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
          
 
H. influenzae 
  
    
      
 
S. pneumoniae 
  
    
      
 
Acinetobacter  
          
 
Coliform 
           
 
 
  
252 
ID:80 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
  
  
       
 
P. aeruginosa 
          
 
H. influenzae 
  
  
 
    
    
 
S. pneumoniae 
          
 
Acinetobacter  
          
 
Coliform 
  
  
        
 
 
ID:81 Day 0-2 
 
3 
 
4-6 
 
7-9 
 
13-15 
 
  
Tongue Throat Tongue Throat Tongue Throat Tongue Throat Tongue Throat 
 
S. aureus 
          
 
MRSA 
          
 
E. coli 
          
 
P. aeruginosa 
      
  
   
 
H. influenzae 
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7.7 Appendix G  Additional tables relating to Chapter 4  
 
Table 81. Demography of study participants 
Factor  Median (range) n=93 
Age  82                               (65-101) 
Weight (in kilograms) 62                               (36-102)* 
Barthel score  20                                    (4-20) 
HABAM score  53                                    (18-67) 
Clinical frailty score  4                                       (1-9) 
Number of teeth 4                                        (0-28) 
Number of prescribed drugs at 
admission 
6                                       (0-19) 
Number of comorbidities 6                                       (0-15)** 
Number of complications 7                                       (0-50) 
COPD (%) 17     (18.28% 95%CI 10.26-26.3) 
*n=92 **One patient did not have hearing or vision recorded.   
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Table 82. Numbers of patients prescribed drugs previously associated with 
pneumonia 
Drug Number of patients prescribed drug 
Statin 50 
Sedating/cognitively active drugs* 33 
Proton pump inhibitor 26  
Angiotensin converting enzyme 
inhibitor 
21 
Either inhaled or oral steroid 17 
Antibiotic in 3 months prior to 
admission 
15 
Steroid inhaler 14 
Prednisolone 5mg 6 
*Sedating or cognitively active drugs include opiates, moderate opiates, 
selective serotonin reuptake inhibitors, tricyclic antidepressants, anti-epileptic 
drugs, cholinesterase inhibitors (for dementia), hypnotics, major tranquilisers, 
gabapentin and pregabalin. 
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Table 83. Oral examination results by dentate status 
 Dentate with or 
without dentures 
(n=50) 
Dentures only 
(n=42 ) 
P value** 
Median 
Number of 
teeth 
 
5 n/a n/a 
Median 
Xerostomia 
inventory score 
 
17 (n=31) 15 (n=27) 0.132 
Median Dental 
plaque index 
 
1.2 (n=49) n/a n/a 
Median 
Denture plaque 
index 
0.55 (n=20) 0.7 (n=17) 3.544e-06 
Note: One patient had neither teeth nor dentures  ** Wilcoxon test 
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Figure 17. Histograms of Ct values from positive real-time PCR assays for 
each target organism (note varying scales on both axes) 
 
 
Note: Ct values<35 only are shown for E. coli and Acinetobacter spp., and <27 for 
the coliform assay 
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Table 84. Comparing number of samples positive for target organisms by 
PCR over time  
Organism Swab 
1  (%)* 
Swab 2  
(%) 
Swab 3  
(%) 
Swab 4  
(%) 
Swab 5   
(%) 
Total 
positive 
(%) 
Patients 
positive*  
(%) 
S. 
pneumoniae  
52/186 
(27.96) 
40/168 
(23.81) 
41/168  
(24.40) 
33/162  
(20.37) 
29/132 
(21.96) 
195/816 
(22.89) 
38/93 
(40.86) 
H. influenzae   23/186 
(12.36) 
15/168 
(8.93) 
13/168 
(7.74) 
9/162  
(5.56) 
4/132  
(3.03) 
64/816 
(7.84) 
23/93 
(24.73) 
S. aureus  11/186 
(5.91) 
10/168 
(5.95) 
8/168  
(4.76) 
8/162  
(4.94) 
5/132  
(3.79) 
42/816 
(5.15) 
14/93 
(15.05) 
MRSA 10/186 
(5.38) 
5/168  
(2.98) 
3/168  
(1.79) 
5/162  
(3.09) 
2/132  
(1.52) 
25/816 
(3.06) 
11/93 
(11.83) 
E. coli  3/186 
(1.61) 
6/168 
(3.57) 
7/168 
(4.17) 
4/162 
(2.47) 
1/132 
(0.76) 
21/816 
(2.57) 
11/93 
(11.83) 
P. aeruginosa  8/186 
(4.30) 
5/168  
(2.98) 
4/168  
(2.38) 
6/162 
(3.70) 
7/132  
(5.31) 
30/816 
(3.68) 
19/93 
(20.43) 
Acinetobacter 
spp 
2/186 
(1.08) 
5/168 
(2.98) 
1/168 
(0.59)  
2/162 
(1.19) 
3/132 
(2.27) 
16/816 
(1.96) 
8/93 
(8.60) 
Coliform 9/186 
(4.84) 
12/168 
(7.14) 
16/168 
(9.52) 
16/162 
(9.87) 
12/132 
(9.09) 
65/816 
(7.97) 
19/93 
(20.43%) 
*Includes any patient with one or more positive samples (tongue or throat) 
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Table 85. Respiratory commensal pathogens identified in mouths of patients 
who subsequently developed HAP 
Study ID Organisms seen Days to 
HAP 
4 Persistent E. coli plus H. influenzae on day 1 only 2 
5 Persistent S. pneumoniae and E. coli on day 5 only 16 
22 No pathogens detected 40 
25 S. pneumoniae swab 1 and 2 only 38 
28 E. coli on swab 5 only 33 
32 MRSA swab 2 only  8 
43 Acinetobacter spp on day 1, mixed S. aureus and MRSA 
d5,7,14  
88 
47 P. aeruginosa swab 2 only, H. influenzae swab 3 only 27 
83 Persistent S. aureus in throat from swab 2 88 
97 P. aeruginosa on swab 1 and 4 (tongue and throat) 30 
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Table 86. Case vignettes of patients who developed HAP 
Patient  Background Events during admission 
4 81 year old male. 
Nursing home resident 
Vascular dementia, non- insulin 
dependent diabetes mellitus, 
bronchiectasis, recurrent lower 
respiratory tract infections 
48 hours after admission developed fever, green sputum, fever 38.8, CXR shows left 
basal consolidation.  IV antibiotics for 3 days then oral antibiotics.  Speech and language 
review which suggested needed thickened fluids. Developed hyperactive delirium 
(saying “I’m going to die and no one will help me”) then further episode fever, green 
sputum, upper abdominal pain.  Witnessed aspiration following day.  Discharged back 
to nursing home and died of likely pneumonia after course of cefalexin antibiotics 
around 1 month after discharge 
5 85 year old female 
COPD/asthma, pulmonary 
hypertension, pulmonary 
eosinophilia, macular 
degeneration, cataracts, recent 
neurological event thought to be 
stroke  
5 days after admission sudden weakness in arm and witnessed aspiration (by VE) plus 
chest pain.  MRI scan showed high grade glioma accounting for neurological change, 
and troponin was positive indicating non-st elevation myocardial infarction.  Produced 
green sputum but chest x-ray clear on 29/04/09.  01/05/09 Computed tomography 
pulmonary angiogram (CTPA) done for ?pulmonary embolus but found patchy 
consolidation.  Sputum culture from 29/04/09 showed S. pneumoniae. Commenced 
intravenous antibiotics.   Urinary tract infections diagnosed on 12/05 and 19/05.  
Further chest x ray changes plus raised white cell count, treated as HAP with oral 
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Patient  Background Events during admission 
antibiotics. Discharged to continuing care home given terminal illness.  Died within 3 
months in continuing care. 
22 81 year old male 
Atrial fibrillation, heart failure, 
anaemia, leg ulcers, cellulitis, 
benign prostatic hypertrophy 
Admitted after fall in hospital while being treated for cellulitis.  Decision not to operate 
because fracture well aligned. Treated with antibiotics for cellulitis, physiotherapy.  
Discharged “non-weight bearing” after 3 weeks.  Readmitted 3 days later after started 
weight-bearing at home, fracture became unstable and painful.  Decision to operate but 
delays pending investigations (echocardiogram).   Developed severe Clostridium 
difficile infection 24 hours after operation.  MRSA positive (nose) so eradication therapy 
commenced.  48 hours later still sick so antibiotic for C. difficile changed to vancomycin.  
Transferred to intensive care for fluid balance monitoring after further 24 hours.  Given 
ionotropic support and nasogastric tube inserted for feeding.  Developed hyperactive 
delirium.  Oxygen level dropped, white cell count raised and commenced antibiotics for 
HAP.  Died on intensive care after 6 days.  Death certificate stated 1A pneumonia, 1b hip 
fracture II C. difficile colitis  
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Patient  Background Events during admission 
25 79 year old female 
Osteoarthritis, non-insulin 
dependent diabetes, 
hypertension, breast cancer, 
previous tuberculosis, fractured 
clavicle, cholecystectomy, 
hysterectomy. 
Problems with pain control, increased doses of morphine sulphate.  Queries about 
alcohol intake as empty bottles found at home.  Depression but didn’t want 
antidepressants.  ECG showed indications for pacemaker but patient didn’t want one 
inserted.  Slow rehabilitation.  One month after admission, cough, grey sputum (grew S. 
pneumoniae), chest x ray showed consolidation.  Treated with oral antibiotics.  
Discharged home. 
28 93 year old male 
Osteoarthritis 
Cough 48 hours after admission but chest x- ray clear.  3 days later oxygen levels, 
dropped to 92%, blood pressure dropped, temperature 37.5, auscultatory findings at left 
lung base.  Treated with intravenous antibiotics for 10 days. Constipation after but 
otherwise well.    14 days later profound fluid resistant hypotension, tachycardia, 
hypoxia, decreased responsiveness.  CXR showed right lower lobe consolidation.  
Intravenous antibiotics started.  Died 3 days later, after antibiotic change. 
32 101 year old female 7 days after admission developed high respiratory rate, high white cell count and C 
reactive protein.  New right basal consolidation on chest x ray.  Treated with oral 
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Patient  Background Events during admission 
Atrial fibrillation, ischaemic 
heart disease, heart failure, falls, 
peripheral vascular disease, 
fem-pop bypass, throat cancer, 
skin cancer (Squamous cell), 
previous hip replacement 
antibiotics.  Day 14 antibiotics for C. difficile started.Day 21 died, death certificate 1a 
bronchopneumonia, 1b old age, II fractured neck of femur 
35 79 year old female 
Ischaemic heart disease with 
coronary stent insertion, total 
hip replacement, previous 
fractures, tinnitus, gallstones, 
COPD/asthma, osteoarthritis, 
hiatus hernia, mastoidectomy 
Day 3 post-operative anaemia, transfusion and subsequent transfusion reaction treated 
with prednisolone and salbutamol.  Day 4 still anaemic so further transfusion and 
further transfusion reaction.  Day 7 post op had green phlegm, H. influenzae isolated 
from sputum but chest x-ray bibasal atelectasis.  Treated for LRTI with oral antibiotics.  
Day 8 oral thrush treated with nystatin.  Day 36 further operation as implant was cutting 
through bone and then three UTIs before discharge. 
43 83 year old male Operation delayed as needed treatment for heart failure, then postoperative atrial 
fibrillation treated with metoprolol. Day 34, coliform UTI.  Day 44 clot retention and 
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Patient  Background Events during admission 
Heart failure, prostate cancer, 
anaemia, hypertension 
haematuria from active prostate cancer.  Transferred to Freeman hospital for 
radiotherapy and Proteus UTI treated with oral antibiotics.  Following day developed 
bleeding per rectum and transferred to Royal Victoria Infirmary for treatment.  
Difficulty making decision about going into institutional care, said would consider 
suicide but for religious beliefs.Day 57 developed rattly but unproductive cough, 
hypoxia, fever, tachycardia and hypotension but with no chest x ray change.  He was 
given IV Tazocin (antibiotic) for HAP.  Died 5 days later and death certificate recorded 
as 1A Pneumonia II Metastatic prostate carcinoma. 
47 85 year old female 
Ischaemic heart disease, heart 
failure, non-insulin dependent 
diabetes, lymphoma 
Pressure sores on sacrum and heels developed and debrided.  Day 5 dysphagia therefore 
not eaten and blood sugar low.  Also cough productive of green sputum but chest x ray 
clear.  Treated with intravenous antibiotics for aspiration pneumonia though no 
witnessed aspiration plus oral prednisolone in case lymphoma contributing (though 
recent CT suggested no change).  Day 7 green sputum on nightgown and hypoactive 
delirium- no verbal interaction.  Day 28 transferred to Freeman hospital but noted to 
have HAP (consolidation on chest x ray) on arrival and treated with intravenous 
antibiotics (tazocin).  Limited improvement over following month then deteriorated.  
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Patient  Background Events during admission 
Died on day 69, death certificate 1a Pneumonia II Hip fracture, lymphoma 
83 77 year old female 
Non-insulin dependent 
diabetes, hypertension, 
hypercholesterolaemia 
Day  4 hyperactive delirium from UTI treated with oral antibiotics.  Day 11 fall off bed.  
Day 12 DVT treated with warfarin.  Day 29 further hyperactive delirium and given 
regular haloperidol. Day 57 regular quetiapine for ongoing confusion.  Day 67 three 
further falls and two CT head scans.  Warfarin stopped due to risk of falls.  Day 84 
lorazepam added.  Day 86 became unwell and given oxygen and tinzaparin for 
?pulmonary embolus.  Grew S. aureus in blood cultures and clinically evident 
pneumonia on auscultation.  Chest x ray showed atelectasis and effusion.  4 days IV 
antibiotics given.  Further clinical signs of HAP 3 days later so further 14 days IV 
antibiotics given.  Day 104 nasogastric tube inserted for feeding but removed after kept 
being pulled out .  Several further UTIs.  Discharged to nursing home 
97 70 year old female 
Depression and recent suicide 
attempt, breast cancer, lung 
cancer, hypertension, 
Day 5 suicidal thoughts, UTI treated with oral antibiotics.  Day 6 seen by psychiatry and 
deemed moderate to high suicide risk and placed under constant observation.  Day 10 
mood better but cough with green phlegm, treated with oral antibiotics.  Day 15 bone 
biopsy showed pathological fracture and oncology review said “incurable metastatic 
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Patient  Background Events during admission 
hypercholesterolaemia,  cancer”.  Day 17 radiotherapy commenced. Day 21 cough with green phlegm and chest x 
ray showed consolidation so treated with oral antibiotics.  Day 29 acute respiratory 
failure, transferred to high dependency unit, chest drain inserted and non-invasive 
respiratory support commenced.  Antibiotics changed to intravenous tazocin.  Died day 
30, death certificate 1a pneumonia, 1b metastatic squamous lung cancer, II pathological 
fracture of right neck of femur, breast cancer. 
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7.8 Appendix H Additional data relating to Chapter 5 
Table 87. Standard errors for correlation matrix of patient variables 
 
 
Age Female Residence Barthel Weight Teeth Frailty HABAM Charlson Dementia Dentures Smoking Plaque1 IMD COPD Consent 
Age 
                Female 0.14 
               Residence 0.10 0.13 
              Barthel 0.10 0.13 0.09 
             Weight 0.10 0.13 0.10 0.11 
            Teeth 0.10 0.14 0.11 0.10 0.11 
           Frailty 0.09 0.11 0.09 0.07 0.11 0.10 
          HABAM 0.09 0.13 0.09 0.08 0.11 0.10 0.05 
         Charlson 0.09 0.12 0.10 0.09 0.10 0.10 0.09 0.09 
        Dementia 0.23 0.27 0.17 0.13 0.23 0.21 0.18 0.17 0.19 
       Dentures 0.10 0.13 0.11 0.10 0.11 0.03 0.10 0.10 0.11 0.22 
      Smoking 0.10 0.14 0.11 0.11 0.11 0.10 0.10 0.11 0.11 0.21 0.10 
     Plaque1 0.11 0.14 0.10 0.10 0.11 0.09 0.11 0.11 0.11 0.17 0.09 0.10 
    IMD 0.11 0.13 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.19 0.10 0.10 0.10 
   COPD 0.14 0.19 0.18 0.17 0.15 0.16 0.16 0.16 0.16 5.92 0.15 0.14 0.15 0.15 
  Consent 0.09 0.15 0.09 0.08 0.10 0.10 0.10 0.09 0.10 0.12 0.10 0.11 0.11 0.10 0.19 
 Antibiotics 0.15 0.21 0.14 0.13 0.17 0.15 0.15 0.15 0.15 0.26 0.16 0.16 0.16 0.17 0.22 0.13 
 
Barthel=Barthel index, Teeth=number of teeth, Frailty=Clinical frailty score, Charlson=Charlson index, Plaque1=Admission plaque score, 
IMD= Indices of multiple deprivation score, COPD=Combined obstructive respiratory disease, Consent= ability to sign consent for 
oneself, Antibiotics=Prescribed antibiotics within three months prior to hospital admission
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Table 88.  Associations between HAP and patient factors using Fisher’s exact test 
Variable  HAP   (n=10) median 
(min-max) 
No HAP  (n=80) median 
(min-max) 
P value 
Age   82 (70-101) 82 (65-96) 0.061 
Female N=5 N=56 0.281 
Clinical Frailty Scale 5 (3-7) 4 (1-9) 0.570 
Charlson index 6 (4-11) 5 (2-11) 0.067 
HABAM (mobility score) 50.5 (18-61) 53 (20-67) 0.194 
Barthel score 19 (4-20) 20 (4-20) 0.143 
Number of teeth 7 (0-27) 3.5 (0-28) 0.353 
Admission plaque quartile score 3 (1-4) 2 (1-4) 0.265 
Plaque quartile score at 7 days 3.5 (1-4) 3 (1-4) 0.403 
Plaque quartile score at 14 days 3 (1-4) 2 (1-4) 0.451 
Deprivation score 14.02 (3.71-49.48) 22.40 (2.32-71.74) 0.058 
Sedating drug at admission N=6 26 0.157 
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Table 89. Relating HAP/LRTI and patient factors using univariate generalised linear modelling 
Variable Estimate Standard 
error 
Z value P value Null deviance Residual deviance 
Age 0.06208     0.03937    1.577    0.115 90.072  on 89 87.378  on 88 
Clinical frailty scale 0.5266      0.1964    2.682 0.007 ** 90.072  on 89 81.648  on 88 
Decreased mobility -0.04710     0.02282 -2.064    0.039* 90.072  on 89 85.788  on 88 
Barthel index -0.07789     0.06217   -1.253     0.210 90.072  on 89 88.605  on 88 
Charlson index 0.3890      0.1191    3.267   0.001 ** 90.072  on 89 78.302  on 88 
Number of teeth 0.01721     0.02649    0.650     0.516 90.072  on 89 89.656  on 88 
Admission plaque quartile score 0.3267      0.2359    1.385   0.166 89.623  on 88 87.645  on 87 
Day 7 plaque quartile score 0.3673      0.2684    1.368   0.171  79.159  on 77 77.171  on 76$ 
Deprivation score (IMD) -0.004427    0.013755   -0.322   0.748 89.623  on 88 89.518  on 87 
Female -0.9555      0.5399   -1.770    0.077. 90.072  on 89 86.971  on 88 
Sedating drug 1.0441      0.5389    1.937    0.053 . 90.072  on 89 86.288  on 88 
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Table 90. Associations between HAP and in-hospital events using Fisher’s exact test 
Variable HAP 
(N=10) 
No HAP 
(n=80) 
P value Odds ratio (95% confidence 
intervals) 
Length of operation (mins) 90 (45-165) 90 (24-150)* 0.1754  
Delirium 4/10 6/80 0.01 7.89 (1.28-46.31) 
Aspiration  3/10 1/80 <0.01 30.88 (2.18 -1773.08) 
UTI 3/10 17/80 0.6865  
Fall 3/10 5/80 0.04 6.21 (0.80-41.00) 
Cough 9/10 32/80 <0.01 13.17 (1.69 -601.85) 
Infectious illness 2/10 6/80 0.2162  
Increase in analgesia 3/10 13/80 0.3747  
Transfusion 1/10 15/80 0.6839  
 
*Three patients had no operation 
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Table 91. Univariate generalised linear models relating HAP/LRTI and in-hospital events 
Variable Estimate Standard error Z 
value 
P value Null 
deviance (df) 
Residual deviance 
(df) 
Aspiration 2.6532      1.1892    2.231    0.026 * 90.072  on 89 84.104  on 88   
Delirium 1.6397      0.7013    2.338    0.019 * 90.072  on 89 84.870  on 88 
UTI 0.7282      0.5820    1.251     0.211 90.072  on 89 88.575  on 88 
Transfusion -0.09685     0.70276 -0.138      0.89 90.072  on 89 90.053  on 88 
Operation length 0.015566    0.009781    1.591   0.112 88.708  on 86 86.086  on 85 
Fall 2.1800      0.7904    2.758   0.006 ** 90.072  on 89 82.292  on 88 
Analgesia increase 0.3567      0.6492    0.549     0.583 90.072  on 89   89.781  on 88 
Infection (not HAP or LRTI) 0.9858      0.7842    1.257     0.209 90.072  on 89 88.617  on 88 
Non-infectious illness 0.3567      0.6492    0.549     0.583 90.072  on 89 89.781  on 88 
df= degrees of freedom
 278 
 
Table 92. Comparing patient characteristics between patients with and 
without HAP/LRTI  
Variable HAP/LRTI  
(n=18) median 
(min-max) 
No HAP/LRTI 
(n=72) median 
(min-max) 
P value 
Age   82.5 (70-101) 82 (65-96) 0.304 
Female 9/18 52/72 0.087 
Frailty  5 (3-9) 4 (1-7) 0.006** 
Charlson index 6 (4-11) 4 (2-11) <0.001** 
HABAM  50 (18-61) 53 (20-67) 0.010** 
Barthel 19 (4-20) 20 (4-20) 0.013* 
Number of teeth 6 (0-27) 3.5 (0-28) 0.406 
Admission plaque 
quartile score 
3 (1-4) 2 (1-4) (1 NA) 0.24 
Plaque quartile score 
at 7 days 
3 (1-4) (2 NAs) 3 (1-4) (10 NAs) 0.1626 
Deprivation score 16.39 (3.71-65.94) 22.4 (2.32- 71.74) 0.9764 
Sedating drug at 
admission 
10/18 22/72 0.05844 
 
 
Table 93. Comparing in-hospital events and patient outcomes between 
patients with and without HAP/LRTI  
Variable HAP/LRTI 
(n=18) 
median (min-
max) 
No 
HAP/LRTI 
(n=72) 
median (min-
max) 
P value Odds ratio (95% 
CI) 
Delirium 5/18 5/72 0.021 5.25 (1.05- 26.54) 
Aspiration 3/18 1/72 0.022* 14.17 (1.06- 782.77) 
Cough 13/18 28/72 0.009 4.29 (1.27- 17.08) 
Increase in 
analgesia 
4/18 12/72 0.504  
Length of 
operation 
95 (45-165) 22 (4-265) 0.267  
Length of stay 37.5 (13-140) 22 (4-265) 0.002**  
Died during 
study 
8/18 7/72 0.001** 7.52 (1.93-30.84) 
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Table 94. Generalised linear model relating HAP and S. aureus colonisation 
index 
Variable Estimate Std. Error z value P value 
S. aureus  0.2889         0.1737     1.663    0.0963    
Null deviance: 62.79  on 89  degrees of freedom, Residual deviance: 60.05  on 87  
degrees of freedom, AIC: 66.05 
 
Table 95. Generalised linear model relating HAP/LRTI and MRSA 
colonisation index 
Variable Estimate  Std. Error z value p value OR 95%CI 
MRSA 0.5463      0.3047    1.793   0.073 . 1.74 0.96-3.17 
Null deviance: 90.072  on 89  degrees of freedom, Residual deviance: 84.483  on 
87  degrees of freedom, AIC: 90.483 
 
Table 96. Generalised linear model relating HAP/LRTI with E. coli 
colonisation index 
Variable Estimate Std. Error z value P value 
E. coli  0.3297      0.2266    1.455    0.1456  
Null deviance: 90.072  on 89  degrees of freedom, Residual deviance: 86.972  on 
87  degrees of freedom, AIC: 92.972 
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Table 97. Comparing acquisition of pathogens between patients with and 
without HAP/LRTI  
Variable HAP/LRTI  
(N=18) 
No HAP/LRTI  
(n=72) 
P value 
H. influenzae   5/18 18/72 0.765 
S. aureus  5/18 9/72 0.136 
S. pneumoniae   6/18 31/72 0.596 
MRSA  4/18 7/72 0.214 
P. aeruginosa   3/18 15/72 1 
E. coli   3/18 8/72 0.44 
Acinetobacter spp. 1/18 7/72 1 
 
 
Table 98.  Comparing patient characteristics between uncolonised and 
colonised persons  
Variable Uncolonised 
(N=20) 
Colonised 
(n=73) 
P 
value 
Odds ratio (95% 
confidence 
intervals) 
Age (median) 82 82 (65-101) 0.90  
Female  13/20 51/73 0.79  
Clinical frailty score  4 (2-6) 5 (1-9) 0.25  
Barthel score (median) 20 (17-20) 20 (4-20) 0.01** N/A 
HABAM score (median) 52 (20-67) 53 (18-67) 0.90  
Charlson index (median) 4 (2-10) 5 (2-11) 0.18  
Number of teeth 
(median) 
2 (0-27) 6(0-28) 0.53  
COPD 2/20 16/73 0.34  
Dementia 0/20 6/73 0.33  
Diabetes mellitus 0/20 9/73 0.20  
Cerebrovascular disease 5/20 11/73 0.32  
Cognitively active drug 3/20 30/73 0.04* 3.90 (1.00- 22.61) 
Proton pump inhibitor 4/20 22/73 0.57  
Statin 10/20 40/73 0.80  
ACE inhibitor 6/20 15/73 0.38  
Inhaled steroid 4/20 10/73 0.49  
Oral steroids 1/20 5/73 1  
Either oral/inhaled 
steroids 
4/20 13/73 0.76  
Recent antibiotics 1/20 14/73 0.18  
HABAM= Hierarchical assessment of Balance and Mobility score, COPD= 
combined obstructive pulmonary disease, ACE= Angiotensin converting 
enzyme
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Table 99. Comparing infection-related outcomes between colonised and 
uncolonised persons 
Variable Uncolonised 
(N=20) 
Colonised 
(n=73) 
P 
value 
Odds ratio 
(95% 
confidence 
intervals) 
HAP 1/20 9/73 0.446  
HAP/LRTI 2/20 16/73 0.343  
Cough 3/20 38/73 0.004 6.04 (1.56-
34.91) 
UTI 5/20  15/73  0.760  
Other post-operative infection  2/20 6 /73 0.68  
Length of stay 25.5(11-265) 25 (4-189) 0.347  
Death during study 2/20 13/73 0.511  
UTI= Urinary tract infection
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Table 100. Summary of multivariate analysis using generalized linear 
modeling relating acquisition of individual organisms and significant 
associations with patient characteristics   
Organism Significant patient characteristics  Odds ratio 
S. aureus  Recent antibiotics          5.83 
MRSA Recent antibiotics           
Higher Charlson index               
5.40 
1.27 
E. coli  Lower Barthel score                   0.80 
P. aeruginosa  Increased weight                              
Higher clinical frailty score        
1.04 
1.49 
S. pneumoniae  More teeth          
Lower Charlson index              
1.09 
0.76 
H. influenzae  Fewer teeth           
Dementia                        
0.95 
8.26 
Acinetobacter 
spp 
Lower Barthel score                    0.86 
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Table 101. Multivariate generalized linear model relating acquisition of S. 
pneumoniae (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Number of 
teeth 
0.08542     0.02503    3.413 0.001 *** 
Charlson index -0.27569     0.11936   -2.310 0.021 * 
Null deviance: 125.80  on 92  degrees of freedom, Residual deviance: 105.35  on 
90  degrees of freedom, AIC: 111.35 
 
 
Table 102.  Multivariate generalized linear model relating acquisition of H. 
influenzae (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Number of teeth -0.05226     0.03024   -1.728 0.084. 
Dementia 2.11181     0.93669    2.255   0.024 * 
Null deviance: 104.041  on 92  degrees of freedom, Residual deviance:  95.567  
on 90  degrees of freedom, AIC: 101.57 
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Table 103.  Multivariate generalized linear model relating acquisition of S. 
aureus (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Recent 
antibiotics 
1.7636      0.6458    2.731   0.006** 
Null deviance: 78.797  on 92  degrees of freedom, Residual deviance: 71.777  on 
91  degrees of freedom, AIC: 75.777 
 
 
Table 104. Multivariate generalized linear model relating acquisition of 
MRSA (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Recent 
antibiotics 
1.6858      0.7151    2.357    0.018 *   
Charlson index 0.2394      0.1359    1.762    0.078 . 
Null deviance: 67.608  on 92  degrees of freedom, Residual deviance: 58.333  on 
90  degrees of freedom, AIC: 64.333 
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Table 105. Multivariate generalized linear model relating acquisition of P. 
aeruginosa (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Weight 0.03890     0.01937    2.008   0.044* 
Clinical frailty 
score 
0.39928     0.19347    2.064 0.0390 * 
Null deviance: 93.713  on 91  degrees of freedom , Residual deviance: 85.920  on 
89  degrees of freedom (1 observation deleted due to missingness), AIC: 
91.92,   
  
Table 106. Multivariate generalized linear model relating acquisition of E. 
coli (binomial variable) with medical model of patient characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Barthel  -0.22796     0.06984   -3.264    0.001** 
Null deviance: 67.608  on 92  degrees of freedom, Residual deviance: 56.531  on 
91  degrees of freedom, AIC: 60.531 
 
 
Table 107. Multivariate generalized linear model relating acquisition of 
Acinetobacter spp (binomial variable) with medical model of patient 
characteristics 
Variable Estimate  Standard 
Error 
z value P value 
Barthel -0.15503     0.07161   -2.165    0.030 * 
Null deviance: 54.542  on 92  degrees of freedom, Residual deviance: 50.446  on 
91  degrees of freedom, AIC: 54.446
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Table 108. Summary of significant results from univariate analysis using 
generalised linear models relating colonisation index of individual 
organisms and patient factors (S. aureus, MRSA, E. coli and P. aeruginosa) 
Organism Positive risk factors (odds ratio) Negative risk factors 
(odds ratio) 
S. aureus  COPD (2.87) 
Recent Antibiotics (4.61) 
Charlson index (1.17) 
Female (0.38) 
Never smoked (0.26) 
MRSA Age (1.08) 
COPD (3.89) 
Recent antibiotics (6.46) 
Charlson index (1.24) 
Female   (0.26) 
Never smoked (0.11) 
Decreased weight (0.97) 
E. coli  Unable to self consent (3.33) 
Residence in institution (6.86) 
Clinical frailty score (1.84) 
Dementia (9.42) 
Plaque quartile score on 
admission (1.66) 
Female (0.13) 
Never smoked (0.16) 
Decreased weight (0.96) 
Number of teeth (0.91) 
Mobility score (0.92) 
Barthel score (0.81) 
P. aeruginosa   Weight (1.03)  
Acinetobacter 
spp 
Residence in institution (6.23) 
High clinical frailty score (1.66) 
Low barthel score (0.85) 
Low mobility score (0.95) 
 287 
 
Table 109. Summary of significant results from univariate analysis using 
generalised linear models relating colonisation index of individual 
organisms and patient characteristics (S. pneumoniae, H. influenzae and 
Acinetobacter spp.) 
Organism Positive risk factors (odds ratio) Negative risk factors 
(odds ratio) 
S. pneumoniae   Female (2.08)  
Barthel score (1.18) 
Number of teeth (1.05) 
HABAM score (1.06) 
Age (0.96) 
No recent antibiotics 
(0.61) 
Community living (0.12) 
Low clinical frailty score 
(0.75) 
Ex smoker (0.37) 
Never smoked (0.68) 
Low charlson index 
(0.78) 
No cerebrovascular 
disease (0.56) 
H. influenzae  Female (2.24) 
COPD (3.08) 
Unable to self consent (1.84) 
Residence in institution (2.29) 
High clinical frailty score (1.27) 
Dementia (4.10) 
Plaque quartile admission score 
(1.29) 
Age (0.96) 
Low Barthel score (0.90) 
Fewer teeth (0.92) 
Low mobility score (0.96) 
Ex smoker (0.45) 
Never smoker (0.36) 
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Table 110. Univariate generalised linear models relating colonisation index (S. aureus) and baseline patient variables 
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% confidence 
intervals 
Residual deviance 
Age 0.02337     0.02219    1.053   0.292   161.76  on 91  df 
Female -0.9589      0.3190   -3.006   0.003 ** 0.38 0.21-0.72 153.90  on 91 df 
COPD 1.0537      0.3267    3.225   0.001 ** 2.87 1.51-5.44 153.37  on 91 df 
Recent antibiotics 1.5289      0.3231    4.732 <0.001 *** 4.61 2.45-8.69 142.36  on 91 df 
Self-consent  -0.7869      0.5831 -1.349    0.177   160.52  on 91 df 
Residence institution -17.1101   1361.8872   -0.013     0.990   153.08  on 90 df 
Residence hospital 0.0117      0.7456    0.016     0.987    
Barthel score 0.09586     0.06854    1.399 0.162   160.29  on 91 df 
Weight -0.02538     0.01295 -1.960    0.050   157.96  on 90 df 
Number of teeth -0.005428    0.016606 -0.327     0.744   162.78  on 91 df 
Clincial Frailty Score -0.03751     0.10503 -0.357     0.721   162.76  on 91 df  
HABAM score 0.008352    0.015600    0.535     0.592   162.59  on 91 df 
Ex-smoker -0.2566      0.3861   -0.665    0.5063   153.95  on 90 df 
Never smoker -1.3487      0.5276   -2.556    0.011 * 0.26 0.09-0.73  
Charlson index 0.15844     0.06236    2.541    0.011 * 1.17 1.04-1.32 156.91  on 91 df 
CVD -0.4470      0.4853 -0.921     0.357   161.95  on 91 df 
Dementia 0.6832      0.4976    1.373      0.17   161.26  on 91 df 
Plaque quartile score 
admission 
0.2637       0.1424    1.852      0.064 .        158.75  on 90 df 
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease                        
Null deviance 162.89 on 92  df , df=degrees of freedom, *p<0.05,**p<0.01,and ***p<0.001
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Table 111. Univariate generalised linear models relating colonisation index (MRSA) and baseline patient variables 
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% 
confidence 
intervals 
Null Deviance Residual 
deviance 
Age 0.07505     0.02950      2.544 0.011 * 1.08 1.02-1.14 113.45  on 92 df 106.75  on 91 df 
Female -1.3432      0.4234 -3.172   0.002 ** 0.26 0.11-0.60 113.45  on 92 df 102.84  on 91  df 
COPD 1.3593      0.4101    3.315 0.001 *** 3.89 1.74-8.70 113.45  on 92 df 103.28  on 91 df 
Recent antibiotics  1.8654      0.4138    4.508 <0.001 *** 6.46 2.87-14.53 113.45  on 92 df 94.10  on 91 df 
Self-consent -0.2706      0.5838   -0.463     0.643   113.45  on 92 df 113.21  on 91 df 
Residence in institution -16.5567   1361.8872   -0.012     0.990     113.45  on 92 df 107.06  on 90 df 
Residence in hospital 0.5651      0.7579    0.746     0.456     
Barthel score 0.02511     0.06506    0.386   0.700     113.45  on 92 df 113.29  on 91 df 
Weight -0.03505     0.01724  -2.033    0.042 * 0.97 0.93-1.00 112.96  on 91 df 108.40  on 90 df 
Number of teeth -0.04927     0.02635   -1.87    0.062 .   113.45  on 92 df 109.26  on 91 df 
Clinical Frailty Score 0.2144      0.1317    1.628     0.104   113.45  on 92 df 110.83  on 91 df 
HABAM score -0.01803     0.01733 -1.040   0.298   113.45  on 92 df 112.43  on 91 df 
Ex-smoker 0.3973      0.5573    0.713    0.476   113.45  on 92 df 99.067  on 90 df 
Never smoker -2.2242      1.1233   -1.980    0.048 * 0.11 0.01-0.98   
Charlson index 0.21243     0.07756    2.739   0.006** 1.24 1.06-1.44 113.45  on 92 df 106.58  on 91 df 
CVD -0.4380      0.6223   -0.704     0.482   113.45  on 92 df 112.90  on 91 df 
Dementia -0.4934      1.0306   -0.479     0.632   113.45  on 92 df 113.18  on 91 df 
Plaque quartile score on 
admission 
0.1925      0.1802    1.068     0.285         113.08  on 91 df 111.92  on 90 df 
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease, 
df=degrees of freedom *p<0.05,**p<0.01,and ***p<0.001,
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Table 112. Univariate generalised linear models relating colonisation index (E. coli) and baseline patient variables  
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% 
confidence 
intervals 
Null Deviance Residual 
deviance 
Age 0.04904     0.03071    1.597    0.110   108.68  on 92 df 106.06  on 91 df 
Female -2.0487      0.5111   -4.008 <0.001 *** 0.13 0.05-0.35 108.68  on 92 df 88.22  on 91 df 
COPD -0.1188      0.5573 -0.213     0.831   108.68  on 92 df 108.64  on 91 df 
Recent antibiotics -0.7271      0.7459 -0.975      0.33   108.68  on 92 df 107.53  on 91 df 
Self-consent  1.2026      0.3452    3.484 <0.001*** 3.33 1.69-6.55 108.68  on 92 df 98.86  on 91 df 
Residence institution 1.9250      0.4319    4.457 <0.001*** 6.86 2.94-15.98 108.68  on 92 df 89.354  on 90 df 
Residence hospital -14.9045   1357.6515 -0.011     0.991     
Barthel score -0.20937     0.03423 -6.117 <0.001 *** 0.81 0.76-0.87 108.68  on 92 df 76.025  on 91 df 
Weight -0.04435     0.02305 -1.924    0.054 . 0.96 0.91-1.00 69.960  on 91 df 65.771  on 90 df 
Number of teeth -0.09109     0.03620 -2.516    0.012 *   0.91 0.85-0.98 108.68  on 92 df 99.052  on 91 df 
Clinical Frailty Score 0.6100      0.1365    4.468 <0.001*** 1.84 1.41-2.40 108.68  on 92 df 88.334  on 91 df 
HABAM score -0.078338    0.014761   -5.307 <0.001*** 0.92 0.90-0.95 108.68  on 92 df 82.257  on 91 df 
Ex smoker -0.8067      0.4679 -1.724   0.085   108.68  on 92 df 100.48  on 90 df 
Never smoker -1.8187      0.6856 -2.653   0.008 ** 0.16 0.04-0.62   
Charlson index -0.007187    0.099062   -0.073     0.942   108.68  on 92 df 108.68  on 91 df 
CVD -0.3427      0.6260 -0.547     0.584     108.68  on 92 df 108.36  on 91 df 
Dementia 2.2429      0.4506    4.977 <0.001*** 9.42 3.90-22.78 108.68  on 92 df 89.197  on 91 df  
Plaque quartile score 
on admission 
0.5048      0.2097    2.408      0.016 *    1.66 1.10-2.50 106.87  on 91 df 100.40  on 90 df   
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease, 
df=degrees of freedom, *p<0.05,**p<0.01,and ***p<0.00
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Table 113. Univariate generalised linear models relating colonisation index (P. aeruginosa) and baseline patient variables  
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% 
confidence 
intervals 
Null Deviance Residual 
deviance 
Age -0.005945     0.025532 -0.233     0.816   97.063  on 92 df 97.009  on 91 df 
Female 0.4218      0.4382    0.963     0.336      97.063  on 92 df 96.073  on 91 df 
COPD 0.5921      0.4082     1.45     0.147      97.063  on 92 df 95.122  on 91 df 
Recent antibiotics  -0.5730      0.6159   -0.93     0.352     97.063  on 92 df 96.063  on 91 df 
Self-consent  -1.544       1.002 -1.540     0.124   97.063  on 92 df 92.857  on 91 df 
Residence institution -1.3553      1.0231 -1.325     0.185   97.063  on 92 df 91.842  on 90 df 
Residence hospital -15.7869   1357.6515 -0.012     0.991        
Barthel score 0.01607     0.05759    0.279 0.780   97.063  on 92 df 96.982  on 91 df 
Weight 0.03239     0.01271    2.548    0.011 * 1.03 0.91-1.14 97.063  on 92 df 90.253  on 90 df 
Number of teeth 0.01135     0.01861     0.61     0.542   97.063  on 92 df 96.697  on 91 df 
Clincial Frailty Score 0.1000      0.1209    0.827     0.408     97.063  on 92 df 96.385  on 91 df 
HABAM score 0.004375    0.017880    0.245 0.807     97.063  on 92 df 97.002  on 91 df 
Ex smoker 0.4618      0.6375    0.724     0.469   97.063  on 92 df 96.433  on 90 df 
Never smoker 0.4614      0.6603    0.699     0.485     
Charlson index 0.1269      0.0757    1.677    0.0936    97.063  on 92 df 94.444  on 91 df 
CVD 0.5428      0.4231    1.283     0.199   97.063  on 92 df 95.548  on 91 df 
Dementia -16.7507   1839.2432 -0.009     0.993   97.063  on 92 df 93.176  on 91 df 
Plaque quartile score 
on admission 
0.2293      0.1660    1.381      0.167     96.627  on 91 df 94.676  on 90 df 
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease, 
df=degrees of freedom, *p<0.05,**p<0.01,and ***p<0.001
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Table 114. Univariate generalised linear models relating colonisation index (S. pneumoniae) and baseline patient variables  
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% 
confidence 
intervals 
Null Deviance Residual 
deviance 
Age -0.03924     0.01076 -3.646 <0.001 *** 0.96 0.94-0.98 359.72  on 92 df 346.39  on 91 df 
Female 0.7301      0.1992    3.666 <0.001 *** 2.08 1.40-3.07 359.72  on 92 df 344.85  on 91 df 
COPD 0.25071     0.19050    1.316     0.188   359.72  on 92 df 358.03  on 91 df 
Recent antibiotics  -0.50171     0.24947 -2.011    0.044 * 0.61 0.37-0.99 359.72  on 92 df 355.29  on 91 df 
Self-consent  0.02973     0.18914    0.157     0.875     359.72  on 92 df 359.70  on 91 df 
Residence institution -2.10432     0.59253 -3.551 <0.001 *** 0.12 0.04-0.39 359.72  on 92 df 334.96  on 90 df 
Residence hospital 0.09508     0.36919    0.258 0.797     
Barthel score 0.16253     0.04272    3.805 <0.001 *** 1.18 1.08-1.28 359.72  on 92 df 337.51  on 91 df 
Weight -0.001848    0.005838   -0.317   0.752   359.26  on 91 df 359.16  on 90 df 
Number of teeth 0.050890    0.007926    6.421 <0.001 *** 1.05 1.04-1.07 359.72  on 92 df 317.71  on 91 df 
Clinical Frailty Score -0.28837     0.05499   -5.244 <0.001 *** 0.75 0.67-0.83 359.72  on 92 df 330.79  on 91 df 
HABAM score 0.054108    0.009557    5.661 <0.001 *** 1.06 1.04-1.08 359.72  on 92 df 321.48  on 91 df 
Ex smoker -1.0045      0.2133   -4.710 <0.001 *** 0.37 0.24-0.56 359.72  on 92 df 335.37  on 90 df 
Never smoker -0.3947      0.2081 -1.896    0.058 . 0.68 1.45-1.01   
Charlson index -0.25026     0.04831   -5.18 <0.001 *** 0.78 0.71-0.86 359.72  on 92 df 327.38  on 91 df 
CVD -0.57153     0.24866 -2.298    0.022 * 0.56 0.35-0.92 359.72  on 92 df 353.86  on 91 df 
Dementia -0.14315     0.34180   -0.419     0.675   359.72  on 92 df 359.54  on 91 df 
Plaque quartile score 
on admission 
-0.29922     0.07242   -4.132 <0.001 *** 0.74 0.64-0.85 357.11  on 91 df 339.40  on 90 df 
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease, 
df=degrees of freedom, numbers to 2 d.p., *p<0.05,**p<0.01,and ***p<0.001
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Table 115. Univariate generalised linear models relating colonisation index (H. influenzae) and baseline patient variables  
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% CI Null deviance Residual 
deviance 
Age -0.04393     0.01722   -2.551    0.011 *    0.96 0.93-0.99 189.49  on 92 df 183.04  on 91 df 
Female 0.8046      0.3398    2.368    0.018* 2.24 1.15-4.35 189.49  on 92 df 182.99  on 91 df 
COPD 1.1243      0.2683     4.19 <0.001 *** 3.08 1.82-5.21 189.49  on 92 df 173.25  on 91 df 
Recent antibiotics  0.3513      0.3168    1.109     0.267   189.49  on 92 df 188.33  on 91 df 
Self-consent  0.6107      0.2619    2.332    0.020* 1.84 1.10-3.08 189.49  on 92 df 184.68  on 91 df 
Residence institution 0.8282      0.3153    2.627   0.009 ** 2.29 1.23-4.25 189.49  on 92 df 178.13  on 90 df 
Residence hospital -16.3114   1357.6515   -0.012   0.990      
Barthel score -0.10073     0.02754 -3.657 <0.001 *** 0.90 0.86-0.95 189.49  on 92 df 178.07  on 91 df 
Weight -0.006119    0.010017 -0.611 0.541   187.78  on 91 df 187.40  on 90 df 
Number of teeth -0.07959     0.02029   -3.923 <0.001 *** 0.92 0.89-0.96 189.49  on 92 df 167.90  on 91 df 
Clincial Frailty Score 0.23538     0.08551    2.753   0.006 ** 1.27 1.07-1.50 189.49  on 92 df 181.88  on 91 df 
HABAM score -0.03654     0.01050   -3.480 0.001*** 0.96 0.94-0.98 189.49  on 92 df 178.25  on 91 df 
Ex smoker -0.7893      0.3127   -2.524   0.012 * 0.45 0.25-0.84 189.49  on 92 df 180.90  on 90 df 
Never smoker -1.0097      0.3562   -2.835   0.005 ** 0.36 0.18-0.73   
Charlson index -0.08676     0.06644 -1.306     0.192   189.49  on 92 df 187.67  on 91 df 
CVD 0.08809     0.33331    0.264     0.792   189.49  on 92 df 189.42  on 91 df 
Dementia 1.4117      0.3346    4.219 <0.001 *** 4.10 2.13-7.91 189.49  on 92 df 174.88  on 91 df 
Plaque quartile score on 
admission 
0.2516      0.1161     2.167    0.030*   1.29 1.02-1.61 188.58  on 91 df 183.75  on 90 df 
COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, CVD=cerebrovascular disease, 
df=degrees of freedom, numbers to 2 d.p., *p<0.05,**p<0.01,and ***p<0.001
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Table 116. Univariate generalised linear models relating colonisation index (Acinetobacter spp) and baseline patient variables  
Factor Estimate Standard 
Error 
Z value P value Odds 
ratio 
95% CI Null deviance Residual 
deviance 
Age 0.007832    0.042237    0.185     0.853   52.703  on 92 df 52.669  on 91 df 
Female -0.5855      0.6102   -0.960     0.337   52.703  on 92 df 51.810  on 91 df 
COPD 0.8797      0.6331     1.39     0.165   52.703  on 92 df 50.956  on 91 df 
Recent antibiotics 0.6434      0.6836    0.941     0.347   52.703  on 92 df 51.904  on 91 df 
Self-consent  0.5611      0.5952    0.943     0.346   52.703  on 92 df 51.942  on 91 df 
Residence institution 1.8297      0.6156    2.972   0.003 ** 6.23 1.86-20.83 52.703  on 92 df 44.213  on 90 df 
Residence hospital -15.2114   2238.3889 -0.007   0.995     
Barthel score -0.16780     0.05036 -3.332 0.001*** 0.85 0.67-0.93 52.703  on 92 df 43.946  on 91 df 
Weight -0.03499     0.02576 -1.358     0.174   50.462  on 90 df 50.462  on 90 df 
Number of teeth -0.06468     0.04354   -1.486     0.137   52.703  on 92 df 49.817  on 91 df 
Clincial Frailty Score 0.5078      0.1885    2.693   0.007** 1.66 1.15-2.40 52.703  on 92 df 45.703  on 91 df 
HABAM score -0.04762     0.02249   -2.118    0.034 * 0.95 0.91-1.00 52.703  on 92 df 48.757  on 91 df 
Ex smoker 0.5796      1.0850    0.534     0.593     52.703  on 92 df 52.363  on 90   df 
Never smoker 0.5484      1.1233    0.488     0.625          
Charlson index 0.03372     0.13482    0.250     0.803   52.703  on 92 df 52.642  on 91 df 
CVD 0.5736      0.6833    0.839     0.401   52.703  on 92 df 52.060  on 91 df 
Dementia 0.3821      1.0586    0.361     0.718   52.703  on 92 df 52.585  on 91 df 
Plaque score quartile on 
admission 
0.1491      0.2939    0.507     0.612   43.915  on 91 df 43.655  on 90 df 
CI= confidence intervals, COPD=Combined obstructive pulmonary disease, HABAM= Hierarchical balance and mobility score, 
CVD=cerebrovascular disease, df=degrees of freedom, numbers to 2 d.p., *p<0.05,**p<0.01,and ***p<0.0
  
Table 117. Multivariate generalised linear model relating colonisation index (S. aureus) and baseline patient characteristics (medical 
model) 
   Patient variable Estimate Standard error Z value P value 
Female -1.19617     0.41121   -2.909 0.004 ** 
Recent antibiotics 2.60964     0.48437    5.388 <0.001 *** 
Self-consent          -2.11681     0.81878   -2.585 0.010 ** 
Weight           -0.04233     0.01624   -2.606 0.010** 
Number of teeth        -0.05705     0.02403   -2.374 0.018 *   
Frailty score            -0.57686     0.19224   -3.001 0.003 ** 
Not smoking currently         -2.08445     0.57667   -3.615 <0.001*** 
Charlson index     0.46496     0.11340    4.100 <0.001 *** 
Dementia    2.17319     0.69347    3.134 0.002 ** 
Null deviance: 162.081  on 91  degrees of freedom,   , Residual deviance:  85.298  on 82  degrees of freedom    (1 observation deleted due 
to missingness)     AIC: 140.31 
  
Table 118. Multivariate generalised linear model relating colonisation index (S. aureus) using the dental model 
Patient variable Estimate Standard error Z value P value 
Charlson index 0.22338     0.07684    2.907   0.004 ** 
Plaque quartile score day 1        0.40577     0.16075    2.524   0.012 * 
Female -1.04207     0.35366   -2.947   0.003 ** 
Deprivation score (IMD) -0.01747     0.01003   -1.742   0.082 . 
Current smoking -1.18256     0.45728   -2.586   0.010 ** 
Barthel index 0.16317     0.07445    2.192   0.028 * 
Null deviance: 161.26  on 90  degrees of freedom, Residual deviance: 128.57  on 84  degrees of freedom, (2 observations deleted due to 
missingness), AIC: 177.58 
 
  
Table 119. Multivariate generalised linear model relating colonisation index 
(MRSA) and baseline patient variables (medical model) 
Patient variable Estimate Standard error Z value P value 
Recent 
antibiotics 
2.73471     0.48441    5.645 <0.001 *** 
Barthel index        0.26737     0.08777    3.046   0.002 ** 
Number of 
teeth          
-0.07573     0.02776   -2.728   0.006 ** 
Ever smoked       -3.15218     1.06884   -2.949   0.003 ** 
Charlson index     0.34315     0.10948    3.134   0.002 ** 
Null deviance: 113.445  on 92  degrees of freedom, Residual deviance:  57.507  
on 87  degrees of freedom, AIC: 94.774 
 
Table 120. Multivariate generalised linear model relating colonisation index 
(MRSA) using the dental model 
Patient variable Estimate Standard 
error 
Z value P value 
Age          0.09624     0.03858    2.494   0.013* 
Charlson index 0.21556     0.09634     2.238   0.025 * 
Ever smoked -2.44064     1.02793   -2.374   0.018 * 
Barthel index 0.17428     0.08653    2.014   0.044 * 
Null deviance: 113.445  on 92  degrees of freedom, Residual deviance:  85.862  
on 88   degrees of freedom, AIC: 121.13 
  
 
Table 121.  Multivariate generalised linear model relating colonisation index 
(S. pneumoniae) and baseline patient variables (medical model) 
Patient variable Estimate Standard error Z value P value 
Plaque quartile 
score day1          
-0.23552     0.09256   -2.545 0.011 * 
Female       0.65446     0.24166    2.708 0.007 ** 
Recent 
antibiotics 
-0.89130     0.29322   -3.040 0.002 ** 
Self-consent           0.43530     0.21823    1.995 0.046 * 
Number of 
teeth           
0.04441     0.01044    4.253 <0.001 *** 
HABAM             0.04803     0.01113    4.315 <0.001 *** 
Ever smoked       -0.53310     0.21077   -2.529 0.011* 
Charlson index    -0.14629     0.05318   -2.751 0.006 ** 
Dementia  1.17022     0.45638    2.564 0.010 * 
Null deviance: 357.11  on 91  degrees of freedom, Residual deviance: 247.91  on 
82  degrees of freedom    (1 observation deleted due to missingness) AIC: 374.3 
 
Table 122. Multivariate generalised linear model relating colonisation index 
(S. pneumoniae) using the dental model 
Patient variable Estimate Standard 
error 
Z value P value 
Clinical frailty score         -0.126637    0.061986   -2.043    0.041* 
Charlson index  -0.117752    0.052891   -2.226    0.026 * 
Teeth number       0.043151    0.009431    4.576 <0.001 *** 
FemaleTRUE      0.534771    0.236574    2.260    0.024 * 
Current smoking -0.892464    0.228295   -3.909 <0.001*** 
Deprivation score 
(IMD) 
-0.010290    0.005465   -1.883    0.060. 
Null deviance: 353.82  on 91  degrees of freedom, Residual deviance: 260.40  on 
85   degrees of freedom, (1 observation deleted due to missingness), AIC: 377.49 
  
 
Table 123. Multivariate generalised linear model relating colonisation index 
(H. influenzae) and baseline patient variables (medical model) 
Patient 
variable 
Estimate Standard error Z value P value 
Female     0.93102     0.39793    2.340   0.019* 
COPD 0.96067     0.34225    2.807   0.005** 
Barthel index -0.07338     0.03587   -2.046   0.041 * 
Number of 
teeth       
-0.07072     0.02155   -3.282   0.001 ** 
Not currently 
smoking 
-0.83846     0.36119   -2.321   0.020 * 
Dementia 1.86245     0.40935    4.550 <0.001 *** 
Null deviance: 189.49  on 92  degrees of freedom, Residual deviance: 118.88  on 
86  degrees of freedom, AIC: 188.72 
 
Table 124. Multivariate generalised linear model relating colonisation index 
(H. influenzae) using the dental model 
Patient 
variable 
Estimate Standard error Z value P value 
Age         -0.054508    0.020021   -2.723   0.006 ** 
Dentures   0.498582    0.160148    3.113   0.002 ** 
Female    1.293585    0.411110    3.147   0.002 ** 
IMD   0.021399    0.007844    2.728   0.006 ** 
Barthel index -0.168932    0.036667   -4.607 <0.001 *** 
Null deviance: 188.29  on 91  degrees of freedom, Residual deviance: 114.28  on 
86  degrees of freedom, (1 observation deleted due to missingness), AIC: 179.68 
  
Table 125. Multivariate generalised linear model relating colonisation index 
(E. coli) using the dental model 
Patient variable Estimate Standard 
error 
Z value P value 
Teeth number       -0.23707      0.07618   -3.112 0.002 ** 
Dentures      -0.65410      0.30161   -2.169 0.030 * 
Female   -2.30236      0.62617   -3.677 <0.001 ***    
Current smoking     -2.40923     0.67333   -3.578 <0.001  *** 
Barthel index   -0.22273     0.05207   -4.278 <0.001  *** 
Null deviance: 108.682  on 92  degrees of freedom, Residual deviance:  34.083  
on 87  degrees of freedom, AIC: 69.894 
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